ANNUAL REPORT
FY2020 — Annual report (Form 10-K)
FY2020PDF · 242 pages1.4 MB
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
(Mark one)
[x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 TRUE
For the Fiscal Year Ended June 30, 2020
OR
[ ]]FALSE TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File No. 1-434
Cincinnati THE PROCTER & GAMBLE COMPANY OH
One Procter &
Gamble Plaza One Procter & Gamble Plaza, Cincinnati, Ohio 45202 45202
513 Telephone (513) 983-1100 983-1100
IRS Employer Identification No. 31-0411980 31-0411980
State of Incorporation: Ohio OH
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, without Par Value PG New York Stock Exchange
4.125% EUR notes due December 2020 PG20A New York Stock Exchange
2.000% notes due 2021 PG21 New York Stock Exchange
2.000% notes due 2022 PG22B New York Stock Exchange
1.125% notes due 2023 PG23A New York Stock Exchange
0.500% notes due 2024 PG24A New York Stock Exchange
0.625% notes due 2024 PG24B New York Stock Exchange
1.375% notes due 2025 PG25 New York Stock Exchange
4.875% EUR notes due May 2027 PG27A New York Stock Exchange
1.200% notes due 2028 PG28 New York Stock Exchange
1.250% notes due 2029 PG29B New York Stock Exchange
1.800% notes due 2029 PG29A New York Stock Exchange
6.250% GBP notes due January 2030 PG30 New York Stock Exchange
5.250% GBP notes due January 2033 PG33 New York Stock Exchange
1.875% notes due 2038 PG38 New York Stock Exchange
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes o No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the
definitions of "large accelerated filed," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer þ Accelerated filer ¨
Non-accelerated filer ¨ Smaller reporting company ¨ FALSE
Emerging growth company ¨ FALSE
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ False
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of
the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.
7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes þ No o TRUE
The aggregate market value of the voting stock held by non-affiliates amounted to $304 billion on December 31, 2019.
There were 2,486,086,692 shares of Common Stock outstanding as of July 31, 2020.
Documents Incorporated by Reference
Portions of the Proxy Statement for the 2020 Annual Meeting of Shareholders, which will be filed within one hundred and twenty days of the fiscal year ended June 30, 2020 (2020 Proxy
Statement), are incorporated by reference into Part III of this report to the extent described herein.
-- 1 of 242 --
FORM 10-K TABLE OF CONTENTS Page
PART I Item 1. Business 1
Item 1A. Risk Factors 2
Item 1B. Unresolved Staff Comments 7
Item 2. Properties 7
Item 3. Legal Proceedings 7
Item 4. Mine Safety Disclosure 7
Information about our Executive Officers 8
PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 9
Item 6. Selected Financial Data 11
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 11
Item 7A. Quantitative and Qualitative Disclosures about Market Risk 32
Item 8. Financial Statements and Supplementary Data 33
Management's Report and Reports of Independent Registered Public Accounting Firm 33
Consolidated Statements of Earnings 37
Consolidated Statements of Comprehensive Income 38
Consolidated Balance Sheets 39
Consolidated Statements of Shareholders' Equity 40
Consolidated Statements of Cash Flows 41
Notes to Consolidated Financial Statements 42
Note 1: Summary of Significant Accounting Policies 42
Note 2: Segment Information 44
Note 3: Supplemental Financial Information 46
Note 4: Goodwill and Intangible Assets 47
Note 5: Income Taxes 48
Note 6: Earnings Per Share 50
Note 7: Stock-based Compensation 51
Note 8: Postretirement Benefits and Employee Stock Ownership Plan 53
Note 9: Risk Management Activities and Fair Value Measurements 58
Note 10: Short-term and Long-term Debt 61
Note 11: Accumulated Other Comprehensive Income/(Loss) 62
Note 12: Leases 62
Note 13: Commitments and Contingencies 63
Note 14: Merck Acquisition 64
Note 15: Quarterly Results (Unaudited) 65
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 65
Item 9A. Controls and Procedures 65
Item 9B. Other Information 65
PART III Item 10. Directors, Executive Officers and Corporate Governance 66
Item 11. Executive Compensation 66
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 66
Item 13. Certain Relationships and Related Transactions and Director Independence 67
Item 14. Principal Accountant Fees and Services 67
PART IV Item 15. Exhibits and Financial Statement Schedules 67
Item 16. Form 10-K Summary 69
Signatures 70
Exhibit Index 71
-- 2 of 242 --
The Procter & Gamble Company 1
PART I
Item 1. Business.
Additional information required by this item is incorporated herein by
reference to Management's Discussion and Analysis (MD&A); and Notes 1
and 2 to our Consolidated Financial Statements. Unless the context indicates
otherwise, the terms the "Company," "P&G," "we," "our" or "us" as used
herein refer to The Procter & Gamble Company (the registrant) and its
subsidiaries.
The Procter & Gamble Company is focused on providing branded products of
superior quality and value to improve the lives of the world's consumers, now
and for generations to come. The Company was incorporated in Ohio in 1905,
having first been established as a New Jersey corporation in 1890, and was
built from a business founded in Cincinnati in 1837 by William Procter and
James Gamble. Today, our products are sold in more than 180 countries and
territories.
Throughout this Form 10-K, we incorporate by reference information from
other documents filed with the Securities and Exchange Commission (SEC).
The Company's Annual Report on Form 10-K, quarterly reports on Form 10-
Q and current reports on Form 8-K, and amendments thereto, are filed
electronically with the SEC. The SEC maintains an internet site that contains
these reports at: www.sec.gov. You can also access these reports through
links from our website at: www.pginvestor.com. P&G includes the website
link solely as a textual reference. The information contained on our website is
not incorporated by reference into this report.
Copies of these reports are also available, without charge, by contacting EQ
Shareowner Services, 1100 Centre Pointe Curve, Suite 101, Mendota, MN
55120-4100.
Financial Information about Segments
Information about our reportable segments can be found in the MD&A and
Note 2 to our Consolidated Financial Statements.
Narrative Description of Business
Business Model. Our business model relies on the continued growth and
success of existing brands and products, as well as the creation of new
innovative products and brands. The markets and industry segments in which
we offer our products are highly competitive. Our products are sold in more
than 180 countries and territories through numerous channels as well as
direct-to-consumer. Our growth strategy is to deliver meaningful and
noticeable superiority in all elements of our consumer proposition - product,
packaging, brand communication, retail execution and consumer and
customer value equation. We use our research and development and consumer
insights to provide superior products and packaging. We utilize our marketing
and online presence to deliver superior brand messaging to our consumers.
We work collaboratively with our customers to deliver superior retail
execution, both in-store and online. In conjunction with the above elements,
we provide superior value to consumers and our retail customers in each price
tier
in which we compete. Productivity improvement is also critical to delivering
our objectives of balanced top and bottom-line growth and value creation.
Key Product Categories. Information on key product categories can be
found in the MD&A and Note 2 to our Consolidated Financial Statements.
Key Customers. Our customers include mass merchandisers, e-commerce,
grocery stores, membership club stores, drug stores, department stores,
distributors, wholesalers, baby stores, specialty beauty stores (including
airport duty-free stores), high-frequency stores, pharmacies, electronics stores
and professional channels. These customers sell our products to individual
consumers. We also sell direct to consumers. Sales to Walmart Inc. and its
affiliates represent approximately 15% of our total sales in 2020, 2019 and
2018. No other customer represents more than 10% of our total sales. Our top
ten customers accounted for approximately 38% of our total sales in 2020 and
36% in 2019 and 2018. The nature of our business does not result in material
backlog orders or contracts with the government. We believe our practices
related to working capital items for customers and suppliers are consistent
with the industry segments in which we compete.
Sources and Availability of Materials. Almost all of the raw and packaging
-- 3 of 242 --
materials used by the Company are purchased from third parties, some of
whom are single-source suppliers. We produce certain raw materials,
primarily chemicals, for further use in the manufacturing process. In addition,
fuel, natural gas and derivative products are important commodities
consumed in our manufacturing processes and in the transportation of input
materials and finished products to customers. The prices we pay for materials
and other commodities are subject to fluctuation. When prices for these items
change, we may or may not pass the change to our customers. The Company
purchases a substantial variety of other raw and packaging materials, none of
which are material to our business taken as a whole.
Trademarks and Patents. We own or have licenses under patents and
registered trademarks, which are used in connection with our activity in all
businesses. Some of these patents or licenses cover significant product
formulation and processes used to manufacture our products. The trademarks
are important to the overall marketing and branding of our products. All
major trademarks in each business are registered. In part, our success can be
attributed to the existence and continued protection of these trademarks,
patents and licenses.
Competitive Condition. The markets in which our products are sold are
highly competitive. Our products compete against similar products of many
large and small companies, including well-known global competitors. In
many of the markets and industry segments in which we sell our products, we
compete against other branded products as well as retailers' private-label
brands. We are well positioned in
-- 4 of 242 --
2 The Procter & Gamble Company
the industry segments and markets in which we operate, often holding a
leadership or significant market share position. We support our products with
advertising, promotions and other marketing vehicles to build awareness and
trial of our brands and products in conjunction with our sales force. We
believe this combination provides the most efficient method of marketing for
these types of products. Product quality, performance, value and packaging
are also important differentiating factors.
Expenditures for Environmental Compliance. Expenditures for compliance
with federal, state and local environmental laws and regulations are fairly
consistent from year to year and are not material to the Company. No material
change is expected in fiscal year 2021.
Employees. As of June 30, 2020, the Company had approximately 99,000
employees, an increase of two percent versus the prior year due to business
growth and in-sourcing of certain media planning and other services. The
total number of employees is an estimate of total Company employees
excluding interns, co-ops, contractors and employees of joint ventures. The
number of employees includes manufacturing and non-manufacturing
employees.
Item 1A. Risk Factors.
We discuss our expectations regarding future performance, events and
outcomes, such as our business outlook and objectives in this Form 10-K, as
well as in our quarterly and annual reports, current reports on Form 8-K, press
releases and other written and oral communications. All statements, except
for historical and present factual information, are “forward-looking
statements” and are based on financial data and business plans available only
as of the time the statements are made, which may become outdated or
incomplete. We assume no obligation to update any forward-looking
statements as a result of new information, future events or other factors,
except to the extent required by law. Forward-looking statements are
inherently uncertain, and investors must recognize that events could
significantly differ from our expectations.
The following discussion of “risk factors” identifies significant factors that
may adversely affect our business, operations, financial position or future
financial performance. This information should be read in conjunction with
Management's Discussion and Analysis and the Consolidated Financial
Statements and related Notes incorporated in this report. The following
discussion of risks is not all inclusive, but is designed to highlight what we
believe are important factors to consider when evaluating our expectations.
These and other factors could cause our future results to differ from those in
the forward-looking statements and from historical trends, perhaps materially.
Our business is subject to numerous risks as a result of our having
significant operations and sales in international markets, including
foreign currency fluctuations, currency exchange or pricing controls and
localized volatility.
We are a global company, with operations in approximately 70 countries and
products sold in more than 180 countries
and territories around the world. We hold assets, incur liabilities, generate
sales and pay expenses in a variety of currencies other than the U.S. dollar,
and our operations outside the U.S. generate more than fifty percent of our
annual net sales. Fluctuations in exchange rates for foreign currencies have
and could continue to reduce the U.S. dollar value of sales, earnings and cash
flows we receive from non-U.S. markets, increase our supply costs (as
measured in U.S. dollars) in those markets, negatively impact our
competitiveness in those markets or otherwise adversely impact our business
results or financial condition. Moreover, discriminatory or conflicting fiscal
or trade policies in different countries, including changes to tariffs and
existing trade policies and agreements, could adversely affect our results. See
also the Results of Operations and Cash Flow, Financial Condition and
Liquidity sections of the MD&A, and the Consolidated Financial Statements
and related Notes.
We also have businesses and maintain local currency cash balances in a
number of countries with currency exchange, import authorization, pricing or
other controls or restrictions, such as Nigeria, Algeria, Argentina, Egypt and
Turkey. Our results of operations, financial condition and cash flows could be
adversely impacted if we are unable to successfully manage such controls and
restrictions, continue existing business operations and repatriate earnings
from overseas, or if new or increased tariffs, quotas, exchange or price
-- 5 of 242 --
controls, trade barriers or similar restrictions are imposed on our business.
Additionally, our business, operations or employees have been and could
continue to be adversely affected by political volatility, labor market
disruptions or other crises or vulnerabilities in individual countries or regions,
including political instability or upheaval, broad economic instability or
sovereign risk related to a default by or deterioration in the creditworthiness
of local governments, particularly in emerging markets.
Uncertain economic conditions may adversely impact demand for our
products or cause our customers and other business partners to suffer
financial hardship, which could adversely impact our business.
Our business could be negatively impacted by reduced demand for our
products related to one or more significant local, regional or global economic
disruptions. These disruptions have included and may in the future include: a
slow-down or recession in the general economy; reduced market growth rates;
tighter credit markets for our suppliers, vendors or customers; a significant
shift in government policies; the deterioration of economic relations between
countries or regions, including potential negative consumer sentiment toward
non-local products or sources; or the inability to conduct day-to-day
transactions through our financial intermediaries to pay funds to or collect
funds from our customers, vendors and suppliers. Additionally, these and
other economic conditions may cause our suppliers, distributors, contractors
or other third-party partners to suffer financial or operational difficulties that
they cannot overcome, resulting in their inability to provide us with the
-- 6 of 242 --
The Procter & Gamble Company 3
materials and services we need, in which case our business and results of
operations could be adversely affected. Customers may also suffer financial
hardships due to economic conditions such that their accounts become
uncollectible or are subject to longer collection cycles. In addition, if we are
unable to generate sufficient sales, income and cash flow, it could affect the
Company’s ability to achieve expected share repurchase and dividend
payments.
Disruptions in credit markets or changes to our credit ratings may
reduce our access to credit.
A disruption in the credit markets or a downgrade of our current credit rating
could increase our future borrowing costs and impair our ability to access
capital and credit markets on terms commercially acceptable to us, which
could adversely affect our liquidity and capital resources or significantly
increase our cost of capital.
Our business results depend on our ability to manage disruptions in our
global supply chain.
Our ability to meet our customers’ needs and achieve cost targets depends on
our ability to maintain key manufacturing and supply arrangements, including
execution of supply chain optimizations and certain sole supplier or sole
manufacturing plant arrangements. The loss or disruption of such
manufacturing and supply arrangements, including for issues such as labor
disputes, loss or impairment of key manufacturing sites, discontinuity in our
internal information and data systems, inability to procure sufficient raw or
input materials, significant changes in trade policy, natural disasters,
increasing severity or frequency of extreme weather events due to climate
change or otherwise, acts of war or terrorism, disease outbreaks or other
external factors over which we have no control, have interrupted product
supply and, if not effectively managed and remedied, could have an adverse
impact on our business, financial condition, results of operations or cash
flows.
Our businesses face cost fluctuations and pressures that could affect our
business results.
Our costs are subject to fluctuations, particularly due to changes in the prices
of commodities and raw materials and the costs of labor, transportation,
energy, pension and healthcare. Therefore, our business results depend, in
part, on our continued ability to manage these fluctuations through pricing
actions, cost saving projects and sourcing decisions, while maintaining and
improving margins and market share. Failure to manage these fluctuations
could adversely impact our results of operations or cash flows.
Our ability to meet our growth targets depends on successful product,
marketing and operations innovation and successful responses to
competitive innovation and changing consumer habits.
We are a consumer products company that relies on continued global demand
for our brands and products. Achieving our business results depends, in part,
on successfully developing, introducing and marketing new products and on
making significant improvements to our equipment and manufacturing
processes. The success of such innovation depends on our ability to correctly
anticipate
customer and consumer acceptance and trends, to obtain, maintain and
enforce necessary intellectual property protections and to avoid infringing
upon the intellectual property rights of others. We must also successfully
respond to technological advances made by, and intellectual property rights
granted to, competitors. Failure to continually innovate, improve and respond
to competitive moves and changing consumer habits could compromise our
competitive position and adversely impact our financial condition, results of
operations or cash flows.
The ability to achieve our business objectives depends on how well we
can compete with our local and global competitors in new and existing
markets and channels.
The consumer products industry is highly competitive. Across all of our
categories, we compete against a wide variety of global and local competitors.
As a result, we experience ongoing competitive pressures in the environments
in which we operate, which may result in challenges in maintaining profit
margins. To address these challenges, we must be able to successfully
respond to competitive factors and emerging retail trends, including pricing,
promotional incentives, product delivery windows and trade terms. In
addition, evolving sales channels and business models may affect customer
-- 7 of 242 --
and consumer preferences as well as market dynamics, which, for example,
may be seen in the growing consumer preference for shopping online, ease of
competitive entry into certain categories, and growth in hard discounter
channels. Failure to successfully respond to competitive factors and emerging
retail trends, and effectively compete in growing sales channels and business
models, particularly e-commerce and mobile commerce applications, could
negatively impact our results of operations or cash flows.
A significant change in customer relationships or in customer demand
for our products could have a significant impact on our business.
We sell most of our products via retail customers, which include mass
merchandisers, e-commerce, grocery stores, membership club stores, drug
stores, department stores, distributors, wholesalers, baby stores, specialty
beauty stores (including airport duty-free stores), high-frequency stores,
pharmacies, electronics stores and professional channels. Our success
depends on our ability to successfully manage relationships with our retail
trade customers, which includes our ability to offer trade terms that are
mutually acceptable and are aligned with our pricing and profitability targets.
Continued concentration among our retail customers could create significant
cost and margin pressure on our business, and our business performance
could suffer if we cannot reach agreement with a key customer on trade terms
and principles. Our business could also be negatively impacted if a key
customer were to significantly reduce the inventory level of or shelf space
allocated to our products as a result of increased offerings of other branded
manufacturers, private label brands and generic non-branded products or for
other reasons, significantly tighten product delivery windows or experience a
significant business disruption.
-- 8 of 242 --
4 The Procter & Gamble Company
If the reputation of the Company or one or more of our brands erodes
significantly, it could have a material impact on our financial results.
The Company's reputation, and the reputation of our brands, form the
foundation of our relationships with key stakeholders and other
constituencies, including consumers, customers and suppliers. The quality
and safety of our products are critical to our business. Many of our brands
have worldwide recognition and our financial success directly depends on the
success of our brands. The success of our brands can suffer if our marketing
plans or product initiatives do not have the desired impact on a brand's image
or its ability to attract consumers. Our results of operations or cash flows
could also be negatively impacted if one of our brands suffers substantial
harm to its reputation due to a significant product recall, product-related
litigation, defects or impurities in our products, product misuse, changing
consumer perceptions of certain ingredients or environmental impacts,
allegations of product tampering or the distribution and sale of counterfeit
products. Additionally, negative or inaccurate postings or comments on social
media or networking websites about the Company or one of its brands could
generate adverse publicity that could damage the reputation of our brands or
the Company. If we are unable to effectively manage real or perceived issues,
including concerns about safety, quality, ingredients, efficacy, environmental
impacts or similar matters, sentiments toward the Company or our products
could be negatively impacted, and our results of operations or cash flows
could suffer. Our Company also devotes time and resources to citizenship
efforts that are consistent with our corporate values and are designed to
strengthen our business and protect and preserve our reputation, including
programs driving ethics and corporate responsibility, strong communities,
diversity and inclusion, gender equality and environmental sustainability. If
these programs are not executed as planned or suffer negative publicity, the
Company's reputation and results of operations or cash flows could be
adversely impacted.
We rely on third parties in many aspects of our business, which creates
additional risk.
Due to the scale and scope of our business, we must rely on relationships with
third parties, including our suppliers, contract manufacturers, distributors,
contractors, commercial banks, joint venture partners and external business
partners, for certain functions. If we are unable to effectively manage our
third-party relationships and the agreements under which our third-party
partners operate, our results of operations and cash flows could be adversely
impacted. Further, failure of these third parties to meet their obligations to the
Company or substantial disruptions in the relationships between the Company
and these third parties could adversely impact our operations and financial
results. Additionally, while we have policies and procedures for managing
these relationships, they inherently involve a lesser degree of control over
business operations, governance and compliance, thereby potentially
increasing our financial, legal, reputational and operational risk.
A significant information security or operational technology incident,
including a cybersecurity breach, or the failure of one or more key
information or operations technology systems, networks, hardware,
processes, and/or associated sites owned or operated by the Company or
one of its service providers could have a material adverse impact on our
business or reputation.
We rely extensively on information and operational technology ("IT/OT")
systems, networks and services, including internet and intranet sites, data
hosting and processing facilities and technologies, physical security systems
and other hardware, software and technical applications and platforms, many
of which are managed, hosted, provided and/or used by third parties or their
vendors, to assist in conducting our business. The various uses of these IT/OT
systems, networks and services include, but are not limited to:
• ordering and managing materials from suppliers;
• converting materials to finished products;
• shipping products to customers;
• marketing and selling products to consumers;
• collecting, transferring, storing and/or processing customer, consumer,
employee, vendor, investor, and other stakeholder information and
personal data, including such data from persons covered by an expanding
landscape of privacy and data regulations, such as citizens of the
European Union who are covered by the General Data Protection
-- 9 of 242 --
Regulation (“GDPR”) or residents of California covered by the
California Consumer Privacy Act ("CCPA");
• summarizing and reporting results of operations, including financial
reporting;
• managing our banking and other cash liquidity systems and platforms;
• hosting, processing and sharing, as appropriate, confidential and
proprietary research, business plans and financial information;
• collaborating via an online and efficient means of global business
communications;
• complying with regulatory, legal and tax requirements;
• providing data security; and
• handling other processes necessary to manage our business.
Numerous and evolving information security threats, including advanced
persistent cybersecurity threats, pose a risk to the security of our services,
systems, networks and supply chain, as well as to the confidentiality,
availability and integrity of our data and of our critical business operations. In
addition, because the techniques, tools and tactics used in cyber-attacks
frequently change and may be difficult to detect for periods of time, we may
face difficulties in anticipating and implementing adequate preventative
measures or fully mitigating harms after such an attack.
-- 10 of 242 --
The Procter & Gamble Company 5
Our IT/OT databases and systems and our third-party providers’ databases
and systems have been, and will likely continue to be, subject to advanced
computer viruses or other malicious codes, ransomware, unauthorized access
attempts, denial of service attacks, phishing, social engineering, hacking and
other cyber-attacks. Such attacks may originate from outside parties, hackers,
criminal organizations or other threat actors, including nation states. In
addition, insider actors-malicious or otherwise-could cause technical
disruptions and/or confidential data leakage. We cannot guarantee that our
security efforts or the security efforts of our third-party providers will prevent
material breaches, operational incidents or other breakdowns to our or our
third-party providers’ IT/OT databases or systems.
If the IT/OT systems, networks or service providers we rely upon fail to
function properly or cause operational outages or aberrations, or if we or one
of our third-party providers suffer significant unavailability of key operations,
or inadvertent disclosure of, lack of integrity of, or loss of our sensitive
business or stakeholder information, due to any number of causes, ranging
from catastrophic events or power outages to improper data handling, security
incidents or employee error or malfeasance, and our business continuity plans
do not effectively address these failures on a timely basis, we may be exposed
to reputational, competitive, operational, financial and business harm as well
as litigation and regulatory action. Periodically, we also upgrade our IT/OT
systems or adopt new technologies. If such a new system or technology does
not function properly or otherwise exposes us to increased cybersecurity
breaches and failures, it could affect our ability to order materials, make and
ship orders, and process payments in addition to other operational and
information integrity and loss issues. The costs and operational consequences
of responding to the above items and implementing remediation measures
could be significant and could adversely impact our results of operations and
cash flows.
Changing political conditions could adversely impact our business and
financial results.
Changes in the political conditions in markets in which we manufacture, sell
or distribute our products may be difficult to predict and may adversely affect
our business and financial results. For example, the United Kingdom’s
withdrawal from the European Union ("Brexit") has created uncertainty
regarding, among other things, the U.K.'s future legal and economic
framework and how the U.K. will interact with other countries, including with
respect to the free movement of goods, services, capital and people. In
addition, results of elections, referendums or other political processes in
certain markets in which our products are manufactured, sold or distributed
could create uncertainty regarding how existing governmental policies, laws
and regulations may change, including with respect to sanctions, taxes, tariffs,
import and export controls and the general movement of goods, services,
capital and people between countries and other matters. The potential
implications of such uncertainty, which include, among others, exchange rate
fluctuations, new or increased tariffs, trade barriers and
market contraction, could adversely affect the Company’s results of
operations and cash flows.
We must successfully manage compliance with laws and regulations, as
well as manage new and pending legal and regulatory matters in the U.S.
and abroad.
Our business is subject to a wide variety of laws and regulations across the
countries in which we do business, including those laws and regulations
involving intellectual property, product liability, product composition or
formulation, packaging content or end-of-life responsibility, marketing,
antitrust, data protection, environmental (including increasing focus on the
climate, water, and waste impacts of consumer packaged goods companies'
operations and products), employment, anti-bribery, anti-corruption, tax,
accounting and financial reporting or other matters. Rapidly changing laws,
regulations, policies and related interpretations, as well as increased
enforcement actions, create challenges for the Company, including our
compliance and ethics programs, may alter the environment in which we do
business and may increase the ongoing costs of compliance, which could
adversely impact our results of operations and cash flows. If we are unable to
continue to meet these challenges and comply with all laws, regulations,
policies and related interpretations, it could negatively impact our reputation
and our business results. Failure to successfully manage regulatory and legal
matters and resolve such matters without significant liability or damage to our
-- 11 of 242 --
reputation may materially adversely impact our financial condition, results of
operations and cash flows. Furthermore, if pending legal or regulatory matters
result in fines or costs in excess of the amounts accrued to date, that may also
materially impact our results of operations and financial position.
Changes in applicable tax regulations and resolutions of tax disputes
could negatively affect our financial results.
The Company is subject to taxation in the U.S. and numerous foreign
jurisdictions. Changes in the various tax laws can and do occur. For example,
the U.S. government enacted comprehensive tax legislation commonly
referred to as the Tax Cuts and Jobs Act (the “U.S. Tax Act”). The changes
included in the U.S. Tax Act are broad and complex. The ongoing impacts of
the U.S. Tax Act may differ from the estimates provided elsewhere in the
reports we file with the Securities and Exchange Commission, possibly
materially, due to, among other things, changes in interpretations, any
regulatory guidance or legislative action to address questions that arise or any
updates or changes to estimates the Company has used to calculate the
impacts.
Additionally, longstanding international tax norms that determine each
country’s jurisdiction to tax cross-border international trade are subject to
potential evolution. An outgrowth of the original Base Erosion and Profit
Shifting (“BEPS") project is a project undertaken by the more than 130
member countries of the expanded OECD Inclusive Framework focused on
"Addressing the Challenges of the Digitalization of the Economy." The
breadth of this project extends beyond pure digital businesses and is likely to
-- 12 of 242 --
6 The Procter & Gamble Company
impact all multinational businesses by potentially redefining jurisdictional
taxation rights. As this and other tax laws and related regulations change or
evolve, our financial condition, results of operations and cash flows could be
materially impacted. Given the unpredictability of these possible changes, it is
very difficult to assess whether the overall effect of such potential tax changes
would be cumulatively positive or negative, but such changes could adversely
impact our results of operations and cash flows.
Furthermore, we are subject to regular review and audit by both foreign and
domestic tax authorities. While we believe our tax positions will be sustained,
the final outcome of tax audits and related litigation, including maintaining
our intended tax treatment of divestiture transactions such as the fiscal 2017
Beauty Brands transaction with Coty, may differ materially from the tax
amounts recorded in our Consolidated Financial Statements, which could
adversely impact our results of operations and cash flows.
We must successfully manage ongoing acquisition, joint venture and
divestiture activities.
As a company that manages a portfolio of consumer brands, our ongoing
business model includes a certain level of acquisition, joint venture and
divestiture activities. We must be able to successfully manage the impacts of
these activities, while at the same time delivering against our business
objectives. Specifically, our financial results have been, and in the future
could be, adversely impacted by the dilutive impacts from the loss of earnings
associated with divested brands or dissolution of joint ventures. Our results of
operations and cash flows have been and, in the future could also be,
impacted by acquisitions or joint venture activities, if: 1) changes in the cash
flows or other market-based assumptions cause the value of acquired assets to
fall below book value, or 2) we are not able to deliver the expected cost and
growth synergies associated with such acquisitions and joint ventures,
including as a result of integration and collaboration challenges, which could
also result in an impairment of goodwill and intangible assets.
Our business results depend on our ability to successfully manage
productivity improvements and ongoing organizational change, including
attracting and retaining key talent as part of our overall succession
planning.
Our financial projections assume certain ongoing productivity improvements
and cost savings, including staffing adjustments as well as employee
departures. Failure to deliver these planned productivity improvements and
cost savings, while continuing to invest in business growth, could adversely
impact our results of operations and cash flows. Additionally, successfully
executing organizational change, management transitions at leadership levels
of the Company and motivation and retention of key employees, is critical to
our business success. Factors that may affect our ability to attract and retain
sufficient numbers of qualified employees include employee morale, our
reputation, competition from other employers and availability of qualified
individuals. Our success depends on identifying, developing and retaining key
employees to provide uninterrupted leadership
and direction for our business. This includes developing and retaining
organizational capabilities in key growth markets where the depth of skilled
or experienced employees may be limited and competition for these resources
is intense, as well as continuing the development and execution of robust
leadership succession plans.
We must successfully manage the demand, supply, and operational
challenges associated with the actual or perceived effects of a disease
outbreak, including epidemics, pandemics, or similar widespread public
health concerns.
Our business may be negatively impacted by the fear of exposure to or actual
effects of a disease outbreak, epidemic, pandemic, or similar widespread
public health concern, such as travel restrictions or recommendations or
mandates from governmental authorities to avoid large gatherings or to self-
quarantine as a result of the novel coronavirus (COVID-19) pandemic. These
impacts include, but are not limited to:
• Significant reductions in demand or significant volatility in demand for
one or more of our products, which may be caused by, among other
things: the temporary inability of consumers to purchase our products
due to illness, quarantine or other travel restrictions, or financial
hardship, shifts in demand away from one or more of our more
discretionary or higher priced products to lower priced products, or
-- 13 of 242 --
stockpiling or similar pantry-loading activity. If prolonged, such impacts
can further increase the difficulty of business or operations planning and
may adversely impact our results of operations and cash flows;
• Inability to meet our customers’ needs and achieve cost targets due to
disruptions in our manufacturing and supply arrangements caused by
constrained workforce capacity or the loss or disruption of other essential
manufacturing and supply elements such as raw materials or other
finished product components, transportation, or other manufacturing and
distribution capability;
• Failure of third parties on which we rely, including our suppliers,
contract manufacturers, distributors, contractors, commercial banks, joint
venture partners and external business partners, to meet their obligations
to the Company, or significant disruptions in their ability to do so, which
may be caused by their own financial or operational difficulties and may
adversely impact our operations; or
• Significant changes in the political conditions in markets in which we
manufacture, sell or distribute our products, including quarantines,
import/export restrictions, price controls, or governmental or regulatory
actions, closures or other restrictions that limit or close our operating and
manufacturing facilities, restrict our employees’ ability to travel or
perform necessary business functions, or otherwise prevent our third-
party partners, suppliers, or customers from sufficiently staffing
operations, including operations necessary for the production,
distribution, sale, and support of our products, which
-- 14 of 242 --
The Procter & Gamble Company 7
could adversely impact our results of operations and cash flows.
Despite our efforts to manage and remedy these impacts to the Company,
their ultimate impact also depends on factors beyond our knowledge or
control, including the duration and severity of any such outbreak as well as
third-party actions taken to contain its spread and mitigate its public health
effects.
Item 1B. Unresolved Staff Comments.
None.
Item 2. Properties.
In the U.S., we own and operate 23 manufacturing sites located in 17 different
states. In addition, we own and operate 84 manufacturing sites in 37 other
countries. Many of the domestic and international sites manufacture products
for multiple businesses. Beauty products are manufactured at 24 of these
locations; Grooming products at 19; Health Care products at 21; Fabric &
Home Care products at 38; and Baby, Feminine & Family Care at 36. We
own our Corporate headquarters in Cincinnati, Ohio. We own or lease our
principal regional general offices in Switzerland, Panama, Singapore, China
and Dubai. We own or lease our principal regional shared service centers in
Costa Rica, the United Kingdom and the Philippines. Management believes
that the Company's sites are adequate to support the business and that the
properties and equipment have been well maintained.
Item 3. Legal Proceedings.
The Company is subject, from time to time, to certain legal proceedings and
claims arising out of our business, which cover a wide range of matters,
including antitrust and trade regulation, product liability, advertising,
contracts, environmental issues, patent and trademark matters, labor and
employment matters and tax. See Note 13 to our Consolidated Financial
Statements for information on certain legal proceedings for which there are
contingencies.
This item should be read in conjunction with the Company's Risk Factors in
Part I, Item 1A for additional information.
Item 4. Mine Safety Disclosure.
Not applicable.
-- 15 of 242 --
8 The Procter & Gamble Company
INFORMATION ABOUT OUR EXECUTIVE OFFICERS
The names, ages and positions held by the Executive Officers of the Company on August 6, 2020, are:
Name Position Age
First Elected to
Officer Position
David S. Taylor Chairman of the Board, President and Chief Executive Officer 62 2013a
Jon R. Moeller Vice Chairman, Chief Operating Officer and Chief Financial Officer 56 2009b
Steven D. Bishop Chief Executive Officer - Health Care 56 2016c
Gary A. Coombe Chief Executive Officer - Grooming 56 2014d
Mary Lynn Ferguson-McHugh Chief Executive Officer - Family Care and P&G Ventures 60 2016e
Ma. Fatima D. Francisco Chief Executive Officer - Baby and Feminine Care 52 2018f
Shailesh Jejurikar Chief Executive Officer - Fabric and Home Care 53 2018g
R. Alexandra Keith Chief Executive Officer - Beauty 52 2017h
Carolyn M. Tastad Group President - North America and Chief Sales Officer 59 2014i
M. Tracey Grabowski Chief Human Resources Officer 52 2018j
Kathleen B. Fish Chief Research, Development and Innovation Officer 63 2014
Deborah P. Majoras Chief Legal Officer and Secretary 56 2010
Marc S. Pritchard Chief Brand Officer 60 2008
Valarie L. Sheppard Controller and Treasurer and Group Vice President - Company
Transition Leader 56 2005
All the Executive Officers named above have been employed by the Company for more than the past five years.
aMr. Taylor previously served as Group President - Global Beauty, Grooming & Health Care (February - October 2015).
bMr. Moeller previously served as Vice Chairman and Chief Financial Officer (2017 - 2019) and as Chief Financial Officer (2009 - 2017).
cMr. Bishop previously served as Group President - Global Oral Care (January - October 2015).
dMr. Coombe previously served as President - Europe Selling & Market Operations (November 2014 - February 2018).
eMs. Ferguson-McHugh previously served as Group President - Global Family Care (2014-2015).
fMs. Francisco previously served as President - Global Feminine Care (November 2015 - August 2018) and as Vice President - Brand Franchise Leader, Feminine Care (January - October
2015).
gMr. Jejurikar previously served as President - Global Fabric Care and Brand-Building Officer Global Fabric & Home Care (November 2015 - July 2018) and as President - Fabric Care, North
America; Brand-Building Officer Fabric & Home Care New Business Creation (November 2014 - October 2015).
hMs. Keith previously served as President - Global Skin & Personal Care (November 2014 - June 2017).
iMs. Tastad previously served as Group President - North America Selling & Market Operations (January 2015 - May 2019).
jMs. Grabowski previously served as Vice President - Human Resources, North America Selling and Market Operations (April 2015 - July 2018).
-- 16 of 242 --
The Procter & Gamble Company 9
PART II
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
ISSUER PURCHASES OF EQUITY SECURITIES
Period
Total Number of
Shares Purchased
Average Price
Paid per Share
Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs (1)
Approximate Dollar Value of Shares that May
Yet Be Purchased Under Our Share
Repurchase Program
4/1/2020 - 4/30/2020 0 n/a 0 (1)
5/1/2020 - 5/31/2020 0 n/a 0 (1)
6/1/2020 - 6/30/2020 0 n/a 0 (1)
Total 0 n/a 0 (1)
(1) On April 17, 2020, the Company stated that in fiscal year 2020 the Company expected to reduce outstanding shares through direct share repurchases at a value of $7 to $8
billion, notwithstanding any purchases under the Company's compensation and benefit plans. The share repurchases were authorized pursuant to a resolution issued by the
Company's Board of Directors and were financed through a combination of operating cash flows and issuance of long-term and short-term debt. The total value of the shares
purchased under the share repurchase plan was $7.4 billion. The share repurchase plan ended on June 30, 2020.
Additional information required by this item can be found in Part III, Item 12 of this Form 10-K.
SHAREHOLDER RETURN PERFORMANCE GRAPHS
Market and Dividend Information
P&G has been paying a dividend for 130 consecutive years since its original incorporation in 1890 and has increased its dividend for 64 consecutive years.
Nevertheless, as in the past, further dividends will be considered after reviewing dividend yields, profitability and cash flow expectations and financing needs and
will be declared at the discretion of the Company's Board of Directors.
(in dollars; split-adjusted) 1956 1970 1980 1990 2000 2010 2020
Dividends per share $ 0.01 $ 0.04 $ 0.11 $ 0.22 $ 0.64 $ 1.80 $ 3.03
-- 17 of 242 --
10 The Procter & Gamble Company
Common Stock Information
P&G trades on the New York Stock Exchange under the stock symbol PG. As of June 30, 2020, there were approximately 4 million common stock shareowners,
including shareowners of record, participants in P&G stock ownership plans and beneficial owners with accounts at banks and brokerage firms.
Shareholder Return
The following graph compares the cumulative total return of P&G’s common stock for the five-year period ended June 30, 2020, against the cumulative total return
of the S&P 500 Stock Index (broad market comparison) and the S&P 500 Consumer Staples Index (line of business comparison). The graph and table assume $100
was invested on June 30, 2015, and that all dividends were reinvested.
Cumulative Value of $100 Investment, through June 30
Company Name/Index 2015 2016 2017 2018 2019 2020
P&G $ 100 $ 112 $ 119 $ 110 $ 160 $ 179
S&P 500 Stock Index 100 104 123 140 155 166
S&P 500 Consumer Staples Index 100 119 122 117 137 142
-- 18 of 242 --
The Procter & Gamble Company 11
Item 6. Selected Financial Data.
The information required by this item is incorporated by reference to Note 1 and Note 2 to our Consolidated Financial Statements. For further details behind the
business drivers for recent results presented below, see the Management's Discussion and Analysis.
Financial Summary (Unaudited)
Amounts in millions, except per share amounts 2020 2019 2018 2017 2016
Net sales $ 70,950 $ 67,684 $ 66,832 $ 65,058 $ 65,299
Gross profit 35,700 32,916 32,400 32,420 32,275
Operating income 15,706 5,487 13,363 13,766 13,258
Net earnings from continuing operations 13,103 3,966 9,861 10,194 10,027
Net earnings from discontinued operations — — — 5,217 577
Net earnings attributable to Procter & Gamble 13,027 3,897 9,750 15,326 10,508
Net earnings margin from continuing operations 18.5 % 5.9 % 14.8 % 15.7 % 15.4 %
Basic net earnings per common share: (1)
Earnings from continuing operations $ 5.13 $ 1.45 $ 3.75 $ 3.79 $ 3.59
Earnings from discontinued operations — — — 2.01 0.21
Basic net earnings per common share $ 5.13 $ 1.45 $ 3.75 $ 5.80 $ 3.80
Diluted net earnings per common share: (1)
Earnings from continuing operations $ 4.96 $ 1.43 $ 3.67 $ 3.69 $ 3.49
Earnings from discontinued operations — — — 1.90 0.20
Diluted net earnings per common share $ 4.96 $ 1.43 $ 3.67 $ 5.59 $ 3.69
Dividends per common share $ 3.03 $ 2.90 $ 2.79 $ 2.70 $ 2.66
Research and development expense $ 1,834 $ 1,861 $ 1,908 $ 1,874 $ 1,879
Advertising expense 7,326 6,751 7,103 7,118 7,243
Total assets 120,700 115,095 118,310 120,406 127,136
Capital expenditures 3,073 3,347 3,717 3,384 3,314
Long-term debt 23,537 20,395 20,863 18,038 18,945
Shareholders' equity $ 46,878 $ 47,579 $ 52,883 $ 55,778 $ 57,983
(1) Basic net earnings per common share and Diluted net earnings per common share are calculated based on Net earnings attributable to Procter & Gamble.
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Management's Discussion and Analysis
Forward-Looking Statements
Certain statements in this report, other than purely historical information,
including estimates, projections, statements relating to our business plans,
objectives, and expected operating results, and the assumptions upon which
those statements are based, are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. Forward-looking statements may appear throughout this report,
including without limitation, the following sections: “Management's
Discussion and Analysis,” “Risk Factors” and "Notes 4 and 13 to the
Consolidated Financial Statements." These forward-looking statements
generally
are identified by the words “believe,” “project,” “expect,” “anticipate,”
“estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,”
“should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and
similar expressions. Forward-looking statements are based on current
expectations and assumptions, which are subject to risks and uncertainties
that may cause results to differ materially from those expressed or implied in
the forward-looking statements. We undertake no obligation to update or
revise publicly any forward-looking statements, whether because of new
information, future events or otherwise, except to the extent required by law.
Risks and uncertainties to which our forward-looking statements are subject
include, without limitation: (1) the ability to successfully manage global
-- 19 of 242 --
financial risks,
-- 20 of 242 --
12 The Procter & Gamble Company
including foreign currency fluctuations, currency exchange or pricing controls
and localized volatility; (2) the ability to successfully manage local, regional
or global economic volatility, including reduced market growth rates, and to
generate sufficient income and cash flow to allow the Company to effect the
expected share repurchases and dividend payments; (3) the ability to manage
disruptions in credit markets or changes to our credit rating; (4) the ability to
maintain key manufacturing and supply arrangements (including execution of
supply chain optimizations and sole supplier and sole manufacturing plant
arrangements) and to manage disruption of business due to factors outside of
our control, such as natural disasters, acts of war or terrorism, or disease
outbreaks; (5) the ability to successfully manage cost fluctuations and
pressures, including prices of commodities and raw materials, and costs of
labor, transportation, energy, pension and healthcare; (6) the ability to stay on
the leading edge of innovation, obtain necessary intellectual property
protections and successfully respond to changing consumer habits and
technological advances attained by, and patents granted to, competitors; (7)
the ability to compete with our local and global competitors in new and
existing sales channels, including by successfully responding to competitive
factors such as prices, promotional incentives and trade terms for products;
(8) the ability to manage and maintain key customer relationships; (9) the
ability to protect our reputation and brand equity by successfully managing
real or perceived issues, including concerns about safety, quality, ingredients,
efficacy or similar matters that may arise; (10) the ability to successfully
manage the financial, legal, reputational and operational risk associated with
third-party relationships, such as our suppliers, contract manufacturers,
distributors, contractors and external business partners; (11) the ability to rely
on and maintain key company and third party information and operational
technology systems, networks and services, and maintain the security and
functionality of such systems, networks and services and the data contained
therein; (12) the ability to successfully manage uncertainties related to
changing political conditions (including the United Kingdom’s exit from the
European Union) and potential implications such as exchange rate
fluctuations and market contraction; (13) the ability to successfully manage
regulatory and legal requirements and matters (including, without limitation,
those laws and regulations involving product liability, product and packaging
composition, intellectual property, labor and employment, antitrust, data
protection, tax, environmental, and accounting and financial reporting) and to
resolve pending matters within current estimates; (14) the ability to manage
changes in applicable tax laws and regulations including maintaining our
intended tax treatment of divestiture transactions; (15) the ability to
successfully manage our ongoing acquisition, divestiture and joint venture
activities, in each case to achieve the Company’s overall business strategy
and financial objectives, without impacting the delivery of base business
objectives; (16) the ability to successfully achieve productivity improvements
and cost savings and manage ongoing organizational changes, while
successfully identifying, developing and
retaining key employees, including in key growth markets where the
availability of skilled or experienced employees may be limited; and (17) the
ability to successfully manage the demand, supply, and operational challenges
associated with a disease outbreak, including epidemics, pandemics, or
similar widespread public health concerns (including the novel coronavirus,
COVID-19, outbreak). A detailed discussion of risks and uncertainties that
could cause actual results and events to differ materially from those projected
herein, is included in the section titled "Economic Conditions and
Uncertainties" and the section titled "Risk Factors" (Part I, Item 1A) of this
Form 10-K.
The purpose of Management's Discussion and Analysis (MD&A) is to
provide an understanding of Procter & Gamble's financial condition, results
of operations and cash flows by focusing on changes in certain key measures
from year to year. The MD&A is provided as a supplement to, and should be
read in conjunction with, our Consolidated Financial Statements and
accompanying Notes. The MD&A is organized in the following sections:
• Overview
• Summary of 2020 Results
• Economic Conditions and Uncertainties
• Results of Operations
• Segment Results
-- 21 of 242 --
• Cash Flow, Financial Condition and Liquidity
• Significant Accounting Policies and Estimates
• Other Information
Throughout the MD&A we refer to measures used by management to
evaluate performance, including unit volume growth, net sales and net
earnings. We also refer to a number of financial measures that are not defined
under accounting principles generally accepted in the United States of
America (U.S. GAAP), consisting of organic sales growth, core earnings per
share (Core EPS), adjusted free cash flow and adjusted free cash flow
productivity. Organic sales growth is net sales growth excluding the impacts
of acquisitions, divestitures and foreign exchange from year-over-year
comparisons. Core EPS is diluted net earnings per share from continuing
operations excluding certain items that are not judged to be part of the
Company's sustainable results or trends. Adjusted free cash flow is operating
cash flow less capital spending, transitional tax payments related to the U.S.
Tax Act and tax payments related to the Merck OTC consumer healthcare
acquisition. Adjusted free cash flow productivity is the ratio of adjusted free
cash flow to net earnings. We believe these measures provide our investors
with additional information about our underlying results and trends, as well as
insight to some of the metrics used to evaluate management. The explanation
at the end of the MD&A provides more details on the use and the derivation
of these measures, as well as reconciliations to the most directly comparable
U.S. GAAP measures.
Management also uses certain market share and market consumption
estimates to evaluate performance relative to competition despite some
limitations on the availability and
-- 22 of 242 --
The Procter & Gamble Company 13
comparability of share and consumption information. References to market
share and consumption in the MD&A are based on a combination of vendor
purchased traditional brick-and-mortar and online data in key markets as well
as internal estimates. All market share references represent the percentage of
sales of our products in dollar terms on a constant currency basis, relative to
all product sales in the category. The Company measures fiscal-year-to-date
market shares through the most recent period for which market share data is
available, which typically reflects a lag time of one or two months as
compared to the end of the reporting period. Management also uses unit
volume growth to evaluate and explain drivers of changes in net sales.
Organic volume growth reflects year-over-year changes in unit volume
excluding the impacts of acquisitions and divestitures and certain one-time
items, if applicable, and is used to explain changes in organic sales.
OVERVIEW
Procter & Gamble is a global leader in the fast-moving consumer goods
industry, focused on providing branded consumer packaged goods of superior
quality and value to
our consumers around the world. Our products are sold in more than 180
countries and territories primarily through mass merchandisers, e-commerce,
grocery stores, membership club stores, drug stores, department stores,
distributors, wholesalers, baby stores, specialty beauty stores (including
airport duty-free stores), high-frequency stores, pharmacies, electronics stores
and professional channels. We also sell direct to consumers. We have on-the-
ground operations in approximately 70 countries.
Our market environment is highly competitive with global, regional and local
competitors. In many of the markets and industry segments in which we sell
our products, we compete against other branded products, as well as retailers'
private-label brands. Additionally, many of the product segments in which we
compete are differentiated by price tiers (referred to as super-premium,
premium, mid-tier and value-tier products). We believe we are well
positioned in the industry segments and markets in which we operate, often
holding a leadership or significant market share position.
ORGANIZATIONAL STRUCTURE
In fiscal 2020, our organizational structure was comprised of Sector Business Units (SBUs), Enterprise Markets (EMs), Corporate Functions (CF) and Global
Business Services (GBS).
Sector Business Units
Our SBUs are organized into ten product categories. Under U.S. GAAP, the SBUs underlying the ten product categories are aggregated into five reportable
segments: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The SBUs are responsible for developing overall brand
strategy, new product upgrades and innovations and marketing plans. The following provides additional detail on our reportable segments and the ten product
categories and brand composition within each segment.
Reportable Segments % of
Net Sales (1) % of Net
Earnings (1) Product Categories (Sub-Categories) Major Brands
Beauty 19% 21%
Hair Care (Conditioner, Shampoo, Styling Aids, Treatments) Head & Shoulders, Herbal
Essences, Pantene, Rejoice
Skin and Personal Care (Antiperspirant and Deodorant, Personal
Cleansing, Skin Care)
Olay, Old Spice, Safeguard,
Secret, SK-II
Grooming 9% 10% Grooming (2) (Shave Care - Female Blades & Razors, Male Blades &
Razors, Pre- and Post-Shave Products, Other Shave Care; Appliances) Braun, Gillette, Venus
Health Care 13% 12%
Oral Care (Toothbrushes, Toothpaste, Other Oral Care) Crest, Oral-B
Personal Health Care (Gastrointestinal, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Pain Relief, Other Personal Health
Care)
Metamucil, Neurobion, Pepto-
Bismol, Vicks
Fabric & Home Care 33% 31%
Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents) Ariel, Downy, Gain, Tide
Home Care (Air Care, Dish Care, P&G Professional, Surface Care) Cascade, Dawn, Fairy, Febreze,
Mr. Clean, Swiffer
Baby, Feminine &
Family Care 26% 26%
Baby Care (Baby Wipes, Taped Diapers and Pants) Luvs, Pampers
Feminine Care (Adult Incontinence, Feminine Care) Always, Always Discreet, Tampax
Family Care (Paper Towels, Tissues, Toilet Paper) Bounty, Charmin, Puffs
(1) Percent of Net sales and Net earnings from continuing operations for the year ended June 30, 2020 (excluding results held in Corporate).
(2) The Grooming product category is comprised of the Shave Care and Appliances operating segments.
-- 23 of 242 --
-- 24 of 242 --
14 The Procter & Gamble Company
Recent Developments:
During fiscal 2019, the Company completed the acquisition of the over-the-
counter (OTC) healthcare business of Merck KGaA (Merck OTC) for $3.7
billion (based on exchange rates at the time of closing). This business
primarily sells OTC consumer healthcare products, mainly in markets in
Europe, Latin America and Asia. Total sales for the business during Merck
OTC's fiscal year ended December 31, 2017 were approximately $1 billion.
Refer to Note 14 to our Consolidated Financial Statements for more details on
this transaction.
During fiscal 2019, the Company also dissolved our PGT Healthcare
partnership, a venture between the Company and Teva Pharmaceutical
Industries, Ltd (Teva) in the OTC consumer healthcare business. Pursuant to
the agreement, PGT product assets were returned to the original respective
parent companies to reestablish independent OTC businesses. This transaction
was accounted for as a sale of the Teva portion of the PGT business. The
Company recorded an after-tax gain on the sale of $353 million.
Organization Design Changes:
The Company implemented changes to our organization design effective July
1, 2019. In the new design, the ten product categories were organized into six
SBUs. The SBUs are responsible for global brand strategy, innovation and
supply chain. They have direct profit responsibility for markets representing
the large majority of the Company's sales and earnings (referred to as Focus
Markets) and are responsible for innovation plans, supply plans and operating
frameworks to drive growth and value creation in the remaining markets
(referred to as Enterprise Markets). For segment reporting purposes, the
product categories continue to be aggregated into the same five external
reporting segments. Throughout the MD&A, we reference business results by
region, which are comprised of North America, Europe, Greater China, Latin
America, Asia Pacific and India, Middle East and Africa (IMEA).
Beauty: We are a global market leader in the beauty category. Most of the
beauty markets in which we compete are highly fragmented with a large
number of global and local competitors. We compete in skin and personal
care and in hair care. In skin and personal care, we offer a wide variety of
products, ranging from deodorants to personal cleansing to skin care, such as
our Olay brand, which is one of the top facial skin care brands in the world
with approximately 6% global market share. We are the global market leader
in the retail hair care market with over 20% global market share primarily
behind our Pantene and Head & Shoulders brands.
Grooming: We compete in shave care and appliances. In shave care, we are
the global market leader in the blades and razors market. Our global blades
and razors market share is over 60%, primarily behind our Gillette and Venus
brands. Our appliances, such as electric shavers and epilators, are sold under
the Braun brand in a number of markets around the world where we compete
against both global and regional competitors. We hold nearly 25% of the male
electric shavers market and over 50% of the female epilators market.
Health Care: We compete in oral care and personal health care. In oral care,
there are several global competitors in the market and we have the number
two market share position with nearly 20% global market share behind our
Crest and Oral-B brands. In personal health care, we are a top ten competitor
in a large, highly fragmented industry, primarily behind respiratory treatments
(Vicks brand) and digestive wellness products (Metamucil, Pepto Bismol and
Align brands). As discussed earlier, in fiscal 2019, we dissolved the PGT
Healthcare partnership with Teva, which previously managed nearly all of our
personal health care sales outside the U.S., and reestablished an independent
OTC business. We also acquired Merck OTC as discussed above.
Fabric & Home Care: This segment is comprised of a variety of fabric care
products, including laundry detergents, additives and fabric enhancers; and
home care products, including dishwashing liquids and detergents, surface
cleaners and air fresheners. In fabric care, we generally have the number one
or number two market share position in the markets in which we compete and
are the global market leader with over 25% global market share, primarily
behind our Tide, Ariel and Downy brands. Our global home care market share
is approximately 25% across the categories in which we compete primarily
behind our Cascade, Dawn, Febreze and Swiffer brands.
Baby, Feminine & Family Care: In baby care, we are the global market
leader and compete mainly in taped diapers, pants and baby wipes with nearly
25% global market share. We have the number one or number two market
-- 25 of 242 --
share position in most of the key markets in which we compete, primarily
behind Pampers, the Company's largest brand, with annual net sales of over
$7 billion. We are the global market leader in the feminine care category with
25% global market share, primarily behind our Always and Tampax brands.
We also compete in the adult incontinence category in certain markets behind
Always Discreet, achieving nearly 10% market share in most of the key
markets in which we compete. Our family care business is predominantly a
North American business comprised primarily of the Bounty paper towel and
Charmin toilet paper brands. U.S. market shares are over 40% for Bounty and
over 25% for Charmin.
Enterprise Markets
As a result of the changes in our organization design effective July 1, 2019,
EMs are responsible for sales and profit delivery in specific countries,
supported by SBU agreed innovation and supply chain plans, along with
scaled services like planning, distribution and customer management.
Corporate Functions
CF provides company-level strategy and portfolio analysis, corporate
accounting, treasury, tax, external relations, governance, human resources and
legal services.
-- 26 of 242 --
The Procter & Gamble Company 15
Global Business Services
GBS provides technology, processes and standard data tools to enable the
SBUs, the EMs and CF to better understand the business and better serve
consumers and customers. The GBS organization is responsible for providing
world-class solutions at a low cost and with minimal capital investment.
STRATEGIC FOCUS
Procter & Gamble aspires to serve the world’s consumers better than our best
competitors in every category and in every country in which we compete,
and, as a result, deliver total shareholder return in the top one-third of our
peer group. Delivering and sustaining leadership levels of shareholder value
creation requires balanced top- and bottom-line growth and strong cash
generation.
The Company has undertaken an effort to focus and strengthen its business
portfolio to compete in categories and with brands that are structurally
attractive and that play to P&G's strengths. The ongoing portfolio of
businesses consists of ten product categories where P&G has leading market
positions, strong brands and consumer-meaningful product technologies.
Within these categories, our strategic choices are focused on winning with
consumers. The consumers who purchase and use our products are at the
center of everything we do. We win with consumers by delivering superiority
across the five key elements of product, packaging, brand communication,
retail execution and value equation. Winning with consumers around the
world and against our best competitors requires innovation. Innovation has
always been, and continues to be, P&G’s lifeblood. Innovation requires
consumer insights and technology advancements that lead to product
improvements, improved marketing and merchandising programs and game-
changing inventions that create new brands and categories.
Productivity improvement is critical to delivering our balanced top- and
bottom-line growth and value creation
objectives. Productivity improvement and sales growth reinforce and fuel
each other. Our objective is to drive productivity improvement across all
elements of cost, including cost of goods sold, marketing and promotional
spending and non-manufacturing overhead. We plan to reinvest productivity
improvements and cost savings in product and packaging improvements,
brand awareness-building advertising and trial-building sampling programs,
increased sales coverage and R&D programs as well as to offset cost
increases (including commodity and foreign exchange impacts) and improve
operating margins.
We are constructively disrupting our industry and the way we do business,
including how we innovate, communicate and leverage new technologies, to
create more value.
We are improving operational effectiveness and organizational culture
through enhanced clarity of roles and responsibilities, accountability and
incentive compensation programs.
We believe these strategies are right for the long-term health of the Company
and our objective of delivering total shareholder return in the top one-third of
our peer group.
The Company expects the delivery of the following long-term annual
financial targets will result in total shareholder returns in the top third of the
competitive fast-moving consumer goods peer group:
• Organic sales growth above market growth rates in the categories and
geographies in which we compete;
• Core earnings per share (EPS) growth of mid-to-high single digits; and
• Adjusted free cash flow productivity of 90% or greater.
In periods with significant macroeconomic pressures, such as the current
COVID-19 pandemic, we intend to maintain a disciplined approach to
investing so as not to sacrifice the long-term health of our businesses to meet
short-term objectives in any given year.
SUMMARY OF 2020 RESULTS
Amounts in millions, except per share amounts 2020 2019 Change vs. Prior Year
Net sales $ 70,950 $ 67,684 5 %
Operating income 15,706 5,487 186 %
Net earnings 13,103 3,966 230 %
-- 27 of 242 --
Net earnings attributable to Procter & Gamble 13,027 3,897 234 %
Diluted net earnings per common share 4.96 1.43 247 %
Core earnings per share 5.12 4.52 13 %
Cash flow from operating activities 17,403 15,242 14 %
• Net sales increased 5% to $71.0 billion on a 4% increase in unit volume.
Foreign exchange had a negative 2% impact on net sales. Net sales
growth was driven by a double digit increase in Health Care, a high
single digit increase in Fabric & Home Care, a mid-single digit increase
in Beauty and a low single digit increase in Baby, Feminine & Family
Care. Grooming net sales
decreased low single digits. Organic sales increased 6% on a 4% increase
in organic volume. Organic sales increased high single digits in Health
Care and in Fabric & Home Care, increased mid-single digits in Beauty
and in Baby, Feminine & Family Care and increased low single digits in
Grooming.
-- 28 of 242 --
16 The Procter & Gamble Company
• Operating income increased $10.2 billion, or 186% versus year ago, due
primarily to the $8.3 billion base period non-cash impairment charges
related to Shave Care goodwill and Gillette indefinite-lived intangible
assets (Shave Care impairment). The remaining $1.9 billion increase was
driven by the net sales increase and an increase in operating margin.
• Net earnings increased $9.1 billion or 230% versus year ago, due to the
aforementioned items and a reduction in current year effective tax rates,
partially offset by the base period gain on the dissolution of the PGT
Healthcare partnership and other minor divestitures. Foreign exchange
impacts negatively affected net earnings by approximately $390 million.
• Net earnings attributable to Procter & Gamble were $13.0 billion, an
increase of $9.1 billion or 234% versus the prior year primarily due to the
aforementioned items.
• Diluted net earnings per share (EPS) increased 247% to $4.96.
◦ Core EPS increased 13% to $5.12.
• Cash flow from operating activities was $17.4 billion.
◦ Adjusted free cash flow was $14.9 billion.
◦ Adjusted free cash flow productivity was 114%.
ECONOMIC CONDITIONS AND UNCERTAINTIES
We discuss expectations regarding future performance, events and outcomes,
such as our business outlook and objectives, in annual and quarterly reports,
press releases and other written and oral communications. All such
statements, except for historical and present factual information, are
"forward-looking statements" and are based on financial data and our
business plans available only as of the time the statements are made, which
may become out-of-date or incomplete. We assume no obligation to update
any forward-looking statements as a result of new information, future events
or other factors, except as required by law. Forward-looking statements are
inherently uncertain and investors must recognize that events could be
significantly different from our expectations. For more information on risk
factors that could impact our results, please refer to “Risk Factors” in Part I,
Item 1A of this Form 10-K.
Global Economic Conditions. Our products are sold in numerous countries
across North America, Europe, Latin America, Asia and Africa, with more
than half our sales generated outside the United States. As such, we are
exposed to and impacted by global macro-economic factors, U.S. and foreign
government policies and foreign exchange fluctuations. Current global
economic conditions are highly volatile due to the COVID-19 pandemic,
resulting in both market size contractions in certain countries due to economic
slowdowns and government restrictions on movement, as well as market size
increases in certain countries due to pantry loading and increased
consumption of household cleaning and personal health and hygiene products
by consumers. Other macro-economic factors also remain dynamic, and any
causes of market size contraction, such as
reduced GDP in commodity-dependent economies, greater political unrest or
instability in the Middle East, Central & Eastern Europe, certain Latin
American markets, the Hong Kong market in Greater China and the Korean
peninsula and economic uncertainty related to the United Kingdom's exit
from the European Union, could reduce our sales or erode our operating
margin, in either case reducing our net earnings and cash flows.
Changes in Costs. Our costs are subject to fluctuations, particularly due to
changes in commodity prices, transportation costs and our own productivity
efforts. We have significant exposures to certain commodities, in particular
certain oil-derived materials like resins and paper-based materials like pulp,
and volatility in the market price of these commodity input materials has a
direct impact on our costs. Disruptions in our manufacturing, supply and
distribution operations due to the COVID-19 pandemic may also impact our
costs. If we are unable to manage these impacts through pricing actions, cost
savings projects and sourcing decisions, as well as through consistent
productivity improvements, it may adversely impact our gross margin,
operating margin, net earnings and cash flows. Sales could also be adversely
impacted following pricing actions if there is a negative impact on
consumption of our products. We strive to implement, achieve and sustain
cost improvement plans, including outsourcing projects, supply chain
optimization and general overhead and workforce optimization. As discussed
-- 29 of 242 --
later in the MD&A, in 2012 we initiated overhead and supply chain cost
improvement projects. In fiscal 2017, we communicated specific elements of
an additional multi-year cost reduction program which is resulting in targeted
enrollment reductions and other savings. If we are not successful in executing
and sustaining these changes, there could be a negative impact on our gross
margin, operating margin, net earnings and cash flows.
Foreign Exchange. We have both translation and transaction exposure to the
fluctuation of exchange rates. Translation exposures relate to exchange rate
impacts of measuring income statements of foreign subsidiaries that do not
use the U.S. dollar as their functional currency. Transaction exposures relate
to 1) the impact from input costs that are denominated in a currency other
than the local reporting currency and 2) the revaluation of transaction-related
working capital balances denominated in currencies other than the functional
currency. In four of the past five years, including fiscal 2020, the U.S. dollar
has strengthened versus a number of foreign currencies, leading to lower sales
and earnings from these foreign exchange impacts. Certain countries
experiencing significant exchange rate fluctuations, like Argentina, Brazil,
Greater China, Turkey and the United Kingdom have had, and could continue
to have, a significant impact on our sales, costs and net earnings. Increased
pricing in response to certain fluctuations in foreign currency exchange rates
may offset portions of the currency impacts but could also have a negative
impact on consumption of our products, which would affect our sales, gross
margin, operating margin, net earnings and cash flows.
-- 30 of 242 --
The Procter & Gamble Company 17
Government Policies. Our net earnings could be affected by changes in U.S.
or foreign government tax policies, for example, the U.S. Tax Act, and the
current work being led by the OECD for the G20 focused on "Addressing the
Challenges of the Digitalization of the Economy." The breadth of this project
extends beyond pure digital businesses and is likely to impact all
multinational businesses by redefining jurisdictional taxation rights. Further,
our sales, net earnings and cash flows may be impacted by U.S. and foreign
government policies to manage the COVID-19 pandemic, such as movement
restrictions or site closures. Additionally, we attempt to carefully manage our
debt, currency and other exposures in certain countries with currency
exchange, import authorization and pricing controls, such as Nigeria, Algeria,
Egypt, Argentina and Turkey. Further, our sales, net earnings and cash flows
could be affected by changes to international trade agreements in North
America and elsewhere, including increases of import tariffs, both currently
effective and future potential changes. Changes in government policies in
these areas might cause an increase or decrease in our sales, gross margin,
operating margin, net earnings and cash flows.
COVID-19 Pandemic disclosures
The Company’s priorities during the COVID-19 pandemic are protecting the
health and safety of our employees; maximizing the availability of products
that help consumers with their health, hygiene and cleaning needs; and using
our employees’ talents and our resources to help society meet and overcome
the current challenges. Because the Company sells products that are essential
to the daily lives of consumers, the COVID-19 pandemic has not had a
material net impact to our consolidated sales, net earnings and cash flows in
the current year. However, the pandemic has had offsetting impacts during the
period. For example, during the second half of fiscal 2020 we experienced a
significant increase in demand and consumption of certain of our product
categories (health, hygiene and home cleaning products) primarily in North
America, caused in part by changing consumer habits and pantry stocking,
due to the COVID-19 pandemic, contributing to increases in sales, net
earnings and cash flows. At the same time, we experienced a decrease in sales
due to the economic slowdown and restricted consumer movements in certain
regions, including Europe, IMEA, Asia Pacific and Latin America, in certain
channels, including travel retail, professional and electronics stores, and in
certain of our beauty and grooming products. While we experienced a
decrease in sales in Greater China during the third quarter of fiscal 2020,
demand recovered in the fourth quarter as restrictions on consumer movement
were relaxed. In the future, the pandemic may cause reduced demand for our
products if it results in a recessionary global economic environment. Demand
in certain of our Enterprise Markets, including certain countries in Latin
America, Asia Pacific, and IMEA may be particularly susceptible to
recession. It could also lead to volatility in consumer access to our products
due to government actions impacting our ability to produce and ship products
or impacting
consumers’ movements and access to our products. We believe that over the
long term, there will continue to be strong demand for categories in which we
operate, particularly our products that deliver essential health, hygiene and
cleaning benefits. However, the timing and extent of demand recovery in
markets such as Greater China and Japan, the resumption of international
travel, the timing and impact of potential consumer pantry destocking in
markets including North America and Europe, and product demand volatility
caused by future economic trends are unclear. Accordingly, there may be
heightened volatility in sales, net earnings and cash flows during and
subsequent to the duration of the pandemic. Our retail customers are also
being impacted by the pandemic. Their success in addressing the issues and
maintaining their operations could impact consumer access to, and as a result,
sales of our products.
Our ability to continue to operate without any significant negative impacts
will in part depend on our ability to protect our employees and our supply
chain. The Company has endeavored to follow actions recommended by
governments and health authorities to protect our employees world-wide, with
particular measures in place for those working in our plants and distribution
facilities. We have also worked closely with local and national officials to
keep our manufacturing facilities open due to the essential nature of the
majority our products. We were able to broadly maintain our operations in the
current fiscal year, but we have experienced some disruption in our supply
chain in certain Enterprise Markets due primarily to the restriction of
-- 31 of 242 --
employee movements as well as increased transportation and manufacturing
costs. We intend to continue to work with government authorities and
implement our employee safety measures to ensure that we are able to
continue manufacturing and distributing our products during the pandemic.
However, uncertainty resulting from the pandemic could result in an
unforeseen disruption to our supply chain (for example a closure of a key
manufacturing or distribution facility or the inability of a key material or
transportation supplier to source and transport materials) that could impact
our operations.
Because the pandemic has not had a material negative impact on our
operations or demand for our products and resulting sales and net earnings, it
has also not negatively impacted the Company’s liquidity position. We
continue to generate operating cash flows to meet our short-term liquidity
needs, and we expect to maintain access to the capital markets enabled by our
strong short- and long-term credit ratings. We have also not observed any
material impairments of our assets or a significant change in the fair value of
assets due to the COVID-19 pandemic.
For additional information on risk factors that could impact our results, please
refer to “Risk Factors” in Part I, Item 1A of this Form 10-K.
-- 32 of 242 --
18 The Procter & Gamble Company
RESULTS OF OPERATIONS
The key metrics included in the discussion of our consolidated results of
operations include net sales, gross margin, selling, general and administrative
costs (SG&A), other non-operating items and income taxes. The primary
factors driving year-over-year changes in net sales include overall market
growth in the categories in which we compete, product initiatives,
competitive activities (the level of initiatives, pricing and other activities by
competitors), marketing spending, retail executions (both in-store and online),
and acquisition and divestiture activity, all of which drive changes in our
underlying unit volume, as well as our pricing actions (which can also impact
volume), changes in product and geographic mix and foreign currency
impacts on sales outside the U.S.
Most of our cost of products sold and SG&A are to some extent variable in
nature. Accordingly, our discussion of these operating costs focuses primarily
on relative margins rather than the absolute year-over-year changes in total
costs. The primary drivers of changes in gross margin are input costs (energy
and other commodities), pricing impacts, geographic mix (for example, gross
margins in North America are generally higher than the Company average for
similar products), product mix (for example, the Beauty segment has higher
gross margins than the Company average), foreign exchange rate fluctuations
(in situations where certain input costs may be tied to a different functional
currency than the underlying sales), the impacts of manufacturing savings
projects and reinvestments (for example, product or package improvements)
and to a lesser extent scale impacts (for costs that are fixed or less variable in
nature). The primary components of SG&A are marketing-related costs and
non-manufacturing overhead costs. Marketing-related costs are primarily
variable in nature, although we may achieve some level of scale benefit
over time due to overall growth and other marketing efficiencies. While
overhead costs are variable to some extent, we generally experience more
scale-related impacts
for these costs due to our ability to leverage our organization and systems'
infrastructures to support business growth.
For a detailed discussion of the fiscal 2019 year over year changes, please
refer to the MD&A in Part II, Item 7 of the Company's Form 10-K for the
fiscal year ended June 30, 2019.
Net Sales
Net sales increased 5% to $71.0 billion in fiscal 2020 on a 4% increase in unit
volume versus the prior year. Volume increased double digits in Health Care,
increased mid-single digits in Fabric & Home Care and increased low single
digits in Beauty and Baby, Feminine & Family Care. Volume decreased low
single digits in Grooming. Excluding the impacts of acquisitions and
divestitures, including the Merck OTC acquisition, organic volume increased
mid-single digits in Health Care and increased high single digits in Fabric &
Home Care.
On a regional basis, volume increased high single digits in North America and
increased low single digits in Greater China, Europe, Asia Pacific and Latin
America driven by innovation, market growth and increased demand,
particularly in household cleaning and personal health and hygiene products
in the second half of the fiscal year, driven in part by increased consumption
and pantry loading due to the COVID-19 pandemic. Volume decreased low
single digits in IMEA as growth in the first half of the year was more than
offset by market contraction in the second half of the fiscal year driven by
economic slowdown resulting from the COVID-19 pandemic. Unfavorable
foreign exchange reduced net sales by 2%. Increased pricing had a positive
1% impact on net sales. Mix had a positive 1% impact on net sales driven by
the disproportionate organic growth of the Personal Health Care and Home
Care categories and the North America region, all of which have higher than
company average selling prices. Organic sales grew 6% on a 4% increase in
organic volume.
Operating Costs
Comparisons as a percentage of net sales; Years ended June 30 2020 2019
Basis Point
Change
-- 33 of 242 --
Gross margin 50.3 % 48.6 % 170
Selling, general and administrative expense 28.2 % 28.2 % —
Operating margin 22.1 % 8.1 % 1,400
Earnings before income taxes 22.3 % 9.0 % 1,330
Net earnings 18.5 % 5.9 % 1,260
Net earnings attributable to Procter & Gamble 18.4 % 5.8 % 1,260
Gross margin increased 170 basis points to 50.3% of net sales in fiscal 2020.
Gross margin benefited from:
• 150 basis points from total manufacturing cost savings (130 basis
points net of product and packaging reinvestments),
• 90 basis points from lower commodity costs and
• 60 basis points of positive pricing impacts.
These were offset by a 70 basis-point decline from unfavorable product mix
(due to the disproportionate organic
-- 34 of 242 --
The Procter & Gamble Company 19
growth of the Fabric & Home Care segment which has lower than company
average gross margin and mix within segments due to the growth of lower
margin product forms and larger sizes in certain categories), a 20 basis-point
negative impact from unfavorable foreign exchange and 20 basis points of
other impacts.
Total SG&A increased 5% to $20.0 billion, primarily due to increases in
marketing spending and, to a lesser extent, increases in other net operating
expenses and overhead costs. SG&A as a percentage of net sales was
unchanged at 28.2%. An increase in marketing spending and other net
operating expenses as a percentage of net sales was offset by a decrease in
overhead costs as a percentage of net sales.
• Marketing spending as a percentage of net sales increased 10 basis points
due to investments in media and other marketing spending, partially
offset by the positive scale impacts of the net sales increase and savings
in agency compensation, production costs and advertising spending.
• Overhead costs as a percentage of net sales decreased 40 basis points due
to the positive scale impacts of the net sales increase and productivity
savings, partially offset by inflation and other cost increases.
• Other net operating expenses as a percentage of net sales increased
approximately 30 basis points primarily due to the base period gain on
sale of real estate.
Operating margin increased 1,400 basis points to 22.1% for fiscal 2020. 1,230
basis points of this increase is due to the Shave Care impairment charge in the
base period. The remaining increase is due to the increase in gross margin as
discussed above.
Non-Operating Items
• Interest expense was $465 million in fiscal 2020, a decrease of $44
million versus the prior year due primarily to a reduction in U.S. interest
rates, partially offset by an increase in debt.
• Interest income was $155 million in fiscal 2020, a reduction of $65
million versus the prior year due to a reduction in average cash and
investment securities balances and a reduction in U.S. interest rates.
• Other non-operating income, which consists primarily of divestiture
gains and other non-operating items decreased $433 million to $438
million, primarily due to the base period gains from brand divestitures
including a $355 million before-tax gain from the dissolution of the PGT
Healthcare partnership.
Income Taxes
Income taxes increased $628 million to $2.7 billion due to increased earnings,
partially offset by a decline in the effective tax rate. The effective tax rate
decreased 1,750 basis points to 17.2% in 2020 due to:
• a 1,750 basis-point reduction due to the prior year impact of the Shave
Care impairment charge as there was no tax benefit related to the
goodwill portion of the charge and
• a 135 basis-point current year reduction from a tax benefit arising from
transactions to simplify our legal entity structure.
These reductions were partially offset by:
• a 60 basis-point increase from unfavorable impacts from geographic mix
of current year earnings, caused primarily by disproportionately higher
sales and earnings in the U.S.,
• a 40 basis-point increase related to the prior year tax impact of the gain
on the dissolution of the PGT Healthcare partnership,
• a 30 basis-point increase from current year unfavorable discrete impacts
related to uncertain tax positions (15 basis-point increase in the current
year rate versus a 15 basis-point decrease in the prior year rate) and
• a 5 basis-point increase from lower excess tax benefits of share-based
compensation (155 basis-point reduction in the current year versus 160
basis-point reduction in the prior year).
Net Earnings
Operating income increased 186% or $10.2 billion to $15.7 billion. $8.3
billion of the increase was due to the base period charge for the Shave Care
impairment. The remaining $1.9 billion increase was due to the net sales
increase and the increase in gross margin partially offset by the increase in
SG&A, all of which are discussed above.
-- 35 of 242 --
Earnings before income taxes increased 161% or $9.8 billion to $15.8 billion,
as the increase in operating income discussed above was partially offset by
the base period gains from the dissolution of the PGT Healthcare partnership
and other minor brand divestitures. Net earnings increased 230% or $9.1
billion to $13.1 billion due to the increase in operating income and the
reduction in effective income taxes rates discussed above. Foreign exchange
impacts reduced net earnings by approximately $390 million in fiscal 2020
due to weakening of certain currencies against the U.S. dollar, including those
in Argentina, Brazil, China, Turkey and the United Kingdom. This impact
includes both transactional charges and translational impacts from converting
earnings from foreign subsidiaries to U.S. dollars.
Net earnings attributable to Procter & Gamble increased $9.1 billion, or
234%, to $13.0 billion.
Diluted net EPS increased $3.53, or 247%, to $4.96 due primarily to the
increase in net earnings.
Core EPS increased 13% to $5.12. Core EPS represents diluted net EPS from
continuing operations, excluding the base year charge for the Shave Care
impairment, the base year gain on the dissolution of the PGT Healthcare
partnership and incremental restructuring charges in both years related to our
productivity and cost savings plans. The increase was primarily driven by the
increase in net sales and the increase in operating margin discussed
previously.
-- 36 of 242 --
20 The Procter & Gamble Company
SEGMENT RESULTS
Segment results reflect information on the same basis we use for internal management reporting and performance evaluation. The results of these reportable
segments do not include certain non-business unit specific costs. These costs, including the Shave Care impairment in fiscal 2019, are reported in our Corporate
segment and are included as part of our Corporate segment discussion. Additionally, we apply blended statutory tax rates in the segments. Eliminations to adjust
segment results to arrive at our consolidated effective tax rate are included in Corporate. See Note 2 to the Consolidated Financial Statements for additional
information on items included in the Corporate segment.
Net Sales Change Drivers 2020 vs. 2019 (1)
Volume with
Acquisitions &
Divestitures
Volume Excluding
Acquisitions &
Divestitures
Foreign
Exchange Price Mix Other (2)
Net Sales
Growth
Beauty 3 % 2 % (2) % 2 % 1 % — % 4 %
Grooming (1) % (1) % (3) % 2 % — % — % (2) %
Health Care 10 % 5 % (2) % 1 % 1 % — % 10 %
Fabric & Home Care 6 % 7 % (1) % 1 % 1 % — % 7 %
Baby, Feminine & Family Care 3 % 3 % (2) % 1 % 1 % — % 3 %
TOTAL COMPANY 4 % 4 % (2) % 1 % 1 % 1 % 5 %
(1) Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.
(2) Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.
BEAUTY
($ millions) 2020 2019 Change vs. 2019
Volume N/A N/A 3%
Net sales $13,359 $12,897 4%
Net earnings $2,737 $2,637 4%
% of net sales 20.5% 20.4% 10 bps
Beauty net sales increased 4% to $13.4 billion in fiscal 2020 on a 3% increase
in unit volume. Unfavorable foreign exchange impacts reduced net sales by
2%. Higher pricing increased net sales by 2%. Favorable product mix added
1% to net sales due to the disproportionate growth of the Skin and Personal
Care category, including the Olay skin care brand, which has higher than
segment average selling prices. Organic sales increased 5% on a 2% increase
in organic volume. Global market share of the Beauty segment increased 0.2
points. Volume increased mid-single digits in North America, Europe and
Asia Pacific and increased low single digits in Greater China and Latin
America. Volume decreased high single digits in IMEA.
• Volume in Hair Care increased low single digits. Volume increased mid-
single digits in Europe and Asia Pacific and increased low single digits in
North America and Latin America due to product innovation and market
growth. Volume decreased double digits in IMEA and decreased low
single digits in Greater China due to the economic slowdown caused by
the COVID-19 pandemic in the second half of the fiscal year and market
declines in certain countries. Global market share of the hair care
category was unchanged.
• Volume in Skin and Personal Care increased mid-single digits. Volume
increased double digits in Greater China,
increased mid-single digits in North America, and increased low single
digits in Europe and Asia Pacific due to premium innovation, increased
marketing spending and market growth, partially offset by a volume
decrease in the SK-II brand and a mid-single digits decline in IMEA due
to the COVID-19 pandemic related travel restrictions. Global market
share of the skin and personal care category increased nearly half a point.
Net earnings increased 4% to $2.7 billion in fiscal 2020 due to the increase in
net sales and a 10 basis-point increase in net earnings margin. Net earnings
margin increased due to a decrease in SG&A as a percentage of net sales,
partially offset by a decrease in gross margin and an increase in the effective
tax rate. The gross margin decrease was mainly driven by the negative
impacts of unfavorable mix (due to the decline of the super-premium SK-II
brand, driven by the impacts of the COVID-19 pandemic, and the
disproportionate growth of large sizes) and other hurts related to new
manufacturing startup costs partially offset by increased selling prices. SG&A
as a percentage of net sales decreased due to the positive scale impacts of the
net sales increase and a reduction in marketing spending due to productivity
-- 37 of 242 --
savings. The increase in the effective tax rate was driven by the unfavorable
geographic mix of earnings.
GROOMING
($ millions) 2020 2019 Change vs. 2019
Volume N/A N/A (1)%
Net sales $6,069 $6,199 (2)%
Net earnings $1,329 $1,529 (13)%
% of net sales 21.9% 24.7% (280) bps
-- 38 of 242 --
The Procter & Gamble Company 21
Grooming net sales decreased 2% to $6.1 billion in fiscal 2020 on a 1%
decrease in unit volume. Unfavorable foreign exchange impacts reduced net
sales by 3%. Increased pricing had a 2% positive impact to net sales. Organic
sales increased 1%. Global market share of the Grooming segment decreased
0.2 points. Volume increased mid-single digits in Asia Pacific and was
unchanged in Europe and Latin America. Volume decreased low single digits
in North America and Greater China and decreased mid-single digits in
IMEA.
• Shave Care volume decreased low single digits. Volume decreased mid-
single digits in IMEA and decreased low single digits in North America
and Europe due to market decline and reduced shaving incidents
resulting from the COVID-19 pandemic and competitive activity. This
was partially offset by a mid-single digit volume increase in Asia Pacific
due to innovation. Global market share of the shave care category was
unchanged.
• Appliances volume increased low single digits. Volume increased mid-
teens in North America and mid-single digits in Europe due to innovation
and increased consumption of at-home styling products due to pandemic
related movement restrictions. Volume decreased double digits in Asia
Pacific, decreased high single digits in Greater China and decreased low
single digits in IMEA due to market contraction, competitive activity and
the economic slowdown caused by the COVID-19 pandemic. Global
market share of the appliances category increased more than a point.
Net earnings decreased 13% to $1.3 billion in fiscal 2020 due to the decrease
in net sales and a 280 basis-point decrease in net earnings margin. The net
earnings margin decreased due to an increase in SG&A as a percentage of net
sales, an increase in the effective tax rate and a decrease in gross margin.
Gross margin decreased due to the negative impact of unfavorable mix (due
to the disproportionate growth of disposable razors, styling appliances and the
Asia Pacific region all of which have lower than segment average margins)
partially offset by the positive impacts of manufacturing cost savings and
increased selling prices. SG&A as a percentage of net sales increased
primarily due to a base period gain on the sale of operating real estate
partially offset by current period reductions in overhead costs and marketing
spending due to productivity savings. The increase in the effective tax rate
was primarily due to a base period benefit from the favorable adjustments to
reserves for uncertain tax positions.
HEALTH CARE
($ millions) 2020 2019 Change vs. 2019
Volume N/A N/A 10%
Net sales $9,028 $8,218 10%
Net earnings $1,652 $1,519 9%
% of net sales 18.3% 18.5% (20) bps
Health Care net sales increased 10% to $9.0 billion in fiscal 2020 on a 10%
increase in unit volume. Unfavorable foreign exchange impacts reduced net
sales by 2%. Increased pricing had a 1% positive impact to net sales.
Favorable mix increased net sales by 1% due to the disproportionate organic
growth of the Personal Health Care category which has higher than segment
average selling prices. Excluding the net impacts of the Merck OTC
consumer healthcare acquisition and minor brand divestitures, organic sales
increased 7% on a 5% increase in organic volume. Global market share of the
Health Care segment increased 0.4 points. Volume increased more than 20%
in IMEA, increased double digits in Latin America and Europe, increased
high single digits in Asia Pacific and increased mid-single digits in North
America. Excluding the net impacts of the Merck OTC consumer healthcare
acquisition and minor brand divestitures, organic volume increased high
single digits in IMEA, increased mid-single digits in Latin America and
increased low single digits in Europe and Asia Pacific.
• Oral Care volume increased low single digits. Volume increased double
digits in IMEA, increased mid-single digits in Latin America and
increased low single digits in North America and Asia Pacific due to
product innovation and market growth. This growth was partially offset
by low single digits volume decreases in Europe and Greater China due
to competitive activities and the COVID-19 pandemic related economic
slowdown and electronics stores closures. Excluding the impact of minor
brand divestitures, organic volume increased low single digits in Europe.
-- 39 of 242 --
Global market share of the oral care category increased less than half a
point.
• Volume in Personal Health Care increased over 20%. Excluding the
impacts of the Merck OTC consumer healthcare acquisition, organic
volume increased double digits. Organic volume increased mid-teens in
North America and Europe and increased mid-single digits in IMEA due
to product innovation, increased marketing spending and increased
consumption and retailer inventory increases in certain markets driven by
the COVID-19 pandemic. This was partially offset by a low single digit
volume decrease in Asia Pacific and Latin America due to devaluation
related price increases and the COVID-19 related economic slowdown.
Global market share of the personal health care category increased nearly
a point.
Net earnings increased 9% to $1.7 billion in fiscal 2020 due to the increase in
net sales partially offset by a 20 basis-point decrease in net earnings margin.
The net earnings margin decreased due to an increase in SG&A as a
percentage of net sales and a reduction in non-operating income, partially
offset by an increase in gross margin. Gross margin increased due to
manufacturing cost savings and increased selling prices partially offset by
unfavorable mix impact (from the disproportionate growth of certain products
and certain markets in IMEA both of which have lower than segment-average
margins). SG&A as a percentage of net
-- 40 of 242 --
22 The Procter & Gamble Company
sales increased due to an increase in overhead costs and other operating
expenses primarily caused by the Merck OTC consumer healthcare
acquisition, partially offset by the positive scale impacts of the net sales
increase. Non-operating income declined due to a base period gain from
minor brand divestitures.
FABRIC & HOME CARE
($ millions) 2020 2019 Change vs. 2019
Volume N/A N/A 6%
Net sales $23,735 $22,080 7%
Net earnings $4,154 $3,518 18%
% of net sales 17.5% 15.9% 160 bps
Fabric & Home Care net sales increased 7% to $23.7 billion in fiscal 2020 on
a 6% increase in unit volume. Unfavorable foreign exchange impacts reduced
net sales by 1%. Higher pricing increased net sales by 1%. Positive mix
impacts increased net sales by 1% due to the disproportionate growth of the
Home Care category and the North America region, both of which have
higher than segment average selling prices. Organic sales increased 9% on a
7% increase in organic volume. Global market share of the Fabric & Home
Care segment increased 0.7 points. Volume increased double digits in North
America, increased high single digits in Latin America, increased mid-single
digits in Greater China and Europe and increased low single digits in Asia
Pacific. Volume decreased low single digits in IMEA.
• Fabric Care volume increased mid-single digits. Volume grew double
digits in North America and Latin America, grew mid-single digits in
Greater China and grew low single digits in Europe. Volume growth was
driven by product innovation and to a lesser extent the consumption
increase and pantry loading driven by the COVID-19 pandemic. This
growth was partially offset by a low single digit volume decrease in
IMEA due to the COVID-19 pandemic related economic slowdown.
Volume in Asia Pacific was unchanged. Global market share of the
Fabric Care category increased a point.
• Home Care volume increased double digits. Volume increased in all
regions led by double digit growth in North America and Europe, high
single digits growth in Asia Pacific, mid-single digits growth in Latin
America and low single digits growth in IMEA. The volume growth was
driven by product innovation as well as the consumption increase and
pantry loading driven by the COVID-19 pandemic. Global market share
of the Home Care category increased more than half a point.
Net earnings increased 18% to $4.2 billion in fiscal 2020 due to the increase
in net sales and a 160 basis-point increase in net earnings margin. The net
earnings margin increased due to an increase in gross margin partially offset
by an increase in the effective tax rate. The gross margin increase was driven
by manufacturing cost savings and a reduction in commodity costs, partially
offset by unfavorable product mix (due to the disproportionate growth of
premium innovation that has not yet been cost optimized). SG&A as a
percentage of net sales was unchanged as an increase in marketing spending
was offset by the positive scale benefits of increased net sales on overhead
costs. The increase in the effective tax rate was driven by the unfavorable
geographical mix of earnings.
BABY, FEMININE & FAMILY CARE
($ millions) 2020 2019 Change vs. 2019
Volume N/A N/A 3%
Net sales $18,364 $17,806 3%
Net earnings $3,465 $2,734 27%
% of net sales 18.9% 15.4% 350 bps
Baby, Feminine & Family Care net sales increased 3% to $18.4 billion in
fiscal 2020 on a 3% increase in unit volume. Unfavorable foreign exchange
impacts reduced net sales by 2%. Increased pricing was a positive 1% impact
to net sales. Positive mix impact increased net sales by 1% due to the
disproportionate growth of the North America region which has higher than
segment average selling prices. Organic sales increased 4%. Global market
share of the Baby, Feminine & Family Care segment decreased 0.3 points.
-- 41 of 242 --
Volume increased high single digits in North America and was unchanged in
Asia Pacific. Volume decreased high single digits in Latin America,
decreased mid-single digits in IMEA and decreased low single digits in
Greater China and Europe.
• Baby Care volume decreased mid-single digits. Volume decreased
double digits in Latin America, decreased high single digits in IMEA,
decreased mid-single digits in Europe and decreased low single digits in
Greater China and Asia Pacific due to competitive activity, devaluation
related price increases, category contraction in certain markets (partly
due to declining birth rates in China) and to a lesser extent the economic
slowdown caused by the COVID-19 pandemic. This was partially offset
by a low single digit volume increase in North America driven by market
growth and product innovation. Global market share of the baby care
category decreased more than a point.
• Feminine Care volume increased low single digits. Volume growth was
led by a double digit increase in Asia Pacific due to a new launch in the
adult incontinence category in Japan, as well as high single digits growth
in North America, mid-single digits growth in Europe and low single
digits growth in Greater China and Latin America, all due to product
innovation, increased marketing spending, adult incontinence category
growth and to a lesser extent the increased consumption and pantry
loading related to the COVID-19 pandemic in certain markets. Excluding
the impact of a minor brand acquisition, volume in North America
increased mid-single digits. This was partially offset by a low single digit
volume decrease in IMEA due to the economic slowdown caused by the
COVID-19 pandemic. Global market share of the feminine care category
increased nearly a point.
-- 42 of 242 --
The Procter & Gamble Company 23
• Volume in Family Care, which is predominantly a North American
business, increased high single digits driven by the COVID-19 pandemic
related market growth, consumption increase and pantry loading, product
innovation, increased marketing spending and market growth. In the
U.S., all-outlet share of the family care category decreased more than
half a point.
Net earnings in fiscal 2020 increased 27% to $3.5 billion due to the increase
in net sales and a 350 basis-point increase in net earnings margin. Net
earnings margin increased primarily due to an increase in gross margin,
partially offset by an increase in the effective tax rate and a marginal increase
in SG&A as a percentage of net sales. The gross margin increase was driven
by manufacturing cost savings, a reduction in commodity costs and higher
selling prices partially offset by unfavorable product mix (due to the
disproportionate growth of large sizes and product forms with lower than
segment average margins). SG&A as a percentage of net sales increased
marginally due primarily to an increase in marketing spending, partially offset
by a reduction in overhead costs driven by productivity savings and the
positive scale benefits of the net sales increase. The increase in the effective
tax rate was driven by an unfavorable geographic mix of earnings.
CORPORATE
($ millions) 2020 2019 Change vs. 2019
Net sales $395 $484 (18)%
Net earnings/(loss) $(234) $(7,971) N/A
Corporate includes certain operating and non-operating activities not
allocated to specific business segments. These include: the incidental
businesses managed at the corporate level; financing and investing activities;
certain employee benefit costs; other general corporate items; gains and losses
related to certain divested brands and categories; certain asset impairment
charges; and certain restructuring-type activities to maintain a competitive
cost structure, including manufacturing and workforce optimization.
Corporate also includes reconciling items to adjust the accounting policies
used in the segments to U.S. GAAP. The most significant ongoing reconciling
item is income taxes, to adjust from blended statutory rates that are reflected
in the segments to the overall Company effective tax rate.
Corporate net sales decreased 18% to $395 million in fiscal 2020 due to a
decrease in the net sales of the incidental businesses managed at the corporate
level. Corporate net loss decreased by $7.7 billion in fiscal 2020 primarily
due to the $8.0 billion after tax ($8.3 billion before tax) base period charge for
the Shave Care impairment, partially offset by higher base period divestiture
gains (primarily driven by gain on the dissolution of the PGT healthcare
partnership).
Restructuring Program to Deliver Productivity and Cost Savings
In fiscal 2012, the Company initiated a productivity and cost savings plan to
reduce costs and better leverage scale in the areas of supply chain, research
and development, marketing
and overheads. The plan was designed to accelerate cost reductions by
streamlining management decision making, manufacturing and other work
processes to both fund the Company's growth strategy and increase the
Company's operating margin. In fiscal 2017, the Company communicated
specific elements of an additional multi-year productivity and cost savings
program.
The current productivity and cost savings plan is further reducing costs in the
areas of supply chain, certain marketing activities and overhead expenses. As
part of this plan, the Company incurred approximately $1.5 billion in total
before- tax restructuring costs across 2019 and 2020. In fiscal 2021 and
onwards, the Company expects to incur restructuring costs within the range of
our historical ongoing level of $250 to $500 million annually. Savings
generated from the Company's restructuring program are difficult to estimate,
given the nature of the activities, the timing of the execution and the degree of
reinvestment. However, we estimate that through 2020, the underlying
restructuring costs incurred since 2012 (approximately $8.2 billion), along
with other non-manufacturing enrollment reductions since 2012 have
delivered approximately $3.7 billion in annual before-tax gross savings.
Restructuring accruals of $472 million as of June 30, 2020 are classified as
current liabilities. Approximately 52% of the restructuring charges incurred in
fiscal 2020 either have been or will be settled with cash. Consistent with our
-- 43 of 242 --
historical policies for ongoing restructuring-type activities, the resulting
charges are funded by and included within Corporate for segment reporting.
In addition to our restructuring programs, we have additional ongoing savings
efforts in our supply chain, marketing and overhead areas that yield additional
benefits to our operating margins.
Refer to Note 3 to the Consolidated Financial Statements for more details on
the restructuring program and to the Operating Costs section of the MD&A
for more information about the total benefit to operating margins from our
total savings efforts.
CASH FLOW, FINANCIAL CONDITION AND LIQUIDITY
We believe our financial condition continues to be of high quality, as
evidenced by our ability to generate substantial cash from operations and to
readily access capital markets at competitive rates.
Operating cash flow provides the primary source of cash to fund operating
needs and capital expenditures. Excess operating cash is used first to fund
shareholder dividends. Other discretionary uses include share repurchases and
acquisitions to complement our portfolio of businesses, brands and
geographies. As necessary, we may supplement operating cash flow with debt
to fund these activities. The overall cash position of the Company reflects our
strong business results and a global cash management strategy that takes into
account liquidity management, economic factors and tax considerations.
-- 44 of 242 --
24 The Procter & Gamble Company
Operating Cash Flow
Operating cash flow was $17.4 billion in 2020, a 14% increase from the prior
year. Net earnings, adjusted for non-cash items (depreciation and
amortization, share-based compensation and deferred income taxes) generated
approximately $16.1 billion of operating cash flow. Working capital and other
impacts generated $1.3 billion of operating cash flow as summarized below.
• A decrease in accounts receivable generated $634 million of cash
primarily due to the timing of the end of the fiscal year (which fell on a
Tuesday versus Sunday in the prior year end, resulting in additional
collection days in the current year) and lower relative sales at the end of
the period in certain markets driven by COVID-19. The number of days
sales outstanding decreased approximately 5 days versus prior year.
• Higher inventory used $637 million of cash mainly due to inventory
increases to support initiatives, business growth across all segments and
to replenish stocks in certain categories depleted by the COVID-19
pandemic related demand increases. Inventory days on hand increased
approximately 4 days primarily due to initiative support and inventory
replenishment.
• Accounts payable, accrued and other liabilities increased, generating $1.9
billion of cash. Approximately $700 million of this was driven by
extended payment terms with our suppliers (see Extended Payment
Terms and Supply Chain Financing below). The remaining amount was
driven by higher payables from increased manufacturing activity due to
the pandemic related demand increases, an increase in marketing
spending in the fourth quarter versus the prior year and increases in taxes
payable related to the Merck integration. Days payable outstanding
increased approximately 4 days to 81 days as of June 30, 2020 due to the
above.
• Other net operating assets and liabilities declined, using $710 million of
cash, primarily driven by the payment of the current year portion of taxes
due related to the U.S. Tax Act repatriation charge ($215 million) and
pension related accruals and contributions.
Adjusted Free Cash Flow. We view adjusted free cash flow as an important
non-GAAP measure because it is a factor impacting the amount of cash
available for dividends, share repurchases, acquisitions and other
discretionary investments. It is defined as operating cash flow less capital
expenditures and excluding payments for the transitional tax resulting from
the U.S. Tax Act and tax payments related to the Merck acquisition. Adjusted
free cash flow is one of the measures used to evaluate senior management and
determine their at-risk compensation.
Adjusted free cash flow was $14.9 billion in 2020, an increase of 23% versus
the prior year. The increase was primarily driven by the increase in operating
cash flows as discussed above. Adjusted free cash flow productivity, defined
as the ratio of adjusted free cash flow to net earnings, was 114% in 2020.
Extended Payment Terms and Supply Chain Financing. Beginning in fiscal
2014, in response to evolving market practices, the Company began a
program to negotiate extended payment terms with its suppliers. At about the
same time, the Company initiated a Supply Chain Finance program (SCF)
with several global financial institutions (SCF Banks). Under the SCF,
qualifying suppliers may elect to sell their receivables from the Company to
an SCF Bank. These participating suppliers negotiate their receivables sales
arrangements directly with the respective SCF Bank. While the Company is
not party to those agreements, the SCF Banks allow the participating
suppliers to utilize the Company’s creditworthiness in establishing credit
spreads and associated costs. This generally provides the suppliers with more
favorable terms than they would be able to secure on their own. The
Company has no economic interest in a supplier’s decision to sell a
receivable. Once a qualifying supplier elects to participate in the SCF and
reaches an agreement with an SCF Bank, the supplier elects which individual
Company invoices they sell to the SCF bank. However, all the Company’s
payments to participating suppliers are paid to the SCF Bank on the invoice
due date, regardless of whether the individual invoice is sold by the supplier
to the SCF Bank. The SCF Bank pays the supplier on the invoice due date for
any invoices that were not previously sold by the supplier to the SCF Bank.
The terms of the Company’s payment obligation are not impacted by a
supplier’s participation in the SCF. Our payment terms with our suppliers for
similar materials within individual markets are consistent between suppliers
-- 45 of 242 --
that elect to participate in the SCF and those that do not participate.
Accordingly, our average days outstanding are not significantly impacted by
the portion of suppliers or related input costs that are included in the SCF. In
addition, the SCF is available to both material suppliers, where the underlying
costs are largely included in Cost of goods sold, and to service suppliers,
where the underlying costs are largely included in SG&A. As of June 30,
2020, approximately 3% of our global suppliers have elected to participate in
the SCF. Payments to those suppliers during 2020 total approximately $13
billion, which equals approximately 24% of our total Cost of goods sold and
SG&A for the period. For participating suppliers, we believe substantially all
of their receivables with the Company are sold to the SCF Banks.
Accordingly, we would expect that at each balance sheet date, a similar
proportion of amounts originally due to suppliers would instead be payable to
SCF Banks. All outstanding amounts related to suppliers participating in the
SCF are recorded within Accounts payable in our Consolidated Balance
Sheets, and the associated payments are included in operating activities
within our Consolidated Statements of Cash Flows. As of both June 30, 2020
and 2019, the amount due to suppliers participating in the SCF and included
in Accounts payable were approximately $4 billion.
Although difficult to project due to market and other dynamics, we anticipate
incremental cash flow benefits from the extended payment terms with
suppliers could increase at
-- 46 of 242 --
The Procter & Gamble Company 25
a slower rate in fiscal 2021. Future changes in our suppliers’ financing
policies or economic developments, such as changes in interest rates, general
market liquidity or the Company’s creditworthiness relative to participating
suppliers could impact suppliers’ participation in the SCF and/or our ability to
negotiate extended payment terms with our suppliers. However, any such
impacts are difficult to predict.
Investing Cash Flow
Net investing activities generated $3.0 billion in cash in 2020, mainly due to
proceeds from sales and maturities of investment securities, partially offset by
capital spending. Net investing activities consumed $3.5 billion in cash in
2019, mainly due to capital spending and business acquisitions, partially
offset by proceeds from sales and maturities of short-term investments.
Capital Spending. Capital expenditures, primarily to support capacity
expansion, innovation and cost efficiencies, were $3.1 billion in 2020 and
$3.3 billion in 2019. Capital spending as a percentage of net sales decreased
60 basis points to 4.3% in 2020.
Acquisitions. Acquisition activity used cash of $58 million in 2020, primarily
related to final contractual payments from the prior year acquisition of Merck
OTC along with a minor Baby Care acquisition. Acquisition activity used
$3.9 billion in 2019, primarily related to the Merck OTC acquisition.
Proceeds from Divestitures and Other Asset Sales. Proceeds from asset sales
were $30 million and $394 million in 2020 and 2019, respectively, primarily
from minor brand divestitures in both years and the sale of real estate in 2019.
Investment Securities. Investments generated net cash of $6.2 billion in 2020
and $3.5 billion in 2019 primarily from sales and maturities of investment
securities.
Financing Cash Flow
Net financing activities consumed $8.4 billion of cash in 2020, mainly due to
dividends to shareholders and treasury stock purchases, partially offset by a
net increase in debt and the impact of stock options. Net financing activities
consumed $10.0 billion in cash in 2019, mainly due to dividends to
shareholders and treasury stock purchases, partially offset by the impact of
stock options.
Dividend Payments. Our first discretionary use of cash is dividend payments.
Dividends per common share increased 5% to $3.0284 per share in 2020.
Total dividend payments to common and preferred shareholders were $7.8
billion in 2020 and $7.5 billion in 2019. In April 2020, the Board of Directors
declared an increase in our quarterly dividend from $0.7459 to $0.7907 per
share on Common Stock and Series A and B ESOP Convertible Class A
Preferred Stock. This represents a 6% increase compared to the prior
quarterly dividend and is the 64th consecutive year that our dividend has
increased. We have paid a dividend for 130 consecutive years, every year
since our incorporation in 1890.
Long-Term and Short-Term Debt. We maintain debt levels we consider
appropriate after evaluating a number of factors, including cash flow
expectations, cash requirements for
ongoing operations, investment and financing plans (including acquisitions
and share repurchase activities) and the overall cost of capital. Total debt was
$34.7 billion as of June 30, 2020 and $30.1 billion as of June 30, 2019. The
increase is primarily due to the issuance of bonds generating $5.0 billion of
cash.
Treasury Purchases. Total share repurchases were $7.4 billion in 2020 and
$5.0 billion in 2019.
Liquidity
At June 30, 2020, our current liabilities exceeded current assets by $5.0
billion largely due to short-term borrowings under our commercial paper
program. We anticipate being able to support our short-term liquidity and
operating needs largely through cash generated from operations. The
Company regularly assesses its cash needs and the available sources to fund
these needs. As of June 30, 2020, the Company did not have material net cash
and cash equivalents related to foreign subsidiaries nor related to any country
subject to exchange controls that significantly restrict our ability to access or
repatriate the funds. Under current law, we do not expect restrictions or taxes
on repatriation of cash held outside of the U.S. to have a material effect on
our overall liquidity, financial condition or the results of operations for the
foreseeable future.
-- 47 of 242 --
We utilize short- and long-term debt to fund discretionary items, such as
acquisitions and share repurchases. We have strong short- and long-term debt
ratings, which have enabled, and should continue to enable, us to refinance
our debt as it becomes due at favorable rates in commercial paper and bond
markets. In addition, we have agreements with a diverse group of financial
institutions that, if needed, should provide sufficient funding to meet short-
term financing requirements.
On June 30, 2020, our short-term credit ratings were P-1 (Moody's) and A-1+
(Standard & Poor's), while our long-term credit ratings were Aa3 (Moody's)
and AA- (Standard & Poor's), all with a stable outlook.
We maintain bank credit facilities to support our ongoing commercial paper
program. The current facility is an $8.0 billion facility split between a $3.2
billion five-year facility and a $4.8 billion 364-day facility, which expire in
November 2024 and November 2020, respectively. Both facilities can be
extended for certain periods of time as specified in the terms of the credit
agreement. These facilities are currently undrawn and we anticipate that they
will remain undrawn. These credit facilities do not have cross-default or
ratings triggers, nor do they have material adverse events clauses, except at
the time of signing. In addition to these credit facilities, we have an
automatically effective registration statement on Form S-3 filed with the SEC
that is available for registered offerings of short- or long-term debt securities.
For additional details on debt see Note 10 to the Consolidated Financial
Statements.
-- 48 of 242 --
26 The Procter & Gamble Company
Guarantees and Other Off-Balance Sheet Arrangements
We do not have guarantees or other off-balance sheet financing arrangements,
including variable interest entities,
which we believe could have a material impact on our financial condition or
liquidity.
Contractual Commitments
The following table provides information on the amount and payable date of our contractual commitments as of June 30, 2020.
($ millions) Total Less Than 1 Year 1-3 Years 3-5 Years After 5 Years
RECORDED LIABILITIES
Total debt $ 34,589 $ 11,189 $ 5,154 $ 5,148 $ 13,098
Leases 1,023 239 352 220 212
U.S. Tax Act transitional charge (1) 2,346 224 450 984 688
Uncertain tax positions (2) 59 59 — — —
OTHER
Interest payments relating to long-term debt 6,676 673 1,173 955 3,875
Minimum pension funding (3) 603 196 407 — —
Purchase obligations (4) 1,577 782 412 145 238
TOTAL CONTRACTUAL COMMITMENTS $ 46,873 $ 13,362 $ 7,948 $ 7,452 $ 18,111
(1) Represents the U.S. federal tax liability associated with the repatriation provisions of the U.S. Tax Act. Does not include any provisions made for foreign withholding taxes
on expected repatriations as the timing of those payments is uncertain.
(2) As of June 30, 2020, the Company's Consolidated Balance Sheet reflects a liability for uncertain tax positions of $643 million, including $158 million of interest and
penalties. Due to the high degree of uncertainty regarding the timing of future cash outflows of liabilities for uncertain tax positions beyond one year, a reasonable estimate
of the period of cash settlement beyond twelve months from the balance sheet date of June 30, 2020 cannot be made.
(3) Represents future pension payments to comply with local funding requirements. These future pension payments assume the Company continues to meet its future statutory
funding requirements. Considering the current economic environment in which the Company operates, the Company believes its cash flows are adequate to meet the future
statutory funding requirements. The projected payments beyond fiscal year 2023 are not currently determinable.
(4) Primarily reflects future contractual payments under various take-or-pay arrangements entered into as part of the normal course of business. Commitments made under take-
or-pay obligations represent minimum commitments under take-or-pay agreements with suppliers and are in line with expected usage. This includes service contracts for
information technology, human resources management and facilities management activities that have been outsourced. While the amounts listed represent contractual
obligations, we do not believe it is likely that the full contractual amount would be paid if the underlying contracts were canceled prior to maturity. In such cases, we
generally are able to negotiate new contracts or cancellation penalties, resulting in a reduced payment. The amounts do not include other contractual purchase obligations
that are not take-or-pay arrangements. Such contractual purchase obligations are primarily purchase orders at fair value that are part of normal operations and are reflected
in historical operating cash flow trends. We do not believe such purchase obligations will adversely affect our liquidity position.
SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES
In preparing our financial statements in accordance with U.S. GAAP, there
are certain accounting policies that may require a choice between acceptable
accounting methods or may require substantial judgment or estimation in their
application. These include revenue recognition, income taxes, certain
employee benefits and goodwill and intangible assets. We believe these
accounting policies, and others set forth in Note 1 to the Consolidated
Financial Statements, should be reviewed as they are integral to
understanding the results of operations and financial condition of the
Company.
The Company has discussed the selection of significant accounting policies
and the effect of estimates with the Audit Committee of the Company's Board
of Directors.
Revenue Recognition
Our revenue is primarily generated from the sale of finished product to
customers. Those sales predominantly contain a single performance
obligation and revenue is recognized at a
single point in time when ownership, risks and rewards transfer, which can be
on the date of shipment or the date of receipt by the customer. Trade
promotions, consisting primarily of customer pricing allowances, in-store
merchandising funds, advertising and other promotional activities, and
consumer coupons, are offered through various programs to customers and
consumers. Sales are recorded net of trade promotion spending, which is
recognized as incurred at the time of the sale. Amounts accrued for trade
promotions at the end of a period require estimation, based on contractual
terms, sales volumes and historical utilization and redemption rates. The
actual amounts paid may be different from such estimates. These differences,
-- 49 of 242 --
which have historically not been significant, are recognized as a change in
management estimate in a subsequent period. The Company adopted ASU
2014-09, “Revenue from Contracts with Customers (Topic 606)” on July 1,
2018. Adoption of this standard resulted in a change
-- 50 of 242 --
The Procter & Gamble Company 27
in the timing of recognition of certain trade promotional spending.
Income Taxes
Our annual tax rate is determined based on our income, statutory tax rates and
the tax impacts of items treated differently for tax purposes than for financial
reporting purposes. Also inherent in determining our annual tax rate are
judgments and assumptions regarding the recoverability of certain deferred
tax balances, primarily net operating loss and other carryforwards, and our
ability to uphold certain tax positions.
Realization of net operating losses and other carryforwards is dependent upon
generating sufficient taxable income in the appropriate jurisdiction prior to
the expiration of the carryforward periods, which involves business plans,
planning opportunities and expectations about future outcomes. Although
realization is not assured, management believes it is more likely than not that
our deferred tax assets, net of valuation allowances, will be realized.
We operate in multiple jurisdictions with complex tax policy and regulatory
environments. In certain of these jurisdictions, we may take tax positions that
management believes are supportable, but are potentially subject to successful
challenge by the applicable taxing authority. These interpretational
differences with the respective governmental taxing authorities can be
impacted by the local economic and fiscal environment.
A core operating principle is that our tax structure is based on our business
operating model, such that profits are earned in line with the business
substance and functions of the various legal entities. However, because of the
complexity of transfer pricing concepts, we may have income tax uncertainty
related to the determination of intercompany transfer prices for our various
cross-border transactions. We have obtained and continue to prioritize the
strategy of seeking advance rulings with tax authorities to reduce this
uncertainty. We estimate that our current portfolio of advance rulings reduces
this uncertainty with respect to over 70% of our global earnings. We evaluate
our tax positions and establish liabilities in accordance with the applicable
accounting guidance on uncertainty in income taxes. We review these tax
uncertainties in light of changing facts and circumstances, such as the
progress of tax audits, and adjust them accordingly. We have a number of
audits in process in various jurisdictions. Although the resolution of these tax
positions is uncertain, based on currently available information, we believe
that the ultimate outcomes will not have a material adverse effect on our
financial position, results of operations or cash flows.
Because there are a number of estimates and assumptions inherent in
calculating the various components of our tax provision, certain changes or
future events such as changes in tax legislation, geographic mix of earnings,
completion of tax audits or earnings repatriation plans could have an impact
on those estimates and our effective tax rate. See Note 5 to the Consolidated
Financial Statements for additional details on the Company's income taxes.
Employee Benefits
We sponsor various post-employment benefits throughout the world. These
include pension plans, both defined contribution plans and defined benefit
plans, and other post-employment benefit (OPEB) plans, consisting primarily
of health care and life insurance for retirees. For accounting purposes, the
defined benefit pension and OPEB plans require assumptions to estimate the
net projected and accumulated benefit obligations, including the following
variables: discount rate; expected salary increases; certain employee-related
factors, such as turnover, retirement age and mortality; expected return on
assets; and health care cost trend rates. These and other assumptions affect the
annual expense and net obligations recognized for the underlying plans. Our
assumptions reflect our historical experiences and management's best
judgment regarding future expectations. As permitted by U.S. GAAP, the net
amount by which actual results differ from our assumptions is deferred. If this
net deferred amount exceeds 10% of the greater of plan assets or liabilities, a
portion of the deferred amount is included in expense for the following year.
The cost or benefit of plan changes, such as increasing or decreasing benefits
for prior employee service (prior service cost), is deferred and included in
expense on a straight-line basis over the average remaining service period of
the employees expected to receive benefits.
The expected return on plan assets assumption impacts our defined benefit
expense since many of our defined benefit pension plans and our primary
OPEB plan are partially funded. The process for setting the expected rates of
return is described in Note 8 to the Consolidated Financial Statements. For
-- 51 of 242 --
2020, the average return on assets assumptions for pension plan assets and
OPEB assets was 6.6% and 8.4%, respectively. A change in the rate of return
of 100 basis points for both pension and OPEB assets would impact annual
after-tax benefit/expense by approximately $130 million.
Since pension and OPEB liabilities are measured on a discounted basis, the
discount rate impacts our plan obligations and expenses. Discount rates used
for our U.S. defined benefit pension and OPEB plans are based on a yield
curve constructed from a portfolio of high quality bonds for which the timing
and amount of cash outflows approximate the estimated payouts of the plan.
For our international plans, the discount rates are set by benchmarking against
investment grade corporate bonds rated AA or better. The average discount
rate on the defined benefit pension plans of 1.5% represents a weighted
average of local rates in countries where such plans exist. A 100 basis point
change in the discount rate would impact annual after-tax benefit expense by
approximately $220 million. The average discount rate on the OPEB plan of
3.1% reflects the higher interest rates generally applicable in the U.S., which
is where a majority of the plan participants receive benefits. A 100 basis point
change in the discount rate would impact annual after-tax OPEB expense by
approximately $50 million. See Note 8 to the Consolidated Financial
Statements for
-- 52 of 242 --
28 The Procter & Gamble Company
additional details on our defined benefit pension and OPEB plans.
Goodwill and Intangible Assets
Significant judgment is required to estimate the fair value of our goodwill
reporting units and intangible assets. Accordingly, we typically obtain the
assistance of third-party valuation specialists for significant goodwill
reporting units and intangible assets. The fair value estimates are based on
available historical information and on future expectations. We typically
estimate the fair value of these assets using the income method, which is
based on the present value of estimated future cash flows attributable to the
respective assets. The valuations used to establish and to test goodwill and
intangible assets for impairment are dependent on a number of significant
estimates and assumptions, including macroeconomic conditions, overall
category growth rates, competitive activities, cost containment and margin
progression, Company business plans and the discount rate applied to cash
flows.
Indefinite-lived intangible assets and goodwill are not amortized, but are
tested at least annually for impairment. Our ongoing annual impairment
testing for goodwill and indefinite-lived intangible assets occurs during the 3
months ended December 31. Assumptions used in our impairment
evaluations, such as forecasted growth rates and cost of capital, are consistent
with internal projections and operating plans. We believe these estimates and
assumptions are reasonable and comparable to those that would be used by
other marketplace participants. Unanticipated market or macroeconomic
events and circumstances may occur, which could affect the accuracy or
validity of the estimates and assumptions. For example, future changes in the
judgments, assumptions and estimates that are used in our impairment testing
for goodwill and indefinite-lived intangible assets, including discount and tax
rates or future cash flow projections, could result in significantly different
estimates of the fair values. In addition, changes to, or a failure to achieve
business plans or deterioration of macroeconomic conditions could result in
reduced cash flows or higher discount rates, leading to a lower valuation that
would trigger an impairment of the goodwill and intangible assets of these
businesses.
We test individual indefinite-lived intangible assets by comparing the book
value of each asset to the estimated fair value. Our impairment testing for
goodwill is performed separately from our impairment testing of indefinite-
lived intangible assets. The test to evaluate goodwill for impairment is a two-
step process. In the first step (step one), we compare the fair value of the
reporting unit to its carrying value. If the fair value of the reporting unit is less
than its carrying value, we perform a second step (step two) to determine the
implied fair value of the reporting unit's goodwill. The second step of the
impairment analysis requires a valuation of a reporting unit's tangible and
intangible assets and liabilities in a manner similar to the allocation of
purchase price in a business combination. The difference between the step
one fair value and the amounts allocated to the assets and liabilities in step
two is the
implied fair value of the reporting unit’s goodwill. If this implied fair value of
the reporting unit's goodwill is less than its carrying value, that difference
represents an impairment.
Determining the useful life of an intangible asset also requires judgment.
Certain brand intangible assets are expected to have indefinite lives based on
their history and our plans to continue to support and build the acquired
brands. Other acquired intangible assets (e.g., certain brands, all customer
relationships, patents and technologies) are expected to have determinable
useful lives. Our assessment as to brands that have an indefinite life and those
that have a determinable life is based on a number of factors including
competitive environment, market share, brand history, underlying product life
cycles, operating plans and the macroeconomic environment of the countries
in which the brands are sold. Determinable-lived intangible assets are
amortized to expense over their estimated lives. An impairment assessment
for determinable-lived intangibles is only required when an event or change
in circumstances indicates that the carrying amount of the asset may not be
recoverable.
Most of our goodwill reporting units are comprised of a combination of
legacy and acquired businesses and as a result have fair value cushions that, at
a minimum, exceed two times their underlying carrying values. Certain of our
goodwill reporting units, in particular Shave Care and Appliances, are
comprised entirely of acquired businesses and as a result have fair value
-- 53 of 242 --
cushions that are not as high. The Appliances wholly-acquired reporting unit
has a fair value that significantly exceeds the underlying carrying value.
During fiscal 2019, a non-cash before- and after-tax impairment charge of
$6.8 billion was recognized to reduce the carrying amount of goodwill for the
Shave Care reporting unit, and a non-cash, before-tax impairment charge of
$1.6 billion ($1.2 billion after-tax) was recognized to reduce the carrying
amount of the Gillette indefinite-lived intangible asset to its fair value. The
underlying reductions in fair values were due in large part to significant
currency devaluations in a number of countries relative to the U.S. dollar, a
deceleration of category growth caused by changing grooming habits,
primarily in the developed markets, and an increased competitive market
environment in the U.S. and certain other markets. As a result of the fiscal
2019 impairment determined by the step two testing, the Shave Care fair
value exceeded the carrying value by approximately 20% as of June 30, 2019.
Because the impairment testing for intangible assets is a one-step process, the
Gillette indefinite-lived intangible asset fair value approximated its carrying
value at that date. During our annual impairment testing during the quarter
ended December 31, 2019, we reduced the discount rate used in the valuation
based on developments in the macroeconomic environment. As a result of
this change and updates to other underlying cash flow projections, the Shave
Care fair value exceeded the carrying value by more than 20% and the
-- 54 of 242 --
The Procter & Gamble Company 29
Gillette indefinite-lived intangible asset fair value exceeded the carrying
value by approximately 5%.
The most significant assumptions utilized in the determination of the
estimated fair values of the Shave Care reporting unit and the Gillette
indefinite-lived intangible asset are the net sales and earnings growth rates
(including residual growth rates) and discount rate. The residual growth rate
represents the expected rate at which the reporting unit and Gillette brand are
expected to grow beyond the shorter-term business planning period. The
residual growth rate utilized in our fair value estimates is consistent with the
reporting unit and brand operating plans and approximates expected long-
term category market growth rates. The residual growth rate is dependent on
overall market growth rates, the competitive environment, inflation, relative
currency exchange rates and business activities that impact market share. As a
result, the residual growth rate could be adversely impacted by a sustained
deceleration in category growth, grooming habit changes, devaluation of
currencies against the U.S. dollar or an increased competitive environment.
The discount rate, which is consistent with a weighted average cost of capital
that is likely to be expected by a market participant, is based upon industry
required rates of return, including consideration of both debt and equity
components of the capital structure. Our discount rate may be impacted by
adverse changes in the macroeconomic environment, volatility in the equity
and debt markets or other country specific factors, such as further devaluation
of currencies against the U.S. dollar. Spot rates as of the fair value
measurement date are utilized in our fair value estimates for cash flows
outside the U.S.
While management can and has implemented strategies to address these
events, changes in operating plans or adverse changes in the future could
reduce the underlying cash flows used to estimate fair values and could result
in a decline in fair value that would trigger future impairment charges of the
Shave Care reporting unit's goodwill and indefinite-lived intangibles. As of
June 30, 2020, the carrying values of the Shave Care goodwill and the Gillette
indefinite-lived intangible asset were $12.5 billion and $14.1 billion,
respectively.
The COVID-19 pandemic that occurred during the second half of fiscal 2020
resulted in a reduction in shave incidents by consumers and a weakening of
certain currencies relative to the U.S. dollar, which led to a reduction in net
sales for Gillette-branded products. This resulted in a triggering event for the
Gillette indefinite-lived intangible asset, which caused us to perform an
additional impairment assessment for that asset as of June 30, 2020. That
assessment indicated that the fair value of the Gillette trade name
approximated its carrying value. Accordingly, no impairment charge was
recorded during the year ended June 30, 2020.
The duration and severity of the pandemic could result in additional future
impairment charges for the Shave Care reporting unit goodwill and the
Gillette indefinite-lived intangible asset. Our June 30, 2020 impairment
assessment of the Gillette intangible asset assumes the pandemic’s
impact on net sales will begin to abate during the first half of fiscal 2021 and
be largely eliminated by the second half of the fiscal year. There is an
extreme level of uncertainty relating to how the pandemic will evolve and
how governments and consumers will react. Accordingly, there is a
significant amount of uncertainty related to this key assumption. A more
prolonged pandemic could impact the results of operations due to changes to
assumptions utilized in the determination of the estimated fair values of
Shave Care reporting unit and the Gillette indefinite-lived intangible asset that
are significant enough to trigger an impairment. Net sales and earnings
growth rates could be negatively impacted by more prolonged reductions or
changes in demand for our shave care products, which may be caused by,
among other things: the temporary inability of consumers to purchase our
products due to illness, quarantine or other travel restrictions, financial
hardship, changes in the use and frequency of grooming products or by shifts
in demand away from one or more of our higher priced products to lower
priced products. In addition, relative global and country/regional
macroeconomic factors could result in additional and prolonged devaluation
of other countries’ currencies relative to the U.S. dollar. Finally, the discount
rate utilized in our valuation model could be impacted by changes in the
underlying interest rates and risk premiums included in the determination of
the cost of capital.
-- 55 of 242 --
The table below provides a sensitivity analysis for the Shave Care reporting
unit and the Gillette indefinite-lived intangible asset, utilizing reasonably
possible changes in the assumptions for the shorter term and residual growth
rates and the discount rate, to demonstrate the potential impacts to the
estimated fair values. The table below provides, in isolation, the estimated fair
value impacts related to a 25 basis point increase to discount rate or a 25 basis
point decrease to our shorter-term and residual growth rates, either of which,
in isolation, would result in an additional impairment of the Gillette
indefinite-lived intangible asset.
Approximate Percent Change in Estimated Fair
Value
+25 bps Discount
Rate
-25 bps
Growth Rate
Shave Care goodwill reporting
unit (6)% (6)%
Gillette indefinite-lived
intangible asset (6)% (6)%
See Note 4 to the Consolidated Financial Statements for additional discussion
on goodwill and intangible asset impairment testing results.
New Accounting Pronouncements
Refer to Note 1 to the Consolidated Financial Statements for recently adopted
accounting pronouncements and recently issued accounting pronouncements
not yet adopted as of June 30, 2020.
-- 56 of 242 --
30 The Procter & Gamble Company
OTHER INFORMATION
Hedging and Derivative Financial Instruments
As a multinational company with diverse product offerings, we are exposed to
market risks, such as changes in interest rates, currency exchange rates and
commodity prices. We evaluate exposures on a centralized basis to take
advantage of natural exposure correlation and netting. We leverage the
Company's diversified portfolio of exposures as a natural hedge and prioritize
operational hedging activities over financial market instruments. To the extent
we choose to further manage volatility within our financing operations, as
discussed below, we enter into various financial transactions which we
account for using the applicable accounting guidance for derivative
instruments and hedging activities. These financial transactions are governed
by our policies covering acceptable counterparty exposure, instrument types
and other hedging practices. See Note 9 to the Consolidated Financial
Statements for a discussion of our accounting policies for derivative
instruments.
Derivative positions are monitored using techniques including market
valuation, sensitivity analysis and value-at-risk modeling. The tests for
interest rate, currency rate and commodity derivative positions discussed
below are based on the RiskManager™ value-at-risk model using a one-year
horizon and a 95% confidence level. The model incorporates the impact of
correlation (the degree to which exposures move together over time) and
diversification (from holding multiple currency, commodity and interest rate
instruments) and assumes that financial returns are normally distributed.
Estimates of volatility and correlations of market factors are drawn from the
RiskMetrics™ dataset as of June 30, 2020. In cases where data is unavailable
in RiskMetrics™, a reasonable proxy is included.
Our market risk exposures relative to interest rates, currency rates and
commodity prices, as discussed below, have not changed materially versus
the previous reporting period. In addition, we are not aware of any facts or
circumstances that would significantly impact such exposures in the near
term.
Interest Rate Exposure on Financial Instruments. Interest rate swaps are
used to hedge exposures to interest rate movement on underlying debt
obligations. Certain interest rate swaps denominated in foreign currencies are
designated to hedge exposures to currency exchange rate movements on our
investments in foreign operations. These currency interest rate swaps are
designated as hedges of the Company's foreign net investments.
Based on our interest rate exposure as of and during the year ended June 30,
2020, including derivative and other instruments sensitive to interest rates, we
believe a near-term change in interest rates, at a 95% confidence level based
on historical interest rate movements, would not materially affect our
financial statements.
Currency Rate Exposure on Financial Instruments. Because we
manufacture and sell products and finance operations in a number of
countries throughout the world, we are exposed to the impact on revenue and
expenses of movements in currency exchange rates. Corporate policy
prescribes the range of allowable hedging activity. To manage the exchange
rate risk associated with the financing of our operations, we primarily use
forward contracts and currency swaps with maturities of less than 18 months.
Based on our currency rate exposure on derivative and other instruments as of
and during the year ended June 30, 2020, we believe, at a 95% confidence
level based on historical currency rate movements, the impact on such
instruments of a near-term change in currency rates would not materially
affect our financial statements.
Commodity Price Exposure on Financial Instruments. We use raw materials
that are subject to price volatility caused by weather, supply conditions,
political and economic variables and other unpredictable factors. We may use
futures, options and swap contracts to manage the volatility related to the
above exposures.
As of and during the years ended June 30, 2020 and June 30, 2019, we did not
have any commodity hedging activity.
Measures Not Defined By U.S. GAAP
In accordance with the SEC's Regulation S-K Item 10(e), the following
provides definitions of the non-GAAP measures and the reconciliation to the
most closely related GAAP measures. We believe that these measures provide
-- 57 of 242 --
useful perspective of underlying business trends (i.e. trends excluding non-
recurring or unusual items) and results and provide a supplemental measure
of year-on-year results. The non-GAAP measures described below are used
by management in making operating decisions, allocating financial resources
and for business strategy purposes. These measures may be useful to investors
as they provide supplemental information about business performance and
provide investors a view of our business results through the eyes of
management. These measures are also used to evaluate senior management
and are a factor in determining their at-risk compensation. These non-GAAP
measures are not intended to be considered by the user in place of the related
GAAP measure, but rather as supplemental information to our business
results. These non-GAAP measures may not be the same as similar measures
used by other companies due to possible differences in method and in the
items or events being adjusted. These measures include:
Organic Sales Growth. Organic sales growth is a non-GAAP measure of
sales growth excluding the impacts of acquisitions, divestitures and foreign
exchange from year-over-year comparisons. We believe this measure
provides investors with a supplemental understanding of underlying sales
trends by providing sales growth on a consistent basis. This measure is used
in assessing achievement of management goals for at-risk compensation.
-- 58 of 242 --
The Procter & Gamble Company 31
The following tables provide a numerical reconciliation of organic sales
growth to reported net sales growth:
Year ended June 30, 2020
Net Sales
Growth
Foreign
Exchange
Impact
Acquisition &
Divestiture
Impact/Other (1)
Organic Sales
Growth
Beauty 4 % 2 % (1) % 5 %
Grooming (2) % 3 % — % 1 %
Health Care 10 % 2 % (5) % 7 %
Fabric & Home Care 7 % 1 % 1 % 9 %
Baby, Feminine &
Family Care 3 % 2 % (1) % 4 %
TOTAL
COMPANY 5 % 2 % (1) % 6 %
(1) Acquisition & Divestiture Impact/Other includes the volume and mix impact of
acquisitions and divestitures and rounding impacts necessary to reconcile net
sales to organic sales.
Adjusted Free Cash Flow. Adjusted free cash flow is defined as operating
cash flow less capital spending, tax payments related to the Merck OTC
Consumer Healthcare acquisition in 2020 and the transitional tax resulting
from the U.S. Tax Act in 2020 and 2019 (the Company incurred a transitional
tax liability of approximately $3.8 billion from the U.S. Tax Act, which is
payable over a period of 8 years). Adjusted free cash flow represents the cash
that the Company is able to generate after taking into account planned
maintenance and asset expansion. We view adjusted free cash flow as an
important measure because it is one factor used in determining the amount of
cash available for
dividends, share repurchases, acquisitions and other discretionary
investments.
The following table provides a numerical reconciliation of adjusted free cash
flow ($ millions):
Operating
Cash Flow
Capital
Spending
Adjustments to
Operating Cash Flow
(1)
Adjusted Free
Cash Flow
2020 $ 17,403 $ (3,073) $ 543 $ 14,873
2019 $ 15,242 $ (3,347) $ 235 $ 12,130
(1) Adjustments to Operating Cash Flow include tax payments for the transitional tax
resulting from the U.S. Tax Act of $215 and $235 in 2020 and 2019,
respectively, and tax payments related to the Merck acquisition of $328 in
2020.
Adjusted Free Cash Flow Productivity. Adjusted free cash flow productivity
is defined as the ratio of adjusted free cash flow to net earnings. We view
adjusted free cash flow productivity as a useful measure to help investors
understand P&G’s ability to generate cash. Adjusted free cash flow
productivity is used by management in making operating decisions, in
allocating financial resources and for budget planning purposes. This measure
is used in assessing the achievement of management goals for at-risk
compensation. The Company's long-term target is to generate annual adjusted
free cash flow productivity at or above 90 percent.
The following table provides a numerical reconciliation of adjusted free cash
flow productivity ($ millions):
Adjusted Free Cash
Flow
Net
Earnings
Adjusted Free
Cash Flow
Productivity
2020 $ 14,873 $ 13,103 114 %
Core EPS. Core EPS is a measure of the Company's diluted net earnings per share from continuing operations adjusted as indicated. Management views this non-
GAAP measure as a useful supplemental measure of Company performance over time. Core EPS is also used in assessing the achievement of management goals
for at-risk compensation. The table below provides a reconciliation of diluted net earnings per share to Core EPS, including the following reconciling items:
• Incremental Restructuring: The Company has had and continues to have an ongoing level of restructuring activities. Such activities have resulted in ongoing
annual restructuring related charges of approximately $250 - $500 million before tax. In 2012, the Company began a $10 billion strategic productivity and cost
savings initiative that included incremental restructuring activities. In 2017, we communicated details of an additional multi-year productivity and cost savings
plan. This results in incremental restructuring charges to accelerate productivity efforts and cost savings. The adjustment to Core earnings includes only the
restructuring costs above what we believe are the normal recurring level of restructuring costs.
• Gain on Dissolution of the PGT Healthcare Partnership: The Company dissolved our PGT Healthcare partnership, a venture between the Company and Teva
-- 59 of 242 --
Pharmaceuticals Industries, Ltd (Teva) in the OTC consumer healthcare business, during the year ended June 30, 2019. The transaction was accounted for as a
sale of the Teva portion of the PGT business and the Company recognized an after-tax gain on the dissolution of $353 million.
• Shave Care Impairment: As discussed in Note 4 to the Consolidated Financial Statements and in the Significant Accounting Policies and Estimates section of
the MD&A, in the fourth quarter of fiscal 2019, the Company recognized a non-cash after-tax charge of $8.0 billion ($8.3 billion before tax) to adjust the
carrying values of the Shave Care reporting unit and the Gillette indefinite-lived intangible asset. This was comprised of a before and after-tax impairment
charge of $6.8 billion related to goodwill and an after-tax impairment charge of $1.2 billion ($1.6 billion before tax) to reduce the carrying value of the Gillette
indefinite-lived intangible asset.
• Anti-Dilutive Impacts: As discussed in Note 6 to the Consolidated Financial Statements, the Shave Care impairment charges caused preferred shares that are
normally dilutive (and hence, normally assumed converted for purposes of determining diluted earnings per share) to be anti-dilutive. Accordingly, for U.S.
GAAP the preferred shares were not assumed to be converted into common shares for diluted earnings per share and the related dividends paid to the preferred
-- 60 of 242 --
32 The Procter & Gamble Company
shareholders were deducted from net income to calculate net earnings available to common shareholders. As a result of the non-GAAP Shave Care impairment
adjustment, these instruments are dilutive for non-GAAP core EPS.
We do not view the above items to be indicative of underlying business results and their exclusion from Core earnings measures provides a more comparable
measure of year-on-year results. These items are also excluded when evaluating senior management in determining their at-risk compensation.
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
(Amounts in Millions Except Per Share Amounts)
Reconciliation of Non-GAAP Measures
Twelve Months Ended June 30, 2020
AS REPORTED (GAAP) INCREMENTAL RESTRUCTURING NON-GAAP (CORE)
NET EARNINGS ATTRIBUTABLE TO P&G 13,027 415 13,442
Core EPS
DILUTED NET EARNINGS PER COMMON SHARE (1) $ 4.96 $ 0.16 $ 5.12
(1) Diluted net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
CHANGE VERSUS YEAR AGO
CORE EPS 13 %
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
(Amounts in Millions Except Per Share Amounts)
Reconciliation of Non-GAAP Measures
Twelve Months Ended June 30, 2019
AS REPORTED
(GAAP)
ANTI-
DILUTIVE
IMPACTS INCREMENTAL
RESTRUCTURING
SHAVE CARE
IMPAIRMENT
GAIN ON
DISSOLUTION OF
PGT PARTNERSHIP ROUNDING
NON-GAAP
(CORE)
NET EARNINGS ATTRIBUTABLE TO P&G 3,897 — 354 7,978 (353) 1 11,877
Core EPS
Diluted Net Earnings attributable to common
shareholders (1) 3,634 263 354 7,978 (353) 1 11,877
Diluted Weighted Average Common Shares
Outstanding (1) 2,539.5 90.2 2,629.7
DILUTED NET EARNINGS PER COMMON
SHARE $ 1.43 $ 0.06 $ 0.13 $ 3.03 $ (0.13) $ — $ 4.52
(1) The reduction in net earnings from the 2019 charge for the Shave Care impairment caused the preferred shares outstanding to be anti-dilutive. Accordingly, for U.S. GAAP, the preferred shares were not assumed
to be converted into common shares for diluted earnings per share and the related dividends paid to the preferred shareholders were deducted from net income to calculate earnings available to common
shareholders. Excluding the impairment charge results in higher non-GAAP earnings which causes the preferred shares to be dilutive. The adjustments in this row are made to reflect the dilutive preferred share
impact resulting from the Shave Care impairment adjustment.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
The information required by this item is incorporated by reference to the section entitled Other Information under Management's Disclosure and Analysis, and Note
9 to the Consolidated Financial Statements.
-- 61 of 242 --
The Procter & Gamble Company 33
Item 8. Financial Statements and Supplementary Data.
MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
Management is responsible for establishing and maintaining adequate internal control over financial reporting of The Procter & Gamble Company (as defined in
Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended). Our internal control over financial reporting is designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles in the United States of America.
Strong internal controls is an objective that is reinforced through our Worldwide Business Conduct Manual, which sets forth our commitment to conduct business
with integrity, and within both the letter and the spirit of the law. Our people are deeply committed to our Purpose, Values, and Principles, which unite us in doing
what’s right. Our system of internal controls includes written policies and procedures, segregation of duties, and the careful selection and development of
employees. Additional key elements of our internal control structure include our Global Leadership Council, which is actively involved in oversight of the business
strategies, initiatives, results and controls, our Disclosure Committee, which is responsible for evaluating disclosure implications of significant business activities
and events, our Board of Directors, which provides strong and effective corporate governance, and our Audit Committee, which reviews significant accounting
policies, financial reporting and internal control matters.
The Company's internal control over financial reporting includes a Control Self-Assessment Program that is conducted annually for critical financial reporting
areas of the Company and is audited by our Global Internal Audit organization. Management takes the appropriate action to correct any identified control
deficiencies. Global Internal Audit also performs financial and compliance audits around the world, provides training, and continuously improves our internal
control processes.
Because of its inherent limitations, any system of internal control over financial reporting, no matter how well designed, may not prevent or detect misstatements
due to the possibility that a control can be circumvented or overridden or that misstatements due to error or fraud may occur that are not detected. Also, because of
changes in conditions, internal control effectiveness may vary over time.
Management assessed the effectiveness of the Company's internal control over financial reporting as of June 30, 2020, using criteria established in Internal Control
- Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and concluded that the Company
maintained effective internal control over financial reporting as of June 30, 2020, based on these criteria.
Deloitte & Touche LLP, an independent registered public accounting firm, has audited the effectiveness of the Company's internal control over financial reporting
as of June 30, 2020, as stated in their report which is included herein.
/s/ David S. Taylor
(David S. Taylor)
Chairman of the Board, President and Chief Executive Officer
/s/ Jon R. Moeller
(Jon R. Moeller)
Vice Chairman, Chief Operating Officer and Chief Financial Officer
August 6, 2020
-- 62 of 242 --
34 The Procter & Gamble Company
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders and the Board of Directors of The Procter & Gamble Company
Opinion on the Financial Statements
We have audited the accompanying Consolidated Balance Sheets of The Procter & Gamble Company and subsidiaries (the "Company") as of June 30, 2020 and
2019, the related Consolidated Statements of Earnings, Comprehensive Income, Shareholders’ Equity and Cash Flows for each of the three years in the period
ended June 30, 2020 and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all
material respects, the financial position of the Company as of June 30, 2020 and 2019, and the results of its operations and its cash flows for each of the three years
in the period ended June 30, 2020, in conformity with accounting principles generally accepted in the United States of America.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal
control over financial reporting as of June 30, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of
Sponsoring Organizations of the Treadway Commission and our report dated August 6, 2020 expressed an unqualified opinion on the Company's internal control
over financial reporting.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements
based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such
procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe
that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be
communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken
as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or
disclosures to which it relates.
Goodwill and Intangible Assets - Shave Care Goodwill and Gillette Indefinite Lived Intangible Asset - Refer to Notes 1 and 4 to the financial statements
Critical Audit Matter Description
The Company’s evaluation of goodwill and indefinite lived intangible assets for impairment involves the comparison of the fair value of each reporting unit or
indefinite lived intangible asset to its carrying value. The Company estimates fair value using the income method, which is based on the present value of estimated
future cash flows attributable to the respective assets. This requires management to make significant estimates and assumptions related to forecasts of future net
sales and earnings, including growth rates beyond a 10-year time period, royalty rates and discount rates. Changes in the assumptions could have a significant
impact on either the fair value, the amount of any impairment charge, or both. The Company performed their annual impairment assessments of the Shave Care
reporting unit as of October 1, 2019 and the Gillette brand indefinite lived intangible asset (the “Gillette brand”) as of December 31, 2019. Because the estimated
fair values exceeded their carrying values, no impairments were recorded. Given reductions in cash flows caused by currency devaluations, changing consumer
grooming habits, the COVID-19 pandemic affecting demand and an increase in the competitive market environment, the Company revised their cash flow
estimates and updated their fair value estimates for the Gillette brand as of June 30, 2020 and determined that the fair value of the Gillette brand approximated its
carrying value. As of June 30, 2020, the Shave Care reporting unit goodwill was $12.5 billion, and the Gillette brand was $14.1 billion.
We identified the Company’s impairment evaluations of goodwill for the Shave Care reporting unit and the Gillette brand as a critical audit matter because of the
reductions in cash flows and the significant judgments made by management to estimate the
-- 63 of 242 --
The Procter & Gamble Company 35
fair values of the reporting unit and the brand. A high degree of auditor judgment and an increased extent of effort was required when performing audit procedures
to evaluate the reasonableness of management’s estimates and assumptions related to the forecasts of future net sales and earnings as well as the selection of
royalty rates and discount rates, including the need to involve our fair value specialists.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to forecasts of future net sales and earnings and the selection of the royalty rates and discount rates for the Shave Care reporting unit
and the Gillette brand included the following, among others:
• We tested the effectiveness of controls over goodwill and indefinite lived intangible assets, including those over the determination of fair value, such as controls
related to management’s development of forecasts of future net sales, earnings, the selection of royalty rates, and discount rates.
• We evaluated management’s ability to accurately forecast net sales and earnings by comparing actual results to management’s historical forecasts.
• We evaluated the reasonableness of management’s forecast of net sales and earnings by comparing the forecasts to:
• Historical net sales and earnings.
• Underlying analysis detailing business strategies and growth plans including consideration of the effects related to the COVID-19 pandemic.
• Internal communications to management and the Board of Directors.
• Forecasted information included in Company press releases as well as in analyst and industry reports for the Company and certain of its peer companies.
• With the assistance of our fair value specialists, we evaluated the net sales and earnings growth rates, royalty rates, and discount rates by:
• Testing the source information underlying the determination of net sales and earnings growth rates, royalty rates, and discount rates and the mathematical
accuracy of the calculations.
• Developing a range of independent estimates for the discount rates and comparing those to the discount rates selected by management.
/s/ Deloitte & Touche LLP
Cincinnati, Ohio
August 6, 2020
We have served as the Company’s auditor since 1890.
-- 64 of 242 --
36 The Procter & Gamble Company
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders and the Board of Directors of The Procter & Gamble Company
Opinion on Internal Control over Financial Reporting
We have audited the internal control over financial reporting of The Procter & Gamble Company and subsidiaries (the "Company") as of June 30, 2020, based on
criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of June 30, 2020, based on criteria
established in Internal Control - Integrated Framework (2013) issued by COSO.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial
statements as of and for the year ended June 30, 2020, of the Company and our report dated August 6, 2020, expressed an unqualified opinion on those financial
statements.
Basis for Opinion
The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal
control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express
an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the
Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal
control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control
based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable
basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial
reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of
financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in
accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with
the policies or procedures may deteriorate.
/s/ Deloitte & Touche LLP
Cincinnati, Ohio
August 6, 2020
-- 65 of 242 --
The Procter & Gamble Company 37
Consolidated Statements of Earnings
Amounts in millions except per share amounts; Years ended June 30 2020 2019 2018
NET SALES $ 70,950 $ 67,684 $ 66,832
Cost of products sold 35,250 34,768 34,432
Selling, general and administrative expense 19,994 19,084 19,037
Goodwill and indefinite-lived intangibles impairment charges — 8,345 —
OPERATING INCOME 15,706 5,487 13,363
Interest expense (465) (509) (506)
Interest income 155 220 247
Other non-operating income, net 438 871 222
EARNINGS BEFORE INCOME TAXES 15,834 6,069 13,326
Income taxes 2,731 2,103 3,465
NET EARNINGS 13,103 3,966 9,861
Less: Net earnings attributable to noncontrolling interests 76 69 111
NET EARNINGS ATTRIBUTABLE TO PROCTER & GAMBLE (1) $ 13,027 $ 3,897 $ 9,750
NET EARNINGS PER COMMON SHARE: (2)
Basic $ 5.13 $ 1.45 $ 3.75
Diluted $ 4.96 $ 1.43 $ 3.67
(1) Net earnings attributable to Procter & Gamble in fiscal 2019 was negatively impacted by the impairment charges of $8.3 billion related to Shave Care goodwill and Gillette
indefinite-lived intangible assets.
(2) Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
See accompanying Notes to Consolidated Financial Statements.
-- 66 of 242 --
38 The Procter & Gamble Company
Consolidated Statements of Comprehensive Income
Amounts in millions; Years ended June 30 2020 2019 2018
NET EARNINGS $ 13,103 $ 3,966 $ 9,861
OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX
Foreign currency translation (net of $59, $78 and $(279) tax, respectively) (1,083) (213) (305)
Unrealized gains/(losses) on investment securities (net of $(1), $0 and $0 tax, respectively) (12) 184 (148)
Unrealized gains/(losses) on defined benefit retirement plans (net of $(42), $22 and $68 tax, respectively) (150) 169 334
TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX (1,245) 140 (119)
TOTAL COMPREHENSIVE INCOME 11,858 4,106 9,742
Less: Total comprehensive income attributable to noncontrolling interests 60 70 109
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER & GAMBLE $ 11,798 $ 4,036 $ 9,633
See accompanying Notes to Consolidated Financial Statements.
-- 67 of 242 --
The Procter & Gamble Company 39
Consolidated Balance Sheets
Amounts in millions except stated values; As of June 30 2020 2019
Assets
CURRENT ASSETS
Cash and cash equivalents $ 16,181 $ 4,239
Available-for-sale investment securities — 6,048
Accounts receivable 4,178 4,951
INVENTORIES
Materials and supplies 1,414 1,289
Work in process 674 612
Finished goods 3,410 3,116
Total inventories 5,498 5,017
Prepaid expenses and other current assets 2,130 2,218
TOTAL CURRENT ASSETS 27,987 22,473
PROPERTY, PLANT AND EQUIPMENT, NET 20,692 21,271
GOODWILL 39,901 40,273
TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET 23,792 24,215
OTHER NONCURRENT ASSETS 8,328 6,863
TOTAL ASSETS $ 120,700 $ 115,095
Liabilities and Shareholders' Equity
CURRENT LIABILITIES
Accounts payable $ 12,071 $ 11,260
Accrued and other liabilities 9,722 9,054
Debt due within one year 11,183 9,697
TOTAL CURRENT LIABILITIES 32,976 30,011
LONG-TERM DEBT 23,537 20,395
DEFERRED INCOME TAXES 6,199 6,899
OTHER NONCURRENT LIABILITIES 11,110 10,211
TOTAL LIABILITIES 73,822 67,516
SHAREHOLDERS' EQUITY
Convertible Class A preferred stock, stated value $1 per share (600 shares authorized) 897 928
Non-Voting Class B preferred stock, stated value $1 per share (200 shares authorized) — —
Common stock, stated value $1 per share (10,000 shares authorized; shares issued: 2020 - 4,009.2, 2019 - 4,009.2) 4,009 4,009
Additional paid-in capital 64,194 63,827
Reserve for ESOP debt retirement (1,080) (1,146)
Accumulated other comprehensive income/(loss) (16,165) (14,936)
Treasury stock, at cost (shares held: 2020 - 1,529.5, 2019 - 1,504.5) (105,573) (100,406)
Retained earnings 100,239 94,918
Noncontrolling interest 357 385
TOTAL SHAREHOLDERS' EQUITY 46,878 47,579
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 120,700 $ 115,095
See accompanying Notes to Consolidated Financial Statements.
-- 68 of 242 --
40 The Procter & Gamble Company
Consolidated Statements of Shareholders' Equity
Dollars in millions except per
share amounts; shares in
thousands
Common Stock
Preferred
Stock
Add-itional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumu-lated
Other
Comp-rehensive
Income/(Loss) Treasury Stock
Retained
Earnings
Non-
controlling
Interest
Total Share-
holders'
Equity Shares Amount
BALANCE JUNE 30, 2017 2,553,297 $4,009 $1,006 $63,641 ($1,249) ($14,632) ($93,715) $96,124 $594 $55,778
Net earnings 9,750 111 9,861
Other comprehensive
income/(loss) (117) (2) (119)
Dividends and dividend
equivalents ($2.7860 per share):
Common (7,057) (7,057)
Preferred, net of tax benefits (265) (265)
Treasury stock purchases (81,439) (7,004) (7,004)
Employee stock plans 21,655 199 1,469 1,668
Preferred stock conversions 4,580 (39) 6 33 —
ESOP debt impacts 45 89 134
Noncontrolling interest, net (113) (113)
BALANCE JUNE 30, 2018 2,498,093 $4,009 $967 $63,846 ($1,204) ($14,749) ($99,217) $98,641 $590 $52,883
Impact of adoption of new
accounting standards (326) (200) (27) (553)
Net earnings 3,897 69 3,966
Other comprehensive
income/(loss) 139 1 140
Dividends and dividend
equivalents ($2.8975 per share):
Common (7,256) (7,256)
Preferred, net of tax benefits (263) (263)
Treasury stock purchases (53,714) (5,003) (5,003)
Employee stock plans 55,734 93 3,781 3,874
Preferred stock conversions 4,638 (39) 6 33 —
ESOP debt impacts 58 99 157
Noncontrolling interest, net (118) (248) (366)
BALANCE JUNE 30, 2019 2,504,751 $4,009 $928 $63,827 ($1,146) ($14,936) ($100,406) $94,918 $385 $47,579
Net earnings 13,027 76 13,103
Other comprehensive
income/(loss) (1,229) (16) (1,245)
Dividends and dividend
equivalents ($3.0284 per share):
Common (7,551) (7,551)
Preferred, net of tax benefits (263) (263)
Treasury stock purchases (61,346) (7,405) (7,405)
Employee stock plans 32,603 362 2,212 2,574
Preferred stock conversions 3,738 (31) 5 26 —
ESOP debt impacts 66 108 174
Noncontrolling interest, net (88) (88)
BALANCE JUNE 30, 2020 2,479,746 $4,009 $897 $64,194 ($1,080) ($16,165) ($105,573) $100,239 $357 $46,878
See accompanying Notes to Consolidated Financial Statements.
-- 69 of 242 --
The Procter & Gamble Company 41
Consolidated Statements of Cash Flows
Amounts in millions; Years ended June 30 2020 2019 2018
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF YEAR $ 4,239 $ 2,569 $ 5,569
OPERATING ACTIVITIES
Net earnings 13,103 3,966 9,861
Depreciation and amortization 3,013 2,824 2,834
Loss on early extinguishment of debt — — 346
Share-based compensation expense 558 515 395
Deferred income taxes (596) (411) (1,844)
Loss/(gain) on sale of assets 7 (678) (176)
Goodwill and indefinite-lived intangible impairment charges — 8,345 —
Change in accounts receivable 634 (276) (177)
Change in inventories (637) (239) (188)
Change in accounts payable, accrued and other liabilities 1,923 1,856 1,385
Change in other operating assets and liabilities (710) (973) 2,000
Other 108 313 431
TOTAL OPERATING ACTIVITIES 17,403 15,242 14,867
INVESTING ACTIVITIES
Capital expenditures (3,073) (3,347) (3,717)
Proceeds from asset sales 30 394 269
Acquisitions, net of cash acquired (58) (3,945) (109)
Purchases of short-term investments — (158) (3,909)
Proceeds from sales and maturities of investment securities 6,151 3,628 3,928
Change in other investments (5) (62) 27
TOTAL INVESTING ACTIVITIES 3,045 (3,490) (3,511)
FINANCING ACTIVITIES
Dividends to shareholders (7,789) (7,498) (7,310)
Increases/(reductions) in short-term debt 2,345 (2,215) (3,437)
Additions to long-term debt 4,951 2,367 5,072
Reductions of long-term debt (1) (2,447) (969) (2,873)
Treasury stock purchases (7,405) (5,003) (7,004)
Impact of stock options and other 1,978 3,324 1,177
TOTAL FINANCING ACTIVITIES (8,367) (9,994) (14,375)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED
CASH (139) (88) 19
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 11,942 1,670 (3,000)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF YEAR $ 16,181 $ 4,239 $ 2,569
SUPPLEMENTAL DISCLOSURE
Cash payments for interest $ 434 $ 497 $ 529
Cash payment for income taxes 3,550 3,064 2,830
Assets acquired through non-cash finance leases are immaterial for all periods.
(1) Includes early extinguishment of debt costs of $346 in 2018.
See accompanying Notes to Consolidated Financial Statements.
-- 70 of 242 --
42 The Procter & Gamble Company
Notes to Consolidated Financial Statements
NOTE 1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations
The Procter & Gamble Company's (the "Company," "Procter & Gamble,"
"we" or "us") business is focused on providing branded consumer packaged
goods of superior quality and value. Our products are sold in more than 180
countries and territories primarily through mass merchandisers, e-commerce,
grocery stores, membership club stores, drug stores, department stores,
distributors, wholesalers, baby stores, specialty beauty stores (including
airport duty-free stores), high-frequency stores, pharmacies, electronics stores
and professional channels. We have on-the-ground operations in
approximately 70 countries.
Basis of Presentation
The Consolidated Financial Statements include the Company and its
controlled subsidiaries. Intercompany transactions are eliminated.
Because of a lack of control over Venezuelan subsidiaries caused by a
number of currency and other operating controls and restrictions, our
Venezuelan subsidiaries are not consolidated for any year presented. We
account for those subsidiaries at cost, less impairments, plus or minus
observable price changes.
Use of Estimates
Preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America (U.S. GAAP) requires
management to make estimates and assumptions that affect the amounts
reported in the Consolidated Financial Statements and accompanying
disclosures. These estimates are based on management's best knowledge of
current events and actions the Company may undertake in the future.
Estimates are used in accounting for, among other items, consumer and trade
promotion accruals, restructuring reserves, pensions, post-employment
benefits, stock options, valuation of acquired intangible assets, useful lives for
depreciation and amortization of long-lived assets, future cash flows
associated with impairment testing for goodwill, indefinite-lived intangible
assets and other long-lived assets, deferred tax assets and liabilities, uncertain
income tax positions and contingencies. Actual results may ultimately differ
from estimates, although management does not generally believe such
differences would materially affect the financial statements in any individual
year. However, in regard to ongoing impairment testing of goodwill and
indefinite-lived intangible assets, significant deterioration in future cash flow
projections or other assumptions used in estimating fair values versus those
anticipated at the time of the initial valuations, could result in impairment
charges that materially affect the financial statements in a given year.
Revenue Recognition
Our revenue is primarily generated from the sale of finished product to
customers. Those sales predominantly contain a
single performance obligation and revenue is recognized at a single point in
time when ownership, risks and rewards transfer, which can be on the date of
shipment or the date of receipt by the customer. A provision for payment
discounts and product return allowances is recorded as a reduction of sales in
the same period the revenue is recognized. The revenue recorded is presented
net of sales and other taxes we collect on behalf of governmental authorities.
The revenue includes shipping and handling costs, which generally are
included in the list price to the customer.
Trade promotions, consisting primarily of customer pricing allowances,
merchandising funds and consumer coupons, are offered through various
programs to customers and consumers. Sales are recorded net of trade
promotion spending, which is recognized as incurred at the time of the sale.
Most of these arrangements have terms of approximately one year. Accruals
for expected payouts under these programs are included as accrued marketing
and promotion in the Accrued and other liabilities line item in the
Consolidated Balance Sheets.
Cost of Products Sold
Cost of products sold is primarily comprised of direct materials and supplies
consumed in the manufacturing of product, as well as manufacturing labor,
depreciation expense and direct overhead expenses necessary to acquire and
-- 71 of 242 --
convert the purchased materials and supplies into finished products. Cost of
products sold also includes the cost to distribute products to customers,
inbound freight costs, internal transfer costs, warehousing costs and other
shipping and handling activity.
Selling, General and Administrative Expense
Selling, general and administrative expense (SG&A) is primarily comprised
of marketing expenses, selling expenses, research and development costs,
administrative and other indirect overhead costs, depreciation and
amortization expense on non-manufacturing assets and other miscellaneous
operating items. Research and development costs are charged to expense as
incurred and were $1.8 billion in 2020, $1.9 billion in 2019 and $1.9 billion in
2018. Advertising costs, charged to expense as incurred, include worldwide
television, print, radio, internet and in-store advertising expenses and were
$7.3 billion in 2020, $6.8 billion in 2019 and $7.1 billion in 2018. Non-
advertising related components of the Company's total marketing spending
reported in SG&A include costs associated with consumer promotions,
product sampling and sales aids.
Other Non-Operating Income, Net
Other non-operating income, net primarily includes net acquisition and
divestiture gains, net non-service costs related to defined benefit plans,
investment income and other non-operating items.
Currency Translation
Financial statements of operating subsidiaries outside the U.S. generally are
measured using the local currency as the functional currency. Adjustments to
translate those
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 72 of 242 --
The Procter & Gamble Company 43
statements into U.S. dollars are recorded in Other comprehensive income
(OCI). For subsidiaries operating in highly inflationary economies, the U.S.
dollar is the functional currency. Re-measurement adjustments for financial
statements in highly inflationary economies and other transactional exchange
gains and losses are reflected in earnings.
Cash Flow Presentation
The Consolidated Statements of Cash Flows are prepared using the indirect
method, which reconciles net earnings to cash flows from operating activities.
Cash flows from foreign currency transactions and operations are translated at
monthly exchange rates for each period. Cash flows from hedging activities
are included in the same category as the items being hedged. Cash flows from
derivative instruments designated as net investment hedges are classified as
financing activities. Realized gains and losses from non-qualifying derivative
instruments used to hedge currency exposures resulting from intercompany
financing transactions are also classified as financing activities. Cash flows
from other derivative instruments used to manage interest rates, commodity
or other currency exposures are classified as operating activities. Cash
payments related to income taxes are classified as operating activities.
Investments
Investment securities have primarily consisted of readily marketable debt
securities. Unrealized gains or losses from debt securities classified as
trading, if any, are charged to earnings. Unrealized gains or losses on debt
securities classified as available-for-sale are recorded in OCI. If an available-
for-sale security is other than temporarily impaired, the loss is charged to
either earnings or OCI depending on our intent and ability to retain the
security until we recover the full cost basis and the extent of the loss
attributable to the creditworthiness of the issuer. Debt securities are included
as Available-for-sale investment securities and Other noncurrent assets in the
Consolidated Balance Sheets.
In addition to debt securities, we hold minor equity investments in certain
companies over which we exert significant influence, but do not control the
financial and operating decisions. These are accounted for as equity method
investments. Other equity investments that are not controlled, and over which
we do not have the ability to exercise significant influence, and for which
there is a readily determinable market value, are recorded at fair value, with
gains and losses recorded through net earnings. Equity investments without
readily determinable fair values are measured at cost, less impairments, plus
or minus observable price changes. Equity investments are included as Other
noncurrent assets in the Consolidated Balance Sheets.
Inventory Valuation
Inventories are valued at the lower of cost or net realizable value. Product-
related inventories are maintained on the first-in, first-out method. The cost of
spare part inventories is maintained using the average-cost method.
Property, Plant and Equipment
Property, plant and equipment is recorded at cost reduced by accumulated
depreciation. Depreciation expense is recognized over the assets' estimated
useful lives using the straight-line method. Machinery and equipment
includes office furniture and fixtures (15-year life), computer equipment and
capitalized software (3- to 5-year lives) and manufacturing equipment (3- to
20-year lives). Buildings are depreciated over an estimated useful life of 40
years. Estimated useful lives are periodically reviewed and, when appropriate,
changes are made prospectively. When certain events or changes in operating
conditions occur, asset lives may be adjusted and an impairment assessment
may be performed on the recoverability of the carrying amounts.
Goodwill and Other Intangible Assets
Goodwill and indefinite-lived intangible assets are not amortized, but are
evaluated for impairment annually or more often if indicators of a potential
impairment are present. Our annual impairment testing of goodwill is
performed separately from our impairment testing of indefinite-lived
intangible assets.
We have acquired brands that have been determined to have indefinite lives.
We evaluate a number of factors to determine whether an indefinite life is
appropriate, including the competitive environment, market share, brand
history, underlying product life cycles, operating plans and the
macroeconomic environment of the countries in which the brands are sold. In
-- 73 of 242 --
addition, when certain events or changes in operating conditions occur, an
additional impairment assessment is performed and indefinite-lived assets
may be adjusted to a determinable life.
The cost of intangible assets with determinable useful lives is amortized to
reflect the pattern of economic benefits consumed, either on a straight-line or
accelerated basis over the estimated periods benefited. Patents, technology
and other intangible assets with contractual terms are generally amortized
over their respective legal or contractual lives. Customer relationships, brands
and other non-contractual intangible assets with determinable lives are
amortized over periods generally ranging from 5 to 30 years. When certain
events or changes in operating conditions occur, an impairment assessment is
performed and remaining lives of intangible assets with determinable lives
may be adjusted.
For additional details on goodwill and intangible assets see Note 4.
Fair Values of Financial Instruments
Certain financial instruments are required to be recorded at fair value.
Changes in assumptions or estimation methods could affect the fair value
estimates; however, we do not believe any such changes would have a
material impact on our financial condition, results of operations or cash flows.
Other financial instruments, including cash equivalents, certain investments
and short-term debt, are recorded at cost, which approximates fair value. The
fair values of long-term debt and financial instruments are disclosed in Note
9.
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 74 of 242 --
44 The Procter & Gamble Company
New Accounting Pronouncements and Policies
On July 1, 2019, we adopted ASU 2016-02, "Leases (Topic 842)." The new
accounting standard requires the recognition of right-of-use assets and lease
liabilities for all long-term leases, including operating leases, on the balance
sheet. We elected the optional transition method and adopted the new
guidance on a modified retrospective basis with no restatement of prior period
amounts. As allowed under the new accounting standard, we elected to apply
practical expedients to carry forward the original lease determinations, lease
classifications and accounting of initial direct costs for all asset classes at the
time of adoption. The adoption did not have a material impact on our
financial statements, resulting in an increase of approximately 1% to each of
our total assets and total liabilities on our balance sheet as of July 1, 2019.
See Note 12 for further information.
In January 2017, the FASB issued ASU 2017-04, "Intangibles-Goodwill and
Other (Topic 350): Simplifying the Test for Goodwill Impairment." The
standard simplifies the accounting for goodwill impairment by requiring a
goodwill impairment to be measured using a single step impairment model,
whereby the impairment equals the difference between the carrying amount
and the estimated fair value of the specified reporting units in their entirety.
This eliminates the second step of the current impairment model that requires
companies to first estimate the fair value of all assets in a reporting unit and
measure impairments based on those estimated fair values and a residual
measurement approach. The new standard also specifies that any loss
recognized should not exceed the total amount of goodwill allocated to that
reporting unit. We will adopt the standard effective July 1, 2020. The impact
of the new standard will be dependent on the specific facts and circumstances
of future individual impairments, if any.
In March 2020, the FASB issued ASU 2020-04, "Reference Rate Reform
(Topic 848): Facilitation of the Effects of Reference Rate Reform on
Financial Reporting." The amendments provide optional guidance for a
limited time to ease the potential burden in accounting for reference rate
reform. The new guidance provides optional expedients and exceptions for
applying U.S. GAAP to contracts, hedging relationships and other
transactions affected by reference rate reform if certain criteria are met. The
amendments apply only to contracts and hedging relationships that reference
LIBOR or another reference rate expected to be discontinued due to reference
rate reform. These amendments are effective immediately and may be applied
prospectively to contract modifications made and hedging relationships
entered into or evaluated on or before December 31, 2022. We are currently
evaluating our contracts and the optional expedients provided by the new
standard.
No other new accounting pronouncements issued or effective during the fiscal
year or in future years had, or are expected to have, a material impact on our
Consolidated Financial Statements.
NOTE 2
SEGMENT INFORMATION
Under U.S. GAAP, our operating segments are aggregated into five reportable
segments: 1) Beauty, 2) Grooming, 3) Health Care, 4) Fabric & Home Care
and 5) Baby, Feminine & Family Care. Our five reportable segments are
comprised of:
• Beauty: Hair Care (Conditioner, Shampoo, Styling Aids, Treatments);
Skin and Personal Care (Antiperspirant and Deodorant, Personal
Cleansing, Skin Care);
• Grooming: Shave Care (Female Blades & Razors, Male Blades &
Razors, Pre- and Post-Shave Products, Other Shave Care); Appliances
• Health Care: Oral Care (Toothbrushes, Toothpaste, Other Oral Care);
Personal Health Care (Gastrointestinal, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Pain Relief, Other Personal Health
Care);
• Fabric & Home Care: Fabric Care (Fabric Enhancers, Laundry
Additives, Laundry Detergents); Home Care (Air Care, Dish Care, P&G
Professional, Surface Care); and
• Baby, Feminine & Family Care: Baby Care (Baby Wipes, Taped Diapers
and Pants); Feminine Care (Adult Incontinence, Feminine Care); Family
Care (Paper Towels, Tissues, Toilet Paper).
-- 75 of 242 --
While none of our reportable segments are highly seasonal, components
within certain reportable segments, such as Appliances (Grooming) and
Personal Health Care (Health), are seasonal.
The accounting policies of the segments are generally the same as those
described in Note 1. Differences between these policies and U.S. GAAP
primarily reflect income taxes, which are reflected in the segments using
applicable blended statutory rates. Adjustments to arrive at our effective tax
rate are included in Corporate, including the impacts from the U.S. Tax Act in
fiscal 2018 (see Note 5).
Corporate includes certain operating and non-operating activities that are not
reflected in the operating results used internally to measure and evaluate the
businesses, as well as items to adjust management reporting principles to U.S.
GAAP. Operating activities in Corporate include the results of incidental
businesses managed at the corporate level. Operating elements also include
certain employee benefit costs, the costs of certain restructuring-type
activities to maintain a competitive cost structure, including manufacturing
and workforce optimization, certain significant asset impairment charges and
other general Corporate items. The non-operating elements in Corporate
primarily include interest expense, certain pension and other postretirement
benefit costs, certain acquisition and divestiture gains, interest and investing
income and other financing costs.
Total assets for the reportable segments include those assets managed by the
reportable segment, primarily inventory,
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 76 of 242 --
The Procter & Gamble Company 45
fixed assets and intangible assets. Other assets, primarily cash, accounts
receivable, investment securities, leased assets and goodwill, are included in
Corporate.
Our operating segments are comprised of similar product categories.
Operating segments that individually accounted for 5% or more of
consolidated net sales are as follows:
% of Net sales by operating segment (1)
Years ended June 30 2020 2019 2018
Fabric Care 22% 22% 22%
Baby Care 11% 12% 13%
Home Care 11% 10% 10%
Skin and Personal Care 10% 10% 9%
Hair Care 9% 10% 10%
Family Care 9% 9% 8%
Oral Care 8% 8% 8%
Shave Care 7% 8% 8%
Feminine Care 6% 6% 6%
Personal Health Care 5% 4% 4%
All Other 2% 1% 2%
TOTAL 100% 100% 100%
(1) % of Net sales by operating segment excludes sales held in Corporate.
Net sales and long-lived assets in the United States and internationally were
as follows (in billions):
Years ended June 30 2020 2019 2018
NET SALES
United States $ 31.3 $ 28.6 $ 27.3
International $ 39.7 $ 39.1 $ 39.5
LONG-LIVED ASSETS (1)
United States $ 9.9 $ 10.0 $ 9.7
International $ 10.8 $ 11.3 $ 10.9
(1) Long-lived assets consists of property, plant and equipment.
No country, other than the United States, exceeds 10% of the consolidated net
sales or long-lived assets.
Our largest customer, Walmart Inc. and its affiliates, accounted for
consolidated net sales of approximately 15% in 2020, 2019 and 2018. No
other customer represents more than 10% of our consolidated net sales.
Global
Segment
Results Net Sales
Earnings/(Loss)
Before
Income Taxes Net Earnings/(Loss)
Depreciation
and
Amortization
Total
Assets
Capital
Expenditures
BEAUTY 2020 $ 13,359 $ 3,437 $ 2,737 $ 320 $ 5,531 $ 397
2019 12,897 3,282 2,637 272 5,362 634
2018 12,406 3,042 2,320 236 4,709 766
GROOMING 2020 6,069 1,613 1,329 406 20,589 305
2019 6,199 1,777 1,529 429 20,882 367
2018 6,551 1,801 1,432 447 22,609 364
HEALTH
CARE 2020 9,028 2,156 1,652 350 7,726 338
2019 8,218 1,984 1,519 294 7,708 363
2018 7,857 1,922 1,283 230 5,254 330
FABRIC &
HOME CARE 2020 23,735 5,426 4,154 605 7,745 887
2019 22,080 4,601 3,518 557 7,620 984
2018 21,441 4,191 2,708 534 7,295 1,020
BABY,
-- 77 of 242 --
FEMININE &
FAMILY
CARE 2020 18,364 4,534 3,465 839 8,628 764
2019 17,806 3,593 2,734 861 9,271 819
2018 18,080 3,527 2,251 899 9,682 1,016
CORPORATE
(1) 2020 395 (1,332) (234) 493 70,481 382
2019 484 (9,168) (7,971) 411 64,252 180
2018 497 (1,157) (133) 488 68,761 221
TOTAL
COMPANY 2020 $ 70,950 $ 15,834 $ 13,103 $ 3,013 $ 120,700 $ 3,073
2019 67,684 6,069 3,966 2,824 115,095 3,347
2018 66,832 13,326 9,861 2,834 118,310 3,717
(1) The Corporate reportable segment includes the $8.3 billion non-cash before-tax ($8.0
billion after-tax) goodwill and intangible asset impairment charge in fiscal 2019. For
additional details on goodwill and intangible assets see Note 4.
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 78 of 242 --
46 The Procter & Gamble Company
NOTE 3
SUPPLEMENTAL FINANCIAL
INFORMATION
The components of property, plant
and equipment were as follows:
As of June 30 2020 2019
PROPERTY, PLANT AND
EQUIPMENT
Buildings $ 7,700 $ 7,746
Machinery and
equipment 33,260 32,263
Land 777 805
Construction in
progress 2,034 2,579
TOTAL
PROPERTY,
PLANT AND
EQUIPMENT 43,771 43,393
Accumulated
depreciation (23,079) (22,122)
PROPERTY,
PLANT AND
EQUIPMENT,
NET $ 20,692 $ 21,271
Selected components of current and
noncurrent liabilities were as
follows:
As of June 30 2020 2019
ACCRUED AND OTHER
LIABILITIES - CURRENT
Marketing
and
promotion $ 3,531 $ 4,299
Compensation
expenses 1,921 1,623
Restructuring
reserves 472 468
Taxes payable 693 341
Other 3,105 2,323
TOTAL $ 9,722 $ 9,054
OTHER NONCURRENT
LIABILITIES
Pension
benefits $ 6,223 $ 5,622
Other
postretirement
benefits 965 1,098
U.S. Tax Act
transitional
tax payable 2,121 2,343
Uncertain tax
positions 580 472
Long term
operating
leases 652 —
Other 569 676
-- 79 of 242 --
TOTAL $ 11,110 $ 10,211
RESTRUCTURING PROGRAM
The Company has historically
incurred an ongoing annual level of
restructuring-type activities to
maintain a competitive cost
structure, including manufacturing
and workforce optimization. Before-
tax costs incurred under the ongoing
program have generally ranged from
$250 to $500 annually. In fiscal
2012, the Company initiated an
incremental restructuring program
(covering fiscal 2012 through 2017)
as part of a productivity and cost
savings plan to reduce costs in the
areas of supply chain, research and
development, marketing activities
and overhead expenses. The
productivity and cost savings plan
was designed to accelerate cost
reductions by streamlining
management decision making,
manufacturing and other work
processes in order to help fund the
Company's growth strategy.
In fiscal 2017, the Company
announced specific elements of an
additional incremental multi-year
productivity and cost savings plan to
further reduce costs in the areas of
supply chain, certain marketing
activities and overhead expenses.
This program is resulting in
incremental targeted enrollment
reductions, along with further
optimization of the supply chain and
other manufacturing processes.
Restructuring costs incurred consist
primarily of costs to separate
employees, asset-related costs to exit
facilities and other costs. The
Company incurred total restructuring
charges of $782 and $754 for the
years ended June 30, 2020 and 2019,
respectively. Of the charges incurred
for fiscal year 2020, $155 were
recorded in SG&A, $614 in Costs of
products sold, and $13 in Other non-
operating income/(expense), net. Of
the charges incurred for fiscal year
2019, $213 were recorded in SG&A,
$521 in Costs of products sold, and
$20 in Other non-operating
income/(expense), net. The
following table presents restructuring
activity for the years ended June 30,
2020 and 2019:
Separations
Asset-
Related
Costs Other Total
RESERVE
JUNE 30,
2018 $ 259 $ — $ 254 $ 513
Charges 260 252 242 754
Cash spent (239) — (308) (547)
Charges
against
assets — (252) — (252)
RESERVE
-- 80 of 242 --
JUNE 30,
2019 280 — 188 468
Charges 221 372 189 782
Cash spent (216) — (190) (406)
Charges
against
assets — (372) — (372)
RESERVE
JUNE 30,
2020 $ 285 $ — $ 187 $ 472
Separation Costs
Employee separation charges for the
years ended June 30, 2020 and 2019
relate to severance packages for
approximately 1,200 and 1,810
employees, respectively. The
packages were primarily voluntary
and the amounts were calculated
based on salary levels and past
service periods. Severance costs
related to voluntary separations are
generally charged to earnings when
the employee accepts the offer.
Asset-Related Costs
Asset-related costs consist of both
asset write-downs and accelerated
depreciation. Asset write-downs
relate to the establishment of a new
fair value basis for assets held-for-
sale or for disposal. These assets
were written down to the lower of
their current carrying basis or
amounts expected to be realized
upon disposal, less minor disposal
costs. Charges for accelerated
depreciation relate to long-lived
assets that will be taken out of
service prior to the end of their
normal service period. These assets
relate primarily to
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 81 of 242 --
The Procter & Gamble Company 47
manufacturing consolidations and
technology standardizations. The
asset-related charges will not have a
significant impact on future
depreciation charges.
Other Costs
Other restructuring-type charges are
incurred as a direct result of the
restructuring program. Such charges
primarily include asset removal and
termination of contracts related to
supply chain optimization.
Consistent with our historical
policies for ongoing restructuring-
type activities, the restructuring
program charges are funded by and
included within Corporate for both
management and segment reporting.
Accordingly, all of the charges under
the program are included within the
Corporate reportable segment.
However, for information purposes,
the following table summarizes the
total restructuring costs related to our
reportable segments:
Years ended
June 30 2020 2019 2018
Beauty $ 54 $ 49 $ 60
Grooming 102 65 38
Health Care 136 23 21
Fabric &
Home Care 75 84 115
Baby,
Feminine &
Family
Care 192 226 547
Corporate
(1) 223 307 289
Total
Company $ 782 $ 754 $ 1,070
(1) Corporate includes costs related to
allocated overheads, including charges
related to our Enterprise Markets,
Global Business Services and
Corporate Functions activities.
NOTE 4
GOODWILL AND INTANGIBLE ASSETS
The change in the net carrying amount of goodwill by reportable segment was
as follows:
Beauty Grooming
Health
Care
Fabric &
Home
Care
Baby,
Feminine
& Family
Care Corporate
Total
Company
BALANCE
AT JUNE
30, 2018 -
NET (1) $ 12,992 $ 19,820 $ 5,929 $ 1,865 $ 4,569 $ — $ 45,175
Acquisitions
and
divestitures 132 — 2,084 6 57 — 2,279
Goodwill
impairment
charges — (6,783) — — — — (6,783)
Translation
-- 82 of 242 --
and other (139) (156) (41) (16) (46) — (398)
BALANCE
AT JUNE 30,
2019 - NET
(1) 12,985 12,881 7,972 1,855 4,580 — 40,273
Acquisitions
and
divestitures (1) — (46) — 5 — (42)
Translation
and other (82) (66) (140) (14) (28) — (330)
BALANCE
AT JUNE 30,
2020 - NET
(1) $ 12,902 $ 12,815 $ 7,786 $ 1,841 $ 4,557 $ — $ 39,901
(1) Grooming goodwill balance is net of $1.2 billion accumulated impairment losses
as of June 30, 2018 and $7.9 billion as of June 30, 2019 and 2020.
Goodwill and indefinite-lived
intangibles are tested for impairment
at least annually by comparing the
estimated fair values of our reporting
units and underlying indefinite-lived
intangible assets to their respective
carrying values. We typically use an
income method to estimate the fair
value of these assets, which is based
on forecasts of the expected future
cash flows attributable to the
respective assets. Significant
estimates and assumptions inherent
in the valuations reflect a
consideration of other marketplace
participants, and include the amount
and timing of future cash flows
(including expected growth rates and
profitability). Estimates utilized in
the projected cash flows include
consideration of macroeconomic
conditions, overall category growth
rates, competitive activities, cost
containment and margin expansion,
Company business plans, the
underlying product or technology
life cycles, economic barriers to
entry, a brand's relative market
position and the discount rate applied
to the cash flows. Unanticipated
market or macroeconomic events
and
circumstances may occur, which
could affect the accuracy or validity
of the estimates and assumptions.
We believe the estimates and
assumptions utilized in our
impairment testing are reasonable
and are comparable to those that
would be used by other marketplace
participants. However, actual events
and results could differ substantially
from those used in our valuations. To
the extent such factors result in a
failure to achieve the level of
projected cash flows initially used to
estimate fair value for purposes of
establishing or subsequently
impairing the carrying amount of
goodwill and related intangible
assets, we may need to record
additional non-cash impairment
charges in the future.
The change in goodwill during fiscal
-- 83 of 242 --
2020 primarily reflects opening
balance sheet adjustments from the
prior year acquisition of the over-
the-counter (OTC) healthcare
business of Merck KGaA (Merck
OTC) in the Health Care reportable
segment (see Note 14) and currency
translation across all reportable
segments.
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 84 of 242 --
48 The Procter & Gamble Company
During fiscal 2019, we determined
that the estimated fair value of our
Shave Care reporting unit was less
than its carrying value. We also
determined that the estimated fair
value of the Gillette indefinite-lived
intangible asset was less than its
carrying value. As a result, we
recorded non-cash impairment
charges for both assets. These
reductions were due in large part to
significant currency devaluations in
a number of countries relative to the
U.S. dollar, a deceleration of
category growth caused by changing
grooming habits, primarily in the
developed markets, and an increased
competitive market environment in
the U.S. and certain other markets,
which collectively resulted in
reduced cash flow projections. A
non-cash, before and after-tax
impairment charge of $6.8 billion
was recognized to reduce the
carrying amount of goodwill for the
Shave Care reporting unit.
Additionally, a non-cash, before-tax
impairment charge of $1.6
billion ($1.2 billion after-tax) was
recognized to reduce the carrying
amount of the Gillette indefinite-
lived intangible asset to its estimated
fair value as of June 30, 2019.
During fiscal 2019, the Company
completed the acquisition of the
healthcare business of Merck OTC,
which is included in the Health Care
reportable segment (see Note 14),
along with other minor acquisitions
in the Beauty, the Baby, Feminine &
Family Care and the Fabric & Home
Care reportable segments. These
goodwill increases were partially
offset by the divestiture of the Teva
portion of the PGT business in the
Health Care reportable segment and
currency translation in fiscal 2019.
Identifiable intangible assets were
comprised of:
2020 2019
As of June
30
Gross
Carrying
Amount
Accumulated
Amortization
Gross
Carrying
Amount
Accumulated
Amortization
INTANGIBLE ASSETS WITH DETERMINABLE
LIVES
Brands $ 3,820 $ (2,347) $ 3,836 $ (2,160)
Patents and
technology 2,776 (2,513) 2,776 (2,434)
Customer
relationships 1,752 (778) 1,787 (691)
Other 143 (92) 145 (91)
TOTAL $ 8,491 $ (5,730) $ 8,544 $ (5,376)
INTANGIBLE ASSETS WITH INDEFINITE LIVES
Brands 21,031 — 21,047 —
TOTAL $ 29,522 $ (5,730) $ 29,591 $ (5,376)
-- 85 of 242 --
Amortization expense of intangible
assets was as follows:
Years ended
June 30 2020 2019 2018
Intangible
asset
amortization $ 360 $ 349 $ 302
Estimated amortization expense over
the next five fiscal years is as
follows:
Years ending
June 30 2021 2022 2023 2024 2025
Estimated
amortization
expense $ 310 $ 291 $ 280 $ 268 $ 250
NOTE 5
INCOME TAXES
Income taxes are recognized for the
amount of taxes payable for the
current year and for the impact of
deferred tax assets and liabilities,
which represent future tax
consequences of events that have
been recognized differently in the
financial statements than for tax
purposes. Deferred tax assets and
liabilities are established using the
enacted statutory tax rates and are
adjusted for any changes in such
rates in the period of change.
On December 22, 2017, the U.S.
government enacted comprehensive
tax legislation commonly referred to
as the Tax Cuts and Jobs Act (the
U.S. Tax Act). The U.S. Tax Act
significantly revised the future
ongoing U.S. corporate income tax
by, among other things, lowering the
U.S. corporate income tax rates and
implementing a hybrid territorial tax
system. As the Company has a June
30 fiscal year-end, the lower
corporate income tax rate was
phased in, resulting in a U.S.
statutory federal rate of
approximately 28% for our fiscal
year ended June 30, 2018, and 21%
for subsequent fiscal years.
However, the U.S. Tax Act
eliminated the domestic
manufacturing deduction and moved
to a hybrid territorial system, which
also largely eliminated the ability to
credit certain foreign taxes that
existed prior to enactment of the
U.S. Tax Act.
There were also certain transitional
impacts of the U.S. Tax Act. As part
of the transition to the new hybrid
territorial tax system, the U.S. Tax
Act imposed a one-time repatriation
tax on deemed repatriation of
historical earnings of foreign
subsidiaries. In addition, the
reduction of the U.S. corporate tax
rate caused us to adjust our U.S.
deferred tax assets and liabilities to
the lower federal base rate of 21%.
-- 86 of 242 --
These transitional impacts resulted in
a provisional net charge of $602 for
the fiscal year ended June 30, 2018,
comprised of an estimated
repatriation tax charge of $3.8 billion
(comprised of U.S. repatriation taxes
and foreign withholding taxes) and
an estimated net deferred tax benefit
of $3.2 billion. The transitional
impact was finalized during the
fiscal year ended June 30, 2019, with
no significant impact on income tax
expense.
Any legislative changes, as well as
any other new or proposed Treasury
regulations to address questions that
arise because of the U.S. Tax Act,
may result in additional income tax
impacts which could be material in
the period any such changes are
enacted.
The Global Intangible Low-Taxed
Income (GILTI) provision of the
U.S. Tax Act requires the Company
to include in its U.S. Income tax
return foreign subsidiary earnings in
excess of an allowable return on the
foreign subsidiary's tangible assets.
An accounting policy election is
available to account for the tax
effects of GILTI either as a current
period expense when incurred, or to
recognize deferred taxes for book
and tax basis differences expected to
reverse as GILTI in future years. We
have elected to account for the tax
effects of GILTI as a current period
expense when incurred.
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 87 of 242 --
The Procter & Gamble Company 49
Earnings before income taxes
consisted of the following:
Years ended
June 30 2020 2019 2018
United
States $ 10,338 $ 1,659 $ 9,277
International 5,496 4,410 4,049
TOTAL $ 15,834 $ 6,069 $ 13,326
Income taxes consisted of the
following:
Years ended
June 30 2020 2019 2018
CURRENT TAX EXPENSE
U.S. federal $ 1,266 $ 1,064 $ 3,965
International 1,769 1,259 1,131
U.S. state
and local 292 191 213
3,327 2,514 5,309
DEFERRED TAX
EXPENSE/(BENEFIT)
U.S. federal 39 (296) (1,989)
International
and other (635) (115) 145
(596) (411) (1,844)
TOTAL
TAX
EXPENSE $ 2,731 $ 2,103 $ 3,465
A reconciliation of the U.S. federal
statutory income tax rate to our
actual effective income tax rate is
provided below:
Years ended
June 30 2020 2019 2018
U.S. federal
statutory
income tax
rate 21.0 % 21.0 % 28.1 %
Country mix
impacts of
foreign
operations (0.1)% (0.5)% (4.7)%
State income
taxes, net of
federal
benefit 1.4 % 2.6 % 1.4 %
Excess tax
benefits from
the exercise
of stock
options (1.6)% (3.8)% (0.4)%
Tax benefit
from
simplification
of legal entity
structure (1.4)% — % — %
Foreign
derived
-- 88 of 242 --
intangible
income
deduction
(FDII) (1.0)% (2.2)% — %
Changes in
uncertain tax
positions 0.1 % (0.3)% (0.3)%
Goodwill
impairment — % 22.8 % — %
Net
transitional
impact of
U.S. Tax Act — % — % 4.5 %
Other (1.2)% (4.9)% (2.6)%
EFFECTIVE
INCOME
TAX RATE 17.2 % 34.7 % 26.0 %
Country mix impacts of foreign
operations includes the effects of
foreign subsidiaries' earnings taxed
at rates other than the U.S. statutory
rate, the U.S. tax impacts of non-
U.S. earnings repatriation and any
net impacts of intercompany
transactions. Changes in uncertain
tax positions represent changes in
our net liability related to prior year
tax positions.
Excess tax benefits from the exercise
of stock options reflect the excess of
actual tax benefits received on
employee exercises of stock options
and other share-based payments
(which generally equals the income
taxable to the employee) over the
amount of tax benefits that were
calculated at the grant dates of such
instruments.
Tax benefits credited to shareholders'
equity totaled $18 for the year ended
June 30, 2020. This primarily relates
to the tax effects of certain
adjustments to pension obligations
and unrealized foreign exchange
losses recorded in stockholders'
equity, partially offset by the tax
effects of net investment hedges. Tax
costs charged to shareholders' equity
totaled $80 for the year ended
June 30, 2019. This primarily relates
to the tax effects of net investment
hedges and certain adjustments to
pension obligations recorded in
stockholders' equity.
Prior to the passage of the U.S. Tax
Act, the Company asserted that
substantially all of the undistributed
earnings of its foreign subsidiaries
were considered indefinitely invested
and accordingly, no deferred taxes
were provided. Pursuant to the
provisions of the U.S. Tax Act, these
earnings were subjected to a one-
time transition tax. This charge
included taxes for all U.S. income
taxes and for the related foreign
withholding taxes for the portion of
those earnings which are no longer
considered indefinitely invested. We
-- 89 of 242 --
have not provided deferred taxes on
approximately $19 billion of
earnings that are considered
permanently reinvested.
A reconciliation of the beginning and
ending liability for uncertain tax
positions is as follows:
Years ended
June 30 2020 2019 2018
BEGINNING
OF YEAR $ 466 $ 470 $ 465
Increases in
tax positions
for prior years 60 85 26
Decreases in
tax positions
for prior years (21) (94) (38)
Increases in
tax positions
for current
year 82 71 87
Settlements
with taxing
authorities (83) (37) (45)
Lapse in
statute of
limitations (12) (27) (20)
Currency
translation (7) (2) (5)
END OF
YEAR $ 485 $ 466 $ 470
Included in the total liability for
uncertain tax positions at June 30,
2020 is $278 that, depending on the
ultimate resolution, could impact the
effective tax rate in future periods.
The Company is present in
approximately 70 countries and over
150 taxable jurisdictions and, at any
point in time, has 40-50
jurisdictional audits underway at
various stages of completion. We
evaluate our tax positions and
establish liabilities for uncertain tax
positions that may be challenged by
local authorities and may not be fully
sustained, despite our belief that the
underlying tax positions are fully
supportable. Uncertain tax positions
are reviewed on an
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 90 of 242 --
50 The Procter & Gamble Company
ongoing basis and are adjusted in
light of changing facts and
circumstances, including progress of
tax audits, developments in case law
and the closing of statutes of
limitation. Such adjustments are
reflected in the tax provision as
appropriate. We have tax years open
ranging from 2008 and forward. We
are generally not able to reliably
estimate the ultimate settlement
amounts until the close of the audit.
Based on information currently
available, we anticipate that over the
next 12-month period, audit activity
could be completed related to
uncertain tax positions in multiple
jurisdictions for which we have
accrued existing liabilities of
approximately $60, including
interest and penalties.
We recognize the additional accrual
of any possible related interest and
penalties relating to the underlying
uncertain tax position in income tax
expense. As of June 30, 2020, 2019
and 2018, we had accrued interest of
$141, $133 and $99 and accrued
penalties of $17, $17 and $15,
respectively, which are not included
in the above table. During the fiscal
years ended June 30, 2020, 2019 and
2018, we recognized $39, $40 and
$22 in interest expense and $1, $2
and $5 in penalties expense,
respectively.
Deferred income tax assets and
liabilities were comprised of the
following:
As of June 30 2020 2019
DEFERRED
TAX ASSETS
Pension and
postretirement
benefits $ 1,602 $ 1,591
Loss and other
carryforwards 875 1,007
Stock-based
compensation 398 421
Accrued
marketing and
promotion 353 334
Fixed assets 218 232
Lease liabilities 190 —
Unrealized loss
on financial and
foreign
exchange
transactions 64 73
Inventory 27 41
Accrued interest
and taxes 20 15
Other 829 931
Valuation
-- 91 of 242 --
allowances (486) (442)
TOTAL $ 4,090 $ 4,203
DEFERRED
TAX
LIABILITIES
Goodwill and
intangible assets $ 5,775 $ 6,506
Fixed assets 1,485 1,413
Lease right-of-
use assets 185 —
Unrealized gain
on financial and
foreign
exchange
transactions 169 147
Foreign
withholding tax
on earnings to
be repatriated 118 239
Other 366 351
TOTAL $ 8,098 $ 8,656
Net operating loss carryforwards
were $2.9 billion at June 30, 2020
and $3.5 billion at June 30, 2019. If
unused, approximately $900 will
expire between 2020 and 2039. The
remainder, totaling $2.0 billion at
June 30, 2020, may be carried
forward indefinitely.
NOTE 6
EARNINGS PER SHARE
Basic net earnings per common share
are calculated by dividing Net
earnings attributable to Procter &
Gamble less preferred dividends (net
of related tax benefits) by the
weighted average number of
common shares outstanding during
the year. For fiscal years 2020 and
2018, Diluted net earnings per
common share are calculated by
dividing Net earnings attributable to
Procter & Gamble by the diluted
weighted average number of
common shares outstanding during
the year. The diluted shares include
the dilutive effect of stock options
and other stock-based awards based
on the treasury stock method (see
Note 7) and the assumed conversion
of preferred stock (see Note 8).
For fiscal year 2019, Diluted net
earnings per common share do not
include the assumed conversion of
preferred stock because to do so
would have been antidilutive, due to
the lower Net earnings driven by the
Shave Care impairment charges (see
Note 4). Therefore, Diluted net
earnings per common share are
calculated by dividing Net earnings
attributable to Procter & Gamble less
preferred dividends (net of related
tax benefit) by the diluted weighted
-- 92 of 242 --
average number of common shares
outstanding during the year. The
diluted shares include the dilutive
effect of stock options and other
stock-based awards based on the
treasury stock method.
Amounts in millions of dollars except per
share amounts or as otherwise specified.
-- 93 of 242 --
The Procter & Gamble Company 51
Net earnings per share were
calculated as follows:
Years ended June 30 2020 2019 2018
CONSOLIDATED
AMOUNTS
Net earnings $ 13,103 $ 3,966 $ 9,861
Less: Net earnings
attributable to
noncontrolling
interests 76 69 111
Net earnings
attributable to
P&G 13,027 3,897 9,750
Less: Preferred
dividends, net of
tax 263 263 265
Net earnings
attributable to
P&G available to
common
shareholders
(Basic) $ 12,764 $ 3,634 $ 9,485
Net earnings
attributable to
P&G available to
common
shareholders
(Diluted) $ 13,027 $ 3,634 $ 9,750
SHARES IN
MILLIONS
Basic weighted
average common
shares outstanding 2,487.1 2,503.6 2,529.3
Add: Effect of
dilutive securities
Impact of stock
options and other
unvested equity
awards (1) 52.7 35.9 32.5
Conversion of
preferred shares
(2) 86.0 — 94.9
Diluted weighted
average common
shares outstanding 2,625.8 2,539.5 2,656.7
NET EARNINGS
PER SHARE (3)
Basic $ 5.13 $ 1.45 $ 3.75
Diluted $ 4.96 $ 1.43 $ 3.67
(1) Weighted average outstanding
stock options of approximately 6
million in 2020, 13 million in 2019
and 48 million in 2018 were not
included in the Diluted net
earnings per share calculation
because the options were out of the
money or to do so would have been
antidilutive (i.e., the assumed
proceeds upon exercise would have
exceeded the market value of the
underlying common shares).
(2) Despite being included in Diluted
net earnings per common share, the
actual conversion to common stock
-- 94 of 242 --
occurs when the preferred shares
are sold. Shares may only be sold
after being allocated to the ESOP
participants pursuant to the
repayment of the ESOP's
obligations through 2035. In fiscal
year 2019, weighted average
outstanding preferred shares of 90
million were not included in the
Diluted net earnings per share
calculation because to do so would
have been antidilutive, due to
lower Net earnings driven by the
Shave Care impairment charges
(see Note 4).
(3) Net earnings per share are
calculated on Net earnings
attributable to Procter & Gamble.
NOTE 7
STOCK-
BASED
COMPENSATION
The Company
has two primary
stock-based
compensation
programs under
which we
annually grant
stock option,
restricted stock
unit (RSU) and
performance
stock unit (PSU)
awards to key
managers and
directors.
In our main long-
term incentive
program, key
managers can
elect to receive
options or RSUs.
All options vest
after three years
and have a 10-
year life.
Exercise prices
on options are set
equal to the
market price of
the underlying
shares on the date
of the grant.
Effective in fiscal
year 2017, RSUs
vest and settle in
shares of
common stock
three years from
the grant date.
RSUs granted
prior to fiscal
year 2017 vest
and settle in
shares of
common stock
five years from
the grant date.
Senior-level
executives
participate in an
-- 95 of 242 --
additional long-
term incentive
program that
awards PSUs,
which are paid in
shares after the
end of a three-
year performance
period subject to
pre-established
performance
goals. Effective
in fiscal year
2019, we added a
Relative Total
Shareholder
Return (R-TSR)
modifier to the
PSUs, under
which the
number of shares
ultimately
granted is also
impacted by the
Company's actual
shareholder
return relative to
our consumer
products
competitive peer
set.
In addition to
these long-term
incentive
programs, we
award RSUs to
the Company's
non-employee
directors and
make other minor
stock option and
RSU grants to
employees for
which the terms
are not
substantially
different from
our long-term
incentive awards.
A total of
150 million
shares of
common stock
were newly
authorized for
issuance under
the stock-based
compensation
plan approved by
shareholders in
2019.
Additionally, the
number of shares
available for
award under the
2019 plan
includes
37 million
previously
authorized but
not awarded
under the
shareholders
approved plan in
-- 96 of 242 --
2014 plus any
shares of
Common Stock
subject to
outstanding
awards under the
2014 Plan that
are forfeited,
cancelled or
otherwise
terminated
without the
issuance of
shares of
Common Stock
as set forth in the
2019 Plan. A
total of 166
million shares
remain available
for grant under
the 2019 plan.
The Company
recognizes stock-
based
compensation
expense based on
the fair value of
the awards at the
date of grant. The
fair value is
amortized on a
straight-line basis
over the requisite
service period.
Awards to
employees
eligible for
retirement prior
to the award
becoming fully
vested are
recognized as
compensation
expense from the
grant date
through the date
the employee
first becomes
eligible to retire
and is no longer
required to
provide services
to earn the
Amounts in millions of dollars except per
share amounts or as otherwise specified.
-- 97 of 242 --
52 The Procter & Gamble Company
award. Stock-
based
compensation
expense is
included as part
of Cost of
products sold and
SG&A in the
Consolidated
Statement of
Earnings and
includes an
estimate of
forfeitures, which
is based on
historical data.
Total expense
and related tax
benefit were as
follows:
Years
ended
June 30 2020 2019 2018
Stock
options $ 249 $ 246 $ 220
RSUs
and
PSUs 309 269 175
Total
stock-
based
expense $ 558 $ 515 $ 395
Income
tax
benefit $ 97 $ 101 $ 87
We utilize an
industry standard
lattice-based
valuation model
to calculate the
fair value for
stock options
granted.
Assumptions
utilized in the
model, which are
evaluated and
revised to reflect
market
conditions and
experience, were
as follows:
Years
ended
June 30 2020 2019 2018
Interest
rate 1.1 - 1.4 % 2.5 - 2.7 % 1.9 - 2.9 %
Weighted
average
interest
rate 1.3 % 2.6 % 2.8 %
Dividend
yield 2.4 % 3.0 % 3.1 %
Expected
volatility 17 % 17 % 18 %
-- 98 of 242 --
Expected
life in
years 9.2 9.2 9.2
Lattice-based
option valuation
models
incorporate
ranges of
assumptions for
inputs and those
ranges are
disclosed in the
preceding table.
Expected
volatilities are
based on a
combination of
historical
volatility of our
stock and implied
volatilities of call
options on our
stock. We use
historical data to
estimate option
exercise and
employee
termination
patterns within
the valuation
model. The
expected life of
options granted is
derived from the
output of the
option valuation
model and
represents the
average period of
time that options
granted are
expected to be
outstanding. The
interest rate for
periods within
the contractual
life of the options
is based on the
U.S. Treasury
yield curve in
effect at the time
of grant.
A summary of
options
outstanding
under the plans
as of June 30,
2020 and activity
during the year
then ended is
presented below:
Options
Options
(in
thousands)
Weighted
Average
Exercise
Price
Weighted
Average
Contract-
ual Life
in Years
Aggregate
Intrinsic
Value
Outstanding,
beginning of year 164,741 $ 79.59
Granted 14,277 115.01
Exercised (28,722) 70.34
Forfeited/expired (424) 83.23
OUTSTANDING,
-- 99 of 242 --
END OF YEAR 149,872 $ 84.71 5.5 $ 5,241
EXERCISABLE 102,702 $ 79.54 4.2 $ 4,111
The following
table provides
additional
information on
stock options:
Years
ended
June 30 2020 2019 2018
Weighted
average
grant-
date fair
value of
options
granted $ 15.60 $ 13.60 $ 11.89
Intrinsic
value of
options
exercised 1,455 1,770 500
Grant-
date fair
value of
options
that
vested 217 180 209
Cash
received
from
options
exercised 2,019 3,381 1,245
Actual tax
benefit
from
options
exercised 298 221 127
At June 30, 2020,
there was $171 of
compensation
cost that has not
yet been
recognized
related to stock
option grants.
That cost is
expected to be
recognized over a
remaining
weighted average
period of 2.0
years.
A summary of
non-vested RSUs
and PSUs
outstanding
under the plans
as of June 30,
2020 and activity
during the year
then ended is
presented below:
RSUs PSUs
RSU and
PSU
awards
Units (in
thousands)
Weighted
Average
Grant
Date Fair
Value
Units (in
thousands)
Weighted
Average
Grant Date
Fair Value
Non-
vested at
July 1,
-- 100 of 242 --
2019 5,493 $ 84.00 1,295 $ 92.98
Granted 1,516 114.44 562 123.52
Vested (2,376) 88.61 (799) 79.64
Forfeited (135) 84.61 (10) 94.94
Non-
vested at
June 30,
2020 4,498 $ 92.15 1,048 $ 117.02
At June 30, 2020,
there was $251 of
compensation
cost that has not
yet been
recognized
related to RSUs
and PSUs. That
cost is expected
to be recognized
over a remaining
weighted average
period of 1.9
years. The total
grant date fair
value of shares
vested was $264,
$205 and $175 in
2020, 2019 and
2018,
respectively.
The Company
settles equity
issuances with
treasury shares.
We have no
specific policy to
repurchase
common shares
to
Amounts in millions of dollars except per
share amounts or as otherwise specified.
-- 101 of 242 --
The Procter & Gamble Company 53
mitigate the
dilutive impact of
options, RSUs
and PSUs.
However, we
have historically
made adequate
discretionary
purchases, based
on cash
availability,
market trends
and other factors,
to offset the
impacts of such
activity.
NOTE 8
POSTRETIREMENT
BENEFITS
AND
EMPLOYEE
STOCK
OWNERSHIP
PLAN
We offer various
postretirement
benefits to our
employees.
Defined
Contribution
Retirement
Plans
We have defined
contribution
plans, which
cover the
majority of our
U.S. employees,
as well as
employees in
certain other
countries. These
plans are fully
funded. We
generally make
contributions to
participants'
accounts based
on individual
base salaries and
years of service.
Total global
defined
contribution
expense was
$317, $272 and
$292 in 2020,
2019 and 2018,
respectively.
The primary U.S.
defined
contribution plan
(the U.S. DC
plan) comprises
the majority of
the expense for
the Company's
defined
-- 102 of 242 --
contribution
plans. For the
U.S. DC plan, the
contribution rate
is set annually.
Total
contributions for
this plan
approximated
14% of total
participants'
annual wages and
salaries in 2020,
2019 and 2018.
We maintain The
Procter &
Gamble Profit
Sharing Trust
(Trust) and
Employee Stock
Ownership Plan
(ESOP) to
provide a portion
of the funding for
the U.S. DC plan
and other retiree
benefits
(described
below).
Operating details
of the ESOP are
provided at the
end of this Note.
The fair value of
the ESOP Series
A shares
allocated to
participants
reduces our cash
contribution
required to fund
the U.S. DC plan.
Defined Benefit
Retirement
Plans and Other
Retiree Benefits
We offer defined
benefit retirement
pension plans to
certain
employees.
These benefits
relate primarily
to plans outside
the U.S. and, to a
lesser extent,
plans assumed in
previous
acquisitions
covering U.S.
employees.
We also provide
certain other
retiree benefits,
primarily health
care, for the
majority of our
U.S. employees
who become
eligible for these
benefits when
they meet
minimum age
-- 103 of 242 --
and service
requirements.
Generally, the
health care plans
require cost
sharing with
retirees and pay a
stated percentage
of expenses,
reduced by
deductibles and
other coverages.
These benefits
are primarily
funded by ESOP
Series B shares
and certain other
assets contributed
by the Company.
Amounts in millions of dollars except per
share amounts or as otherwise specified.
-- 104 of 242 --
54 The Procter & Gamble Company
Obligation and
Funded Status.
The following
provides a
reconciliation of
benefit
obligations, plan
assets and funded
status of these
defined benefit
plans:
Pension Benefits (1) Other Retiree Benefits
(2)
Years ended June
30 2020 2019 2020 2019
CHANGE IN
BENEFIT
OBLIGATION
Benefit
obligation at
beginning of
year (3) $ 17,037 $ 15,658 $ 4,964 $ 4,778
Service cost 247 259 100 101
Interest cost 276 339 160 187
Participants'
contributions 11 12 74 76
Amendments 3 9 (136) —
Net actuarial
loss/(gain) 951 1,587 (85) 37
Acquisitions — 49 — —
Special
termination
benefits 11 13 2 8
Currency
translation and
other (218) (283) (64) 20
Benefit
payments (557) (606) (245) (243)
BENEFIT
OBLIGATION
AT END OF
YEAR (3) $ 17,761 $ 17,037 $ 4,770 $ 4,964
CHANGE
IN PLAN
ASSETS
Fair value of
plan assets at
beginning of
year $ 11,382 $ 11,267 $ 5,096 $ 3,259
Actual
return on
plan assets 664 739 595 1,918
Acquisitions — 4 — —
Employer
contributions 180 178 33 31
Participants'
contributions 11 12 74 76
Currency
translation
and other (196) (212) 2 (1)
ESOP debt
impacts (4) — — 63 56
-- 105 of 242 --
Benefit
payments (557) (606) (245) (243)
FAIR
VALUE OF
PLAN
ASSETS
AT END
OF YEAR $ 11,484 $ 11,382 $ 5,618 $ 5,096
FUNDED
STATUS $ (6,277) $ (5,655) $ 848 $ 132
(1) Primarily
non-U.S.-
based defined
benefit
retirement
plans.
(2) Primarily
U.S.-based
other
postretirement
benefit plans.
(3) For the
pension
benefit plans,
the benefit
obligation is
the projected
benefit
obligation.
For other
retiree benefit
plans, the
benefit
obligation is
the
accumulated
postretirement
benefit
obligation.
(4) Represents
the net impact
of ESOP debt
service
requirements,
which is
netted against
plan assets for
other retiree
benefits.
The
underfunding of
pension benefits
is primarily a
function of the
different funding
incentives that
exist outside of
the U.S. In
certain countries,
there are no legal
requirements or
financial
incentives
provided to
companies to
pre-fund pension
obligations prior
to their due date.
In these
instances, benefit
payments are
typically paid
directly from the
Company's cash
-- 106 of 242 --
as they become
due.
Pension Benefits Other Retiree Benefits
As of June 30 2020 2019 2020 2019
CLASSIFICATION
OF NET AMOUNT
RECOGNIZED
Noncurrent assets $ 12 $ 19 $ 1,843 $ 1,257
Current liabilities (66) (52) (30) (27)
Noncurrent liabilities (6,223) (5,622) (965) (1,098)
NET AMOUNT
RECOGNIZED $ (6,277) $ (5,655) $ 848 $ 132
AMOUNTS RECOGNIZED IN
ACCUMULATED OTHER COMPREHENSIVE
INCOME (AOCI)
Net actuarial loss $ 5,662 $ 5,062 $ 572 $ 874
Prior service
cost/(credit) 198 214 (511) (424)
NET AMOUNTS
RECOGNIZED IN
AOCI $ 5,860 $ 5,276 $ 61 $ 450
Amounts in millions
of dollars except per
share amounts or as
otherwise specified.
-- 107 of 242 --
The Procter &
Gamble Company
55
The accumulated
benefit obligation
for all defined
benefit pension
plans was $16.5
billion and $15.8
billion as of
June 30, 2020
and 2019,
respectively.
Pension plans
with accumulated
benefit
obligations in
excess of plan
assets and plans
with projected
benefit
obligations in
excess of plan
assets consisted
of the following:
Accumulated Benefit
Obligation
Exceeds the
Fair Value of Plan
Assets
Projected Benefit
Obligation
Exceeds the
Fair Value of Plan Assets
As of June 30 2020 2019 2020 2019
Projected
benefit
obligation $ 12,095 $ 11,604 $ 17,635 $ 16,304
Accumulated
benefit
obligation 11,196 10,711 16,377 15,096
Fair value of
plan assets 5,994 6,026 11,347 10,630
Net Periodic
Benefit Cost.
Components of
the net periodic
benefit cost were
as follows:
Pension Benefits Other Retiree Benefits
Years ended June 30 2020 2019 2018 2020 2019 2018
AMOUNTS RECOGNIZED IN NET PERIODIC BENEFIT COST
Service cost $ 247 $ 259 $ 280 $ 100 $ 101 $ 112
Interest cost 276 339 348 160 187 177
Expected return on
plan assets (740) (732) (751) (473) (447) (451)
Amortization of
net actuarial loss 340 225 295 68 66 69
Amortization of
prior service
cost/(credit) 25 26 28 (48) (48) (41)
Amortization of
net actuarial
loss/prior service
cost due to
settlements and
curtailments 7 9 — — — —
Special
termination
benefits 11 13 8 2 8 7
-- 108 of 242 --
GROSS
BENEFIT
COST/(CREDIT) 166 139 208 (191) (133) (127)
Dividends on
ESOP preferred
stock — — — (19) (28) (37)
NET PERIODIC
BENEFIT
COST/(CREDIT) $ 166 $ 139 $ 208 $ (210) $ (161) $ (164)
CHANGE IN PLAN ASSETS AND BENEFIT OBLIGATIONS
RECOGNIZED IN AOCI
Net actuarial
loss/(gain) -
current year $ 1,027 $ 1,580 $ (207) $ (1,434)
Prior service
cost/(credit) -
current year 3 9 (136) —
Amortization of
net actuarial loss (340) (225) (68) (66)
Amortization of
prior service
(cost)/credit (25) (26) 48 48
Amortization of
net actuarial
loss/prior service
costs due to
settlements and
curtailments (7) (9) — —
Currency
translation and
other (74) (84) (26) 14
TOTAL
CHANGE IN
AOCI 584 1,245 (389) (1,438)
NET AMOUNTS
RECOGNIZED
IN PERIODIC
BENEFIT COST
AND AOCI $ 750 $ 1,384 $ (599) $ (1,599)
The service cost
component of the
net periodic
benefit cost is
included in the
Consolidated
Statements of
Earnings in Cost
of products sold
and SG&A. All
other components
are included in
the Consolidated
Statements of
Earnings in Other
non-operating
income/(expense),
net, unless
otherwise noted.
Amounts
expected to be
amortized from
AOCI into net
periodic benefit
cost during the
year ending
June 30, 2021,
are as follows:
-- 109 of 242 --
Pension Benefits Other Retiree Benefits
Net
actuarial
loss $ 401 $ 47
Prior
service
cost/(credit) 25 (59)
Amounts in millions
of dollars except per
share amounts or as
otherwise specified.
-- 110 of 242 --
56 The Procter &
Gamble Company
Assumptions.
We determine
our actuarial
assumptions on
an annual basis.
These
assumptions are
weighted to
reflect each
country that may
have an impact
on the cost of
providing
retirement
benefits. The
weighted average
assumptions used
to determine
benefit
obligations
recorded on the
Consolidated
Balance Sheets
as of June 30,
were as follows:
(1)
Pension Benefits Other Retiree Benefits
As of June 30 2020 2019 2020 2019
Discount rate 1.5 % 1.9 % 3.1 % 3.7 %
Rate of
compensation
increase 2.5 % 2.6 % N/A N/A
Health care
cost trend
rates assumed
for next year N/A N/A 6.6 % 6.6 %
Rate to which
the health
care cost
trend rate is
assumed to
decline
(ultimate
trend rate) N/A N/A 4.9 % 4.9 %
Year that the
rate reaches
the ultimate
trend rate N/A N/A 2026 2026
(1) Determined as
of end of
fiscal year.
The weighted
average
assumptions used
to determine net
benefit cost
recorded on the
Consolidated
Statement of
Earnings for the
years ended June
30, were as
follows: (1)
Pension Benefits Other Retiree Benefits
Years ended
-- 111 of 242 --
June 30 2020 2019 2018 2020 2019 2018
Discount rate 1.9 % 2.5 % 2.4 % 3.7 % 4.2 % 3.9 %
Expected
return on plan
assets 6.6 % 6.6 % 6.8 % 8.4 % 8.3 % 8.3 %
Rate of
compensation
increase 2.6 % 2.6 % 3.0 % N/A N/A N/A
(1) Determined as
of beginning
of fiscal year.
For plans that
make up the
majority of our
obligation, the
Company
calculates the
benefit obligation
and the related
impacts on
service and
interest costs
using specific
spot rates along
the corporate
bond yield curve.
For the
remaining plans,
the Company
determines these
amounts utilizing
a single weighted
average discount
rate derived from
the corporate
bond yield curve
used to measure
the plan
obligations.
Several factors
are considered in
developing the
estimate for the
long-term
expected rate of
return on plan
assets. For the
defined benefit
retirement plans,
these factors
include historical
rates of return of
broad equity and
bond indices and
projected long-
term rates of
return obtained
from pension
investment
consultants. The
expected long-
term rates of
return for plan
assets are 8% -
9% for equities
and 5% - 6% for
bonds. For other
retiree benefit
plans, the
expected long-
term rate of
return reflects
-- 112 of 242 --
that the assets are
comprised
primarily of
Company stock.
The expected rate
of return on
Company stock
is based on the
long-term
projected return
of 8.5% and
reflects the
historical pattern
of returns.
Assumed health
care cost trend
rates could have
a significant
effect on the
amounts reported
for the other
retiree benefit
plans. A one
percentage point
change in
assumed health
care cost trend
rates would have
the following
effects:
One-
Percentage
Point Increase
One-
Percentage
Point Decrease
Effect on the
total service
and interest
cost
components $ 56 $ (43)
Effect on the
accumulated
postretirement
benefit
obligation 669 (543)
Plan Assets. Our
investment
objective for
defined benefit
retirement plan
assets is to meet
the plans' benefit
obligations and
to improve plan
self-sufficiency
for future benefit
obligations. The
investment
strategies focus
on asset class
diversification,
liquidity to meet
benefit payments
and an
appropriate
balance of long-
term investment
return and risk.
Target ranges for
asset allocations
are determined
by assessing
different
-- 113 of 242 --
investment risks
and matching the
actuarial
projections of the
plans' future
liabilities and
benefit payments
with current as
well as expected
long-term rates
of return on the
assets, taking into
account
investment return
volatility and
correlations
across asset
classes. Plan
assets are
diversified across
several
investment
managers and are
generally
invested in liquid
funds that are
selected to track
broad market
equity and bond
indices.
Investment risk is
carefully
controlled with
plan assets
rebalanced to
target allocations
on a periodic
basis and with
continual
monitoring of
investment
managers'
performance
relative to the
investment
guidelines
established with
each investment
manager.
Amounts in millions
of dollars except per
share amounts or as
otherwise specified.
-- 114 of 242 --
The Procter &
Gamble Company
57
Our target asset
allocation for the
year ended
June 30, 2020,
and actual asset
allocation by
asset category as
of June 30, 2020
and 2019, were
as follows:
Target Asset Allocation Actual Asset Allocation at June 30
Pension Benefits
Other
Retiree
Benefits
Pension Benefits Other Retiree Benefits
Asset
Category 2020 2019 2020 2019
Cash — % 2 % 1 % 1 % 3 % 3 %
Debt
securities 67 % 3 % 66 % 63 % 2 % 2 %
Equity
securities 33 % 95 % 33 % 36 % 95 % 95 %
TOTAL 100 % 100 % 100 % 100 % 100 % 100 %
The following
table sets forth
the fair value of
the Company's
plan assets as of
June 30, 2020
and 2019
segregated by
level within the
fair value
hierarchy (refer
to Note 9 for
further discussion
on the fair value
hierarchy and fair
value principles).
Investments
valued using net
asset value as a
practical
expedient are not
valued using the
fair value
hierarchy, but
rather valued
using the net
asset value
reported by the
managers of the
funds and as
supported by the
unit prices of
actual purchase
and sale
transactions.
Pension Benefits Other Retiree Benefits
As of June 30
Fair
Value
Hierarchy
Level 2020 2019
Fair
Value
Hierarchy
Level 2020 2019
ASSETS AT
FAIR VALUE
Cash and cash
equivalents 1 $ 61 $ 47 1 $ 121 $ 111
Company
common stock — — 1 217 179
-- 115 of 242 --
Company
preferred stock
(1) — — 2 5,139 4,657
Fixed income
securities (2) 2 1,991 265 2 12 1
Insurance
contracts (3) 3 115 113 — —
TOTAL
ASSETS IN
THE FAIR
VALUE
HIERARCHY 2,167 425 5,489 4,948
Investments
valued at net
asset value (4) 9,317 10,957 129 148
TOTAL
ASSETS AT
FAIR VALUE $ 11,484 11,382 $ 5,618 5,096
(1) Company
preferred
stock is
valued based
on the value
of Company
common
stock and is
presented net
of ESOP debt
discussed
below.
(2) Fixed income
securities,
classified as
Level 2, are
estimated by
using pricing
models or
quoted prices
of securities
with similar
characteristics.
(3) Fair values of
insurance
contracts are
valued based
on either their
cash
equivalent
value or
models that
project future
cash flows
and discount
the future
amounts to a
present value
using market-
based
observable
inputs,
including
credit risk and
interest rate
curves. The
activity for
Level 3 assets
is not
significant for
all years
presented.
(4) Investments
valued using
net asset
value as a
practical
expedient are
primarily
-- 116 of 242 --
equity and
fixed income
collective
funds.
Cash
Flows.
Management's
best
estimate
of cash
requirements
and
discretionary
contributions
for the
defined
benefit
retirement
plans
and
other
retiree
benefit
plans
for the
year
ending
June 30,
2021, is
$197
and
$44,
respectively.
Expected
contributions
are
dependent
on
many
variables,
including
the
variability
of the
market
value of
the plan
assets
as
compared
to the
benefit
obligation
and
other
market
or
regulatory
conditions.
In
addition,
we take
into
consideration
our
business
investment
opportunities
and
resulting
cash
requirements.
-- 117 of 242 --
Accordingly,
actual
funding
may
differ
significantly
from
current
estimates.
Total
benefit
payments
expected
to be
paid to
participants,
which
include
payments
funded
from
the
Company's
assets
and
payments
from
the
plans
are as
follows:
Years
ending
June
30
Pension
Benefits
Other Retiree
Benefits
EXPECTED
BENEFIT
PAYMENTS
2021 $ 559 $ 196
2022 534 205
2023 556 214
2024 573 221
2025 608 225
2026
-
2030 3,258 1,199
Amounts in millions
of dollars except per
share amounts or as
otherwise specified.
-- 118 of 242 --
58 The Procter &
Gamble Company
Employee
Stock
Ownership
Plan
We
maintain
the
ESOP
to
provide
funding
for
certain
employee
benefits
discussed
in the
preceding
paragraphs.
The
ESOP
borrowed
$1.0
billion
in 1989
and the
proceeds
were
used to
purchase
Series
A
ESOP
Convertible
Class A
Preferred
Stock to
fund a
portion
of the
U.S.
DC
plan.
Principal
and
interest
requirements
of the
borrowing
were
paid by
the
Trust
from
dividends
on the
preferred
shares
and
from
advances
provided
by the
Company.
The
original
borrowing
of $1.0
billion
-- 119 of 242 --
has
been
repaid
in full,
and
advances
from
the
Company
of $33
remain
outstanding
at
June 30,
2020.
Each
share is
convertible
at the
option
of the
holder
into one
share of
the
Company's
common
stock.
The
dividend
for the
current
year
was
equal to
the
common
stock
dividend
of $3.03
per
share.
The
liquidation
value is
$6.82
per
share.
In 1991,
the
ESOP
borrowed
an
additional
$1.0
billion.
The
proceeds
were
used to
purchase
Series B
ESOP
Convertible
Class A
Preferred
Stock to
fund a
portion
of
retiree
health
care
benefits.
-- 120 of 242 --
These
shares,
net of
the
ESOP's
debt,
are
considered
plan
assets
of the
other
retiree
benefits
plan
discussed
above.
Debt
service
requirements
are
funded
by
preferred
stock
dividends,
cash
contributions
and
advances
provided
by the
Company,
of
which
$928
are
outstanding
at
June 30,
2020.
Each
share is
convertible
at the
option
of the
holder
into one
share of
the
Company's
common
stock.
The
dividend
for the
current
year
was
equal to
the
common
stock
dividend
of $3.03
per
share.
The
liquidation
value is
$12.96
per
share.
-- 121 of 242 --
Our
ESOP
accounting
practices
are
consistent
with
current
ESOP
accounting
guidance,
including
the
permissible
continuation
of
certain
provisions
from
prior
accounting
guidance.
ESOP
debt,
which is
guaranteed
by the
Company,
is
recorded
as debt
(see
Note
10) with
an
offset to
the
Reserve
for
ESOP
debt
retirement,
which is
presented
within
Shareholders'
equity.
Advances
to the
ESOP
by the
Company
are
recorded
as an
increase
in the
Reserve
for
ESOP
debt
retirement.
Interest
incurred
on the
ESOP
debt is
recorded
as
Interest
expense.
Dividends
on all
preferred
-- 122 of 242 --
shares,
net of
related
tax
benefits,
are
charged
to
Retained
earnings.
The
series A
and B
preferred
shares
of the
ESOP
are
allocated
to
employees
based
on debt
service
requirements.
The
number
of
preferred
shares
outstanding
at
June 30
was as
follows:
Shares in
thousands 2020 2019 2018
Allocated 29,591 31,600 34,233
Unallocated 2,479 3,259 4,117
TOTAL
SERIES A 32,070 34,859 38,350
Allocated 27,894 26,790 25,895
Unallocated 24,418 26,471 28,512
TOTAL
SERIES B 52,312 53,261 54,407
For
purposes
of
calculating
diluted
net
earnings
per
common
share,
the
preferred
shares
held by
the
ESOP
are
considered
converted
from
inception.
NOTE
9
-- 123 of 242 --
RISK
MANAGEMENT
ACTIVITIES
AND
FAIR
VALUE
MEASUREMENTS
As a
multinational
company
with
diverse
product
offerings,
we are
exposed
to
market
risks,
such as
changes
in
interest
rates,
currency
exchange
rates
and
commodity
prices.
We
evaluate
exposures
on a
centralized
basis to
take
advantage
of
natural
exposure
correlation
and
netting.
To the
extent
we
choose
to
manage
volatility
associated
with the
net
exposures,
we
enter
into
various
financial
transactions
that we
account
for
using
the
applicable
accounting
guidance
for
derivative
instruments
and
hedging
-- 124 of 242 --
activities.
These
financial
transactions
are
governed
by our
policies
covering
acceptable
counterparty
exposure,
instrument
types
and
other
hedging
practices.
If the
Company
elects to
do so
and if
the
instrument
meets
certain
specified
accounting
criteria,
management
designates
derivative
instruments
as cash
flow
hedges,
fair
value
hedges
or net
investment
hedges.
We
record
derivative
instruments
at fair
value
and the
accounting
for
changes
in the
fair
value
depends
on the
intended
use of
the
derivative,
the
resulting
designation
and the
effectiveness
of the
instrument
in
offsetting
the risk
exposure
it is
-- 125 of 242 --
designed
to
hedge.
We
generally
have a
high
degree
of
effectiveness
between
the
exposure
being
hedged
and the
hedging
instrument.
Credit
Risk
Management
We
have
counterparty
credit
guidelines
and
normally
enter
into
transactions
with
investment
grade
financial
institutions,
to the
extent
commercially
viable.
Counterparty
exposures
are
monitored
daily
and
downgrades
in
counterparty
credit
ratings
are
reviewed
on a
timely
basis.
We
have
not
incurred,
and do
not
expect
to incur,
material
credit
losses
on our
risk
management
or other
financial
instruments.
-- 126 of 242 --
Substantially
all of
the
Company's
financial
instruments
used in
hedging
transactions
are
governed
by
industry
standard
netting
and
collateral
agreements
with
counterparties.
If the
Company's
credit
rating
were to
fall
below
the
levels
stipulated
in the
agreements,
the
counterparties
could
demand
either
collateralization
or
termination
of the
arrangements.
The
aggregate
fair
value of
the
instruments
covered
by these
contractual
features
that are
in a net
liability
position
as of
June 30,
2020,
was not
material.
The
Company
has not
been
required
to post
collateral
as a
result of
these
contractual
features.
Interest
-- 127 of 242 --
Rate
Risk
Management
Our
policy
is to
manage
interest
cost
using a
mixture
of
fixed-
rate and
variable-
rate
debt. To
manage
this risk
in a
cost-
efficient
manner,
we
enter
into
interest
rate
swaps
whereby
we
agree to
exchange
with the
counterparty,
at
specified
intervals,
the
difference
between
fixed
and
variable
interest
amounts
calculated
by
reference
to a
notional
amount.
Amounts in millions
of dollars except per
share amounts or as
otherwise specified.
-- 128 of 242 --
The Procter &
Gamble Company
59
We
designate
certain
interest
rate
swaps
on fixed
rate
debt
that
meet
specific
accounting
criteria
as fair
value
hedges.
For fair
value
hedges,
the
changes
in the
fair
value of
both the
hedging
instruments
and the
underlying
debt
obligations
are
immediately
recognized
in
earnings.
Foreign
Currency
Risk
Management
We
manufacture
and sell
our
products
and
finance
our
operations
in a
number
of
countries
throughout
the
world.
As a
result,
we are
exposed
to
movements
in
foreign
currency
exchange
rates.
We
-- 129 of 242 --
leverage
the
Company’s
diversified
portfolio
of
exposures
as a
natural
hedge.
In
certain
cases,
we
enter
into
non-
qualifying
foreign
currency
contracts
to
hedge
certain
balance
sheet
items
subject
to
revaluation.
The
change
in fair
value of
these
instruments
and the
underlying
exposure
are both
immediately
recognized
in
earnings.
To
manage
exchange
rate risk
related
to our
intercompany
financing,
we
primarily
use
forward
contracts
and
currency
swaps.
The
change
in fair
value of
these
non-
qualifying
instruments
is
immediately
recognized
in
earnings,
substantially
-- 130 of 242 --
offsetting
the
foreign
currency
mark-
to-
market
impact
of the
related
exposure.
Net
Investment
Hedging
We
hedge
certain
net
investment
positions
in
foreign
subsidiaries.
To
accomplish
this, we
either
borrow
directly
in
foreign
currencies
and
designate
all or a
portion
of the
foreign
currency
debt as
a hedge
of the
applicable
net
investment
position
or we
enter
into
foreign
currency
swaps
that are
designated
as
hedges
of net
investments.
Changes
in the
fair
value of
these
instruments
are
recognized
in the
Foreign
Currency
Translation
component
of OCI
and
offset
-- 131 of 242 --
the
change
in the
value of
the net
investment
being
hedged.
The
time
value
component
of the
net
investment
hedge
currency
swaps is
excluded
from
the
assessment
of
hedge
effectiveness.
Changes
in the
fair
value of
the
swap,
including
changes
in the
fair
value of
the
excluded
time
value
component,
are
recognized
in OCI
and
offset
the
value of
the
underlying
net
assets.
The
time
value
component
is
subsequently
reported
in
income
on a
systematic
basis.
Commodity
Risk
Management
Certain
raw
materials
used in
our
products
or
-- 132 of 242 --
production
processes
are
subject
to price
volatility
caused
by
weather,
supply
conditions,
political
and
economic
variables
and
other
unpredictable
factors.
As of
and
during
the
years
ended
June 30,
2020
and
2019,
we did
not
have
any
financial
commodity
hedging
activity
to
manage
such
exposures.
Insurance
We
self-
insure
for most
insurable
risks.
However,
we
purchase
insurance
for
Directors
and
Officers
Liability
and
certain
other
coverage
where it
is
required
by law
or by
contract.
Fair
Value
Hierarchy
Accounting
guidance
on fair
-- 133 of 242 --
value
measurements
for
certain
financial
assets
and
liabilities
requires
that
financial
assets
and
liabilities
carried
at fair
value be
classified
and
disclosed
in one
of the
following
categories:
• Level 1:
Quoted
market
prices
in
active
markets
for
identical
assets
or
liabilities.
• Level 2:
Observable
market-
based
inputs
or
unobservable
inputs
that
are
corroborated
by
market
data.
• Level 3:
Unobservable
inputs
reflecting
the
reporting
entity's
own
assumptions
or
external
inputs
from
inactive
markets.
When
applying
fair
value
principles
in the
valuation
of
-- 134 of 242 --
assets
and
liabilities,
we are
required
to
maximize
the use
of
quoted
market
prices
and
minimize
the use
of
unobservable
inputs.
The
Company
has not
changed
its
valuation
techniques
used in
measuring
the fair
value of
any
financial
assets
or
liabilities
during
the
year.
When
active
market
quotes
are not
available
for
financial
assets
and
liabilities,
we use
industry
standard
valuation
models.
Where
applicable,
these
models
project
future
cash
flows
and
discount
the
future
amounts
to a
present
value
using
market-
based
observable
inputs
-- 135 of 242 --
including
credit
risk,
interest
rate
curves
and
forward
and spot
prices
for
currencies.
In
circumstances
where
market-
based
observable
inputs
are not
available,
management
judgment
is used
to
develop
assumptions
to
estimate
fair
value.
Generally,
the fair
value of
our
Level 3
instruments
is
estimated
as the
net
present
value of
expected
future
cash
flows
based
on
external
inputs.
Assets
and
Liabilities
Measured
at Fair
Value
Other
investments
had a
fair
value of
$67 and
$169 as
of
June 30,
2020
and
2019,
respectively,
and are
presented
in Other
noncurrent
-- 136 of 242 --
assets.
During
the year
ended
June 30,
2020,
the
Company
sold all
of its
existing
U.S.
government
securities
and
corporate
bond
securities.
Such
securities
had fair
values
of $3.6
billion
and
$2.4
billion,
respectively,
and
were
presented
in
Available-
for-sale
investment
securities
at
June 30,
2019.
The
Company's
investments
measured
at fair
value
are
generally
classified
as Level
2 within
the fair
value
hierarchy.
Cash
equivalents
were
$14.6
billion
and
$3.0
billion
as of
June 30,
2020
and
2019,
respectively
and are
classified
as Level
1 within
the fair
value
hierarchy.
-- 137 of 242 --
There
are no
other
material
investment
balances
classified
as Level
1 or
Level 3
within
the fair
value
hierarchy,
or using
net
asset
value as
a
practical
expedient.
Fair
values
are
generally
estimated
based
upon
quoted
market
prices
for
similar
instruments.
The fair
value of
long-
term
debt
was
$29.0
billion
and
$25.4
billion
as of
June 30,
2020
and
2019,
respectively.
This
includes
the
current
portion
of long-
term
debt
instruments
($2.5
billion
and
$3.4
billion
as of
June 30,
2020
and
2019,
respectively).
Certain
long-
term
-- 138 of 242 --
debt
(debt
designated
as a fair
value
hedge)
is
recorded
at fair
value.
All
other
long-
term
debt is
recorded
at
amortized
cost,
but is
measured
at fair
value
for
disclosure
purposes.
We
consider
our debt
to be
Level 2
in the
fair
value
hierarchy.
Fair
values
are
generally
estimated
based
on
quoted
market
prices
for
identical
or
similar
instruments.
Amounts in millions
of dollars except per
share amounts or as
otherwise specified.
-- 139 of 242 --
60 The Procter &
Gamble Company
Disclosures
about Financial
Instruments
The notional
amounts and fair
values of
financial
instruments used
in hedging
transactions as of
June 30, 2020
and 2019 are as
follows:
Notional Amount Fair Value Asset
Fair Value
(Liability)
As of June 30 2020 2019 2020 2019 2020 2019
DERIVATIVES IN FAIR VALUE
HEDGING RELATIONSHIPS
Interest rate
contracts $ 7,114 $ 7,721 $ 269 $ 177 $ — $ (1)
DERIVATIVES IN NET INVESTMENT
HEDGING RELATIONSHIPS
Foreign currency
interest rate
contracts $ 3,856 $ 3,157 $ 26 $ 35 $ (41) $ (24)
TOTAL
DERIVATIVES
DESIGNATED
AS HEDGING
INSTRUMENTS $ 10,970 $ 10,878 $ 295 $ 212 $ (41) $ (25)
DERIVATIVES NOT DESIGNATED AS
HEDGING INSTRUMENTS
Foreign currency
contracts $ 5,986 $ 6,431 $ 23 $ 27 $ (25) $ (20)
TOTAL
DERIVATIVES
AT FAIR
VALUE $ 16,956 $ 17,309 $ 318 $ 239 $ (66) $ (45)
All derivative
assets are
presented in
Prepaid expenses
and other current
assets or Other
noncurrent
assets. All
derivative
liabilities are
presented in
Accrued and
other liabilities or
Other noncurrent
liabilities.
The fair value of
the interest rate
derivative
asset/liability
directly offsets
the cumulative
amount of the
fair value
hedging
-- 140 of 242 --
adjustment
included in the
carrying amount
of the underlying
debt obligation.
The carrying
amount of the
underlying debt
obligation, which
includes the
unamortized
discount or
premium and the
fair value
adjustment, was
$7.4 billion and
$7.9 billion as of
June 30, 2020
and 2019,
respectively. In
addition to the
foreign currency
derivative
contracts
designated as net
investment
hedges, certain of
our foreign
currency
denominated debt
instruments are
designated as net
investment
hedges. The
carrying value of
those debt
instruments
designated as net
investment
hedges, which
includes the
adjustment for
the foreign
currency
transaction gain
or loss on those
instruments, was
$16.0 billion and
$17.2 billion as
of June 30, 2020
and 2019,
respectively.
All of the
Company's
derivative assets
and liabilities are
measured at fair
value that is
derived from
observable
market data,
including interest
rate yield curves
and foreign
exchange rates,
and are classified
as Level 2 within
the fair value
hierarchy. The
Company
recognizes
transfers between
levels within the
fair value
-- 141 of 242 --
hierarchy, if any,
at the end of each
quarter. There
were no transfers
between levels
during the
periods
presented. In
addition, there
was no
significant
activity within
the Level 3 assets
and liabilities
during the
periods
presented. Except
for the
impairment of
the Gillette
indefinite-lived
intangible asset
discussed in Note
4, there were no
significant assets
or liabilities that
were re-measured
at fair value on a
non-recurring
basis during the
years ended
June 30, 2020
and 2019.
Before
tax
gains/(losses)
on our
financial
instruments
in
hedging
relationships
are
categorized
as
follows:
Amount of
Gain/(Loss)
Recognized in
OCI on
Derivatives
Years
ended
June 30 2020 2019
DERIVATIVES IN
NET INVESTMENT
HEDGING
RELATIONSHIPS
(1) (2)
Foreign
currency
interest
rate
contracts $ 66 $ 47
(1) For
the
derivatives
in
net
investment
hedging
relationships,
the
amount
-- 142 of 242 --
of
gain/(loss)
excluded
from
effectiveness
testing,
which
was
recognized
in
earnings,
was
$69
and
$70
for
the
fiscal
year
ended
June 30,
2020
and
2019,
respectively.
(2) In
addition
to
the
foreign
currency
derivative
contracts
designated
as
net
investment
hedges,
certain
of
our
foreign
currency
denominated
debt
instruments
are
designated
as
net
investment
hedges.
The
amount
of
gain/(loss)
recognized
in
AOCI
for
such
instruments
was
$189
and
$299,
as
of
June 30,
2020
and
2019,
respectively.
Amount of
Gain/(Loss)
Recognized in
Earnings
Years
-- 143 of 242 --
ended
June 30 2020 2019
DERIVATIVES IN
FAIR VALUE
HEDGING
RELATIONSHIPS
Interest
rate
contracts $ 93 $ 104
DERIVATIVES NOT
DESIGNATED AS
HEDGING
INSTRUMENTS
Foreign
currency
contracts $ (83) $ 54
The
gain/(loss)
on the
derivatives
in fair
value
hedging
relationships
is fully
offset
by the
mark-
to-
market
impact
of the
related
exposure.
These
are both
recognized
in the
Consolidated
Statement
of
Earnings
in
Interest
Expense.
The
gain/(loss)
on
derivatives
not
designated
as
hedging
instruments
is
substantially
offset
by the
currency
mark-
to-
market
of the
related
exposure.
These
are both
recognized
in the
Consolidated
Statements
-- 144 of 242 --
of
Earnings
in
SG&A.
Amounts in millions
of dollars except per
share amounts or as
otherwise specified.
-- 145 of 242 --
The Procter &
Gamble Company
61
NOTE
10
SHORT-
TERM
AND
LONG-
TERM
DEBT
As of June 30 2020 2019
DEBT DUE WITHIN ONE
YEAR
Current
portion of
long-term
debt $ 2,508 $ 3,388
Commercial
paper 8,545 6,183
Other 130 126
TOTAL $ 11,183 $ 9,697
Short-term
weighted
average
interest
rates (1) 0.7 % 0.5 %
(1) Short-
term
weighted
average
interest
rates
include
the
effects
of
interest
rate
swaps
discussed
in
Note
9.
As of June
30 2020 2019
LONG-
TERM
DEBT
1.90%
USD note
due
October
2020 $ 600 $ 600
4.13%
EUR note
due
December
2020 674 682
9.36%
ESOP
debentures
due 2020-
2021 (1) 119 228
1.85%
USD note
due
-- 146 of 242 --
February
2021 600 600
1.70%
USD note
due
November
2021 875 875
2.00%
EUR note
due
November
2021 843 852
2.30%
USD note
due
February
2022 1,000 1,000
2.15%
USD note
due
August
2022 1,250 1,250
2.00%
EUR note
due
August
2022 1,124 1,137
3.10%
USD note
due
August
2023 1,000 1,000
1.13%
EUR note
due
November
2023 1,405 1,421
0.50%
EUR note
due
October
2024 562 568
0.63%
EUR note
due
October
2024 899 909
2.45%
USD note
due March
2025 750 —
2.70%
USD note
due
February
2026 600 600
2.45%
USD note
due
November
2026 875 875
2.80%
USD note
due March
2027 500 —
4.88%
-- 147 of 242 --
EUR note
due May
2027 1,124 1,137
2.85%
USD note
due
August
2027 750 750
1.20%
EUR note
due
October
2028 899 909
1.25%
EUR note
due
October
2029 562 568
3.00%
USD note
due March
2030 1,500 —
5.55%
USD note
due March
2037 763 763
1.88%
EUR note
due
October
2038 562 568
3.55%
USD note
due March
2040 1,000 —
3.50%
USD note
due
October
2047 600 600
3.60%
USD note
due March
2050 1,250 —
Finance
lease
obligations — 33
All other
long-term
debt 3,359 5,858
Current
portion of
long-term
debt (2,508) (3,388)
TOTAL $ 23,537 $ 20,395
Long-term
weighted
average
interest
rates (2) 2.3 % 2.4 %
(1) Debt
issued
by
the
ESOP
is
guaranteed
by
-- 148 of 242 --
the
Company
and
is
recorded
as
debt
of
the
Company,
as
discussed
in
Note
8.
(2) Long-
term
weighted
average
interest
rates
include
the
effects
of
interest
rate
swaps
discussed
in
Note
9.
Long-
term
debt
maturities
during
the next
five
fiscal
years
are as
follows:
Years
ending
June 30 2021 2022 2023 2024 2025
Debt
maturities $2,508 $2,830 $2,425 $2,481 $2,743
The
Procter
&
Gamble
Company
fully
and
unconditionally
guarantees
the
registered
debt
and
securities
issued
by its
100%
owned
finance
subsidiaries.
Amounts in millions
of dollars except per
share amounts or as
otherwise specified.
-- 149 of 242 --
62 The Procter &
Gamble Company
NOTE 11
ACCUMULATED
OTHER
COMPREHENSIVE
INCOME/(LOSS)
The table below
presents the
changes in
Accumulated
other
comprehensive
income/(loss)
attributable to
Procter &
Gamble (AOCI),
including the
reclassifications
out of AOCI by
component:
Changes in Accumulated Other Comprehensive
Income/(Loss) by Component
Investment
Securities
Post-
retirement
Benefits
Foreign
Currency
Translation Total AOCI
BALANCE at
JUNE 30, 2018 $ (173) $ (4,058) $ (10,518) $ (14,749)
OCI before
reclassifications
(1) 167 (43) (213) (89)
Amounts
reclassified
from AOCI into
the
Consolidated
Statement of
Earnings (2) 17 212 — 229
Net current
period OCI 184 169 (213) 140
Reclassification
to retained
earnings in
accordance with
ASU 2018-02 (3) — (308) (18) (326)
Less: Other
comprehensive
income/(loss)
attributable to
non-controlling
interests — 1 — 1
BALANCE at
JUNE 30, 2019 11 (4,198) (10,749) (14,936)
OCI before
reclassifications
(4) (10) (453) (1,083) (1,546)
Amounts
reclassified
from AOCI into
the
Consolidated
Statement of
Earnings (5) (2) 303 — 301
Net current
period OCI (12) (150) (1,083) (1,245)
Less: Other
comprehensive
income/(loss)
attributable to
non-controlling
-- 150 of 242 --
interests — 2 (18) (16)
BALANCE at
JUNE 30, 2020 $ (1) $ (4,350) $ (11,814) $ (16,165)
(1) Net of tax
benefit)/expense
of $0, $(44)
and $78 for
gains/losses
on investment
securities,
postretirement
benefit items
and foreign
currency
translation,
respectively,
for the period
ended
June 30,
2019.
(2) Net of tax
(benefit)/expense
of $0, $66
and $0 for
gains/losses
on investment
securities,
postretirement
benefit items
and foreign
currency
translation,
respectively,
for the period
ended
June 30,
2019.
(3) Adjustment
made to early
adopt ASU
2018-02:
"Reclassification
of Certain
Effects from
Accumulated
Other
Comprehensive
Income."
(4) Net of tax
(benefit)/expense
of $(1),
$(131) and
$59 for
gains/losses
on investment
securities,
postretirement
benefit items
and foreign
currency
translation,
respectively,
for the period
ended
June 30,
2020.
(5) Net of tax
(benefit)/expense
of $0, $89
and $0 for
gains/losses
on investment
securities,
postretirement
benefit items
and foreign
currency
translation,
-- 151 of 242 --
respectively,
for the period
ended
June 30,
2020.
The below
provides
additional details
on amounts
reclassified from
AOCI into the
Consolidated
Statement of
Earnings:
• Investment
securities:
amounts
reclassified
from AOCI
into Other
non-
operating
income, net.
• Postretirement
benefits:
amounts
reclassified
from AOCI
into Other
non-
operating
income, net
and included
in the
computation
of net
periodic
postretirement
costs (see
Note 8 for
additional
details).
NOTE
12
LEASES
The
Company
determines
whether
a
contract
contains
a lease
at the
inception
of a
contract
by
determining
if the
contract
conveys
the right
to
control
the use
of
identified
property,
plant or
-- 152 of 242 --
equipment
for a
period
of time
in
exchange
for
consideration.
We
lease
certain
real
estate,
machinery,
equipment,
vehicles
and
office
equipment
for
varying
periods.
Many
of these
leases
include
an
option
to either
renew
or
terminate
the
lease.
For
purposes
of
calculating
lease
liabilities,
these
options
are
included
within
the
lease
term
when it
has
become
reasonably
certain
that the
Company
will
exercise
such
options.
The
incremental
borrowing
rate
utilized
to
calculate
our
lease
liabilities
is based
on the
information
available
at
-- 153 of 242 --
commencement
date,
as most
of the
leases
do not
provide
an
implicit
borrowing
rate.
Our
operating
lease
agreements
do not
contain
any
material
guarantees
or
restrictive
covenants.
The
Company
does not
have
any
material
finance
leases
or
sublease
activities.
The
Company
incurred
lease
expense
for
operating
leases
of $347,
$341
and
$340
during
the
years
ended
June 30,
2020,
2019
and
2018,
respectively.
Total
cash
paid for
amounts
included
in the
measurement
of lease
liabilities
during
the year
ended
June 30,
2020
was
$271.
Short-
-- 154 of 242 --
term
leases,
defined
as
leases
with
initial
terms of
12
months
or less,
are not
reflected
on the
Consolidated
Balance
Sheets.
Lease
expense
for such
short-
term
leases is
not
material.
The
most
significant
assets in
our
leasing
portfolio
relate to
real
estate
and
vehicles.
For
purposes
of
calculating
lease
liabilities
for
Amounts in millions
of dollars except per
share amounts or as
otherwise specified.
-- 155 of 242 --
The Procter &
Gamble Company
63
such
leases,
we have
combined
lease
and
non-
lease
components.
The
right-
of-use
assets
obtained
in
exchange
for new
lease
liabilities
were
$126
for the
year
ended
June 30,
2020.
Supplemental
balance
sheet
and
other
information
related
to
leases is
as
follows:
June 30,
2020
Operating
leases:
Other
noncurrent
assets $ 850
Accrued
and other
liabilities 239
Other
noncurrent
liabilities 652
Total
operating
lease
liabilities $ 891
Weighted
average
remaining
lease term:
Operating
leases
6.5
years
Weighted
average
-- 156 of 242 --
discount
rate:
Operating
leases 4.3 %
At
June 30,
2020,
future
payments
of
operating
lease
liabilities
were as
follows:
Operating
Leases
June 30,
2020
1 year $ 239
2 years 191
3 years 161
4 years 134
5 years 86
Over 5
years 212
Total
lease
payments 1,023
Less:
Interest (132)
Present
value of
lease
liabilities $ 891
As of
June 30,
2019,
minimum
lease
payments
under
non-
cancelable
operating
leases
by
fiscal
year
were
expected
to be:
Operating
Leases
June 30,
2019
2020 $ 263
2021 209
2022 165
2023 141
2024 121
After
2024 244
-- 157 of 242 --
Total
lease
payments $ 1,143
NOTE
13
COMMITMENTS
AND
CONTINGENCIES
Guarantees
In
conjunction
with
certain
transactions,
primarily
divestitures,
we may
provide
routine
indemnifications
(e.g.,
indemnification
for
representations
and
warranties
and
retention
of
previously
existing
environmental,
tax and
employee
liabilities)
for
which
terms
range in
duration
and, in
some
circumstances,
are not
explicitly
defined.
The
maximum
obligation
under
some
indemnifications
is also
not
explicitly
stated
and, as
a result,
the
overall
amount
of these
obligations
cannot
be
reasonably
estimated.
Other
than
obligations
recorded
-- 158 of 242 --
as
liabilities
at the
time of
divestiture,
we have
not
made
significant
payments
for
these
indemnifications.
We
believe
that if
we were
to incur
a loss
on any
of these
matters,
the loss
would
not
have a
material
effect
on our
financial
position,
results
of
operations
or cash
flows.
In
certain
situations,
we
guarantee
loans
for
suppliers
and
customers.
The
total
amount
of
guarantees
issued
under
such
arrangements
is not
material.
Off-
Balance
Sheet
Arrangements
We do
not
have
off-
balance
sheet
financing
arrangements,
including
variable
interest
entities,
-- 159 of 242 --
that
have a
material
impact
on our
financial
statements.
Purchase
Commitments
We
have
purchase
commitments
for
materials,
supplies,
services
and
property,
plant
and
equipment
as part
of the
normal
course
of
business.
Commitments
made
under
take-or-
pay
obligations
are as
follows:
Years
ending June
30 2021 2022 2023 2024 2025
There-
after
Purchase
obligations $ 782 $ 257 $ 155 $ 92 $ 53 $ 238
Such
amounts
represent
minimum
commitments
under
take-or-
pay
agreements
with
suppliers
and are
in line
with
expected
usage.
These
amounts
include
purchase
commitments
related
to
service
contracts
for
information
technology,
human
resources
management
and
-- 160 of 242 --
facilities
management
activities
that
have
been
outsourced
to third-
Amounts in millions
of dollars except per
share amounts or as
otherwise specified.
-- 161 of 242 --
64 The Procter &
Gamble Company
party
suppliers.
Due to
the
proprietary
nature
of many
of our
materials
and
processes,
certain
supply
contracts
contain
penalty
provisions
for
early
termination.
We do
not
expect
to incur
penalty
payments
under
these
provisions
that
would
materially
affect
our
financial
position,
results
of
operations
or cash
flows.
Litigation
We are
subject,
from
time to
time, to
certain
legal
proceedings
and
claims
arising
out of
our
business,
which
cover a
wide
range of
matters,
including
antitrust
and
trade
regulation,
product
liability,
advertising,
-- 162 of 242 --
contracts,
environmental,
patent
and
trademark
matters,
labor
and
employment
matters
and tax.
While
considerable
uncertainty
exists,
in the
opinion
of
management
and our
counsel,
the
ultimate
resolution
of the
various
lawsuits
and
claims
will not
materially
affect
our
financial
position,
results
of
operations
or cash
flows.
We are
also
subject
to
contingencies
pursuant
to
environmental
laws
and
regulations
that in
the
future
may
require
us to
take
action
to
correct
the
effects
on the
environment
of prior
manufacturing
and
waste
disposal
practices.
Based
on
currently
-- 163 of 242 --
available
information,
we do
not
believe
the
ultimate
resolution
of
environmental
remediation
will
materially
affect
our
financial
position,
results
of
operations
or cash
flows.
NOTE
14
MERCK
ACQUISITION
On
November
30,
2018,
we
completed
our
acquisition
of the
OTC
healthcare
business
of
Merck
OTC
for $3.7
billion
(based
on
exchange
rates at
the time
of
closing)
in an
all-cash
transaction.
This
business
primarily
sells
OTC
consumer
healthcare
products,
mainly
in
Europe,
Latin
America
and
Asia
markets.
The
results
of
Merck
-- 164 of 242 --
OTC,
which
are not
material
to the
Company,
are
reported
in our
consolidated
financial
statements
beginning
December
1, 2018.
During
the
quarter
ended
December
31,
2019,
we
completed
the
allocation
of the
purchase
price to
the
individual
assets
acquired
and
liabilities
assumed.
The
allocation
is based
on the
final
determination
of fair
values
of the
assets
and
liabilities
acquired.
The
following
table
presents
the
allocation
of
purchase
price
related
to the
Merck
OTC
business
as of
the date
of the
acquisition:
Amounts in
millions
November
30, 2018
Current assets $ 421
Property, plant
and equipment 119
-- 165 of 242 --
Intangible
assets 2,134
Goodwill 2,083
Other non-
current assets 209
Total Assets
Acquired $ 4,966
Current
liabilities $ 232
Deferred
income taxes 763
Non-current
liabilities 94
Total
Liabilities
Acquired $ 1,089
Noncontrolling
Interest (1) $ 169
Net Assets
Acquired $ 3,708
(1) Represents
a
48%
minority
ownership
interest
in
the
Merck
India
company.
The
acquisition
resulted
in $2.1
billion
in
goodwill,
of
which
approximately
$180
million
was
expected
to be
deductible
for tax
purposes
as of
the
acquisition
date.
All of
this
goodwill
was
allocated
to the
Health
Care
Segment.
The
purchase
price
allocation
to
Merck
OTC's
-- 166 of 242 --
identifiable
intangible
assets
and
their
average
useful
lives is
as
follows:
Amounts in
millions
Fair
Value
Average
Useful
Life
Intangible Assets with
Determinable Lives
Brands $ 701 14
Patents
and
technology 162 10
Customer
relationships 325 20
Total $ 1,188 15
Intangible Assets with
Indefinite Lives
Brands 946
Total
Intangible
Assets $ 2,134
The
majority
of the
intangible
valuation
relates
to brand
intangibles.
Our
assessment
as to
brand
intangibles
that
have an
indefinite
life and
those
that
have a
definite
life was
based
on a
number
of
factors,
including
competitive
environment,
market
share,
brand
history,
product
life
cycles,
operating
plan
and the
macroeconomic
environment
-- 167 of 242 --
of the
countries
in
which
the
brands
are
sold.
The
indefinite-
lived
brand
intangibles
include
Neurobion
and
Dolo
Neurobion.
The
definite-
lived
brand
intangibles
primarily
include
regional
or local
brands.
The
definite-
lived
brand
intangibles
have
estimated
lives
ranging
from 10
to 20
years.
The
technology
intangibles
are
related
to R&D
and
manufacturing
know-
how.
The
customer
relationships
intangibles
are
related
to
Merck
OTC’s
relationships
with
health
care
professionals,
retailers
and
distributors.
Amounts in millions
of dollars except per
share amounts or as
otherwise specified.
-- 168 of 242 --
The Procter &
Gamble Company
65
NOTE 15
QUARTERLY
RESULTS
(UNAUDITED)
Quarters Ended Sep 30 Dec 31 Mar 31 Jun 30 Total Year
NET SALES
2019-
2020 $ 17,798 $ 18,240 $ 17,214 $ 17,698 $ 70,950
2018-
2019 16,690 17,438 16,462 17,094 67,684
OPERATING
INCOME
2019-
2020 4,290 4,482 3,453 3,481 15,706
2018-
2019 3,554 3,896 3,229 (5,192) 5,487
GROSS MARGIN
2019-
2020 51.0 % 51.4 % 49.4 % 49.5 % 50.3 %
2018-
2019 49.2 % 48.9 % 48.8 % 47.7 % 48.6 %
NET
EARNINGS/(LOSS):
Net earnings/(loss)
2019-
2020 3,617 3,743 2,957 2,786 13,103
2018-
2019 3,211 3,216 2,776 (5,237) 3,966
Net earnings/(loss)
attributable to
Procter & Gamble
2019-
2020 3,593 3,717 2,917 2,800 13,027
2018-
2019 3,199 3,194 2,745 (5,241) 3,897
DILUTED NET
EARNINGS/(LOSS)
PER COMMON
SHARE (1) (2)
2019-
2020 $ 1.36 $ 1.41 $ 1.12 $ 1.07 $ 4.96
2018-
2019 1.22 1.22 1.04 (2.12) 1.43
(1) Diluted net
earnings/(loss)
per share is
calculated on
Net
earnings/(loss)
attributable to
Procter &
Gamble.
(2) Diluted net
earnings/(loss)
per share in
each quarter
is computed
using the
weighted
average
number of
shares
outstanding
during that
quarter while
Diluted net
earnings/(loss)
per share for
the full year is
computed
using the
weighted
average
number of
shares
-- 169 of 242 --
outstanding
during the
year. In the
quarter ended
June 30,
2019, the
Company
reported a Net
loss
attributable to
P&G, driven
by the Shave
Care
impairment
charges
discussed in
Note 4. This
caused certain
of our equity
instruments to
be antidilutive
for the full
year
(preferred
shares) and
for the quarter
ended June
30, 2019
(preferred
shares and
equity
awards).
Because these
securities
were dilutive
during the
first three
quarters of
this fiscal
year, the sum
of the four
quarters'
Diluted net
earnings/(loss)
per share will
not equal the
full-year
Diluted net
earnings per
common
share.
Item 9.
Changes
in and
Disagreements
with
Accountants
on
Accounting
and
Financial
Disclosure.
Not
applicable.
Item 9A.
Controls
and
Procedures.
Evaluation
of
Disclosure
Controls
and
Procedures.
-- 170 of 242 --
The
Company's
Chairman
of the
Board,
President
and
Chief
Executive
Officer,
David
S.
Taylor,
and the
Company's
Vice
Chairman,
Chief
Operating
Officer
and
Chief
Financial
Officer,
Jon R.
Moeller,
performed
an
evaluation
of the
Company's
disclosure
controls
and
procedures
(as
defined
in Rules
13a-
15(e)
and
15d-
15(e) of
the
Securities
Exchange
Act of
1934
(Exchange
Act)) as
of the
end of
the
period
covered
by this
Annual
Report
on
Form
10-K.
Messrs.
Taylor
and
Moeller
have
concluded
that the
Company's
disclosure
controls
and
procedures
were
-- 171 of 242 --
effective
to
ensure
that
information
required
to be
disclosed
in
reports
we file
or
submit
under
the
Exchange
Act is
(1) recorded,
processed,
summarized
and
reported
within
the time
periods
specified
in
Securities
and
Exchange
Commission
rules
and
forms,
and
(2) accumulated
and
communicated
to our
management,
including
Messrs.
Taylor
and
Moeller,
to allow
their
timely
decisions
regarding
required
disclosure.
Changes
in
Internal
Control
over
Financial
Reporting.
There
were no
changes
in our
internal
control
over
financial
reporting
that
occurred
during
the
Company's
-- 172 of 242 --
fourth
fiscal
quarter
that
have
materially
affected,
or are
reasonably
likely to
materially
affect,
the
Company's
internal
control
over
financial
reporting.
Item 9B.
Other
Information.
Not
applicable.
Amounts in millions
of dollars except per
share amounts or as
otherwise specified.
-- 173 of 242 --
66 The Procter &
Gamble Company
PART III
Item 10.
Directors,
Executive
Officers
and
Corporate
Governance.
The
Board
of
Directors
has
determined
that the
following
members
of the
Audit
Committee
are
independent
and are
Audit
Committee
financial
experts
as
defined
by SEC
rules:
Ms. Patricia A.
Woertz
(Chair)
and Ms.
Christine
M.
McCarthy.
The
information
required
by this
item is
incorporated
by
reference
to the
following
sections
of the
2020
Proxy
Statement
filed
pursuant
to
Regulation
14A:
the
section
entitled
Election
of
Directors;
the
subsection
of the
-- 174 of 242 --
Corporate
Governance
section
entitled
Board
Meetings
and
Committees
of the
Board;
the
subsection
of the
Corporate
Governance
section
entitled
Code of
Ethics;
the
subsections
of the
Other
Matters
section
entitled
Director
Nominations
for
Inclusion
in the
2021
Proxy
Statement
and
entitled
Shareholder
Recommendations
of
Board
Nominees
and
Committee
Process
for
Recommending
Board
Nominees;
and the
section
entitled
Delinquent
Section 16(a)
Reports.
Pursuant
to the
Instruction
to
Item 401
of
Regulation
S-K,
Executive
Officers
of the
Registrant
are
reported
in Part I
of this
report.
Item 11.
Executive
-- 175 of 242 --
Compensation.
The
information
required
by this
item is
incorporated
by
reference
to the
following
sections
of the
2020
Proxy
Statement
filed
pursuant
to
Regulation
14A:
the
subsections
of the
Corporate
Governance
section
entitled
Board
Meetings
and
Committees
of the
Board
and
entitled
Compensation
Committee
Interlocks
and
Insider
Participation;
and the
portion
beginning
with the
section
entitled
Director
Compensation
up to
but not
including
the
section
entitled
Security
Ownership
of
Management
and
Certain
Beneficial
Owners.
Item 12. Security
Ownership of
Certain
Beneficial
Owners and
Management and
Related
Stockholder
-- 176 of 242 --
Matters.
The following
table gives
information
about the
Company's
common stock
that may be
issued upon the
exercise of
options, warrants
and rights under
all of the
Company's
equity
compensation
plans as of
June 30, 2020.
The table
includes the
following plans:
The Procter &
Gamble 1992
Stock Plan; The
Procter &
Gamble 2001
Stock and
Incentive
Compensation
Plan; The Procter
& Gamble 2003
Non-Employee
Directors' Stock
Plan; The Procter
& Gamble 2009
Stock and
Incentive
Compensation
Plan; The Procter
& Gamble 2014
Stock and
Incentive
Compensation
Plan; and The
Procter &
Gamble 2019
Stock and
Incentive
Compensation
Plan.
Plan Category
(a)
Number of securities to
be issued upon exercise
of outstanding options,
warrants and rights
(b)
Weighted
average exercise
price of
outstanding
options,
warrants and
rights
(c)
Number of securities
remaining available for
future issuance under
equity compensation plans
(excluding securities
reflected in column (a))
Equity
compensation plans
approved by
security holders
Options 149,915,111 $84.7316 (1)
Restricted Stock
Units
(RSUs)/Performance
Stock Units (PSUs) 9,814,991 N/A (1)
TOTAL 159,730,102 $84.7316 (2)
(1) Of the plans
listed above,
only The
Procter &
Gamble 2019
Stock and
-- 177 of 242 --
Stock and
Incentive
Compensation
Plan (the
“2019 Plan”)
allows for
future grants
of securities.
The
maximum
number of
shares that
may be
granted under
the 2019 Plan
is
approximately
187 million
shares
(inclusive of
unissued
shares that
were carried
over from the
Procter &
Gamble
Company
2014 Stock
and Incentive
Compensation
Plan), plus
any shares of
Common
Stock subject
to outstanding
awards under
the 2014 Plan
that are
forfeited,
cancelled or
otherwise
terminated
without the
issuance of
shares of
Common
Stock as set
forth in the
2019 Plan.
Stock options
and stock
appreciation
rights are
counted on a
one-for-one
basis while
full value
awards (such
as RSUs and
PSUs) will be
counted as
five shares for
each share
awarded.
Total shares
available for
future
issuance
under this
plan is 166
million.
(2) Weighted
average
exercise price
of outstanding
options only.
-- 178 of 242 --
The Procter &
Gamble Company
67
Additional
information
required
by this
item is
incorporated
by
reference
to the
2020
Proxy
Statement
filed
pursuant
to
Regulation
14A,
beginning
with the
subsection
of the
Beneficial
Ownership
section
entitled
Security
Ownership
of
Management
and
Certain
Beneficial
Owners
and up
to but
not
including
the
subsection
entitled
Delinquent
Section 16(a)
Reports.
Item 13.
Certain
Relationships
and
Related
Transactions
and
Director
Independence.
The
information
required
by this
item is
incorporated
by
reference
to the
following
sections
of the
2020
Proxy
Statement
filed
pursuant
-- 179 of 242 --
to
Regulation
14A:
the
subsections
of the
Corporate
Governance
section
entitled
Director
Independence
and
Review
and
Approval
of
Transactions
with
Related
Persons.
Item 14.
Principal
Accountant
Fees
and
Services.
The
information
required
by this
item is
incorporated
by
reference
to the
following
section
of the
2020
Proxy
Statement
filed
pursuant
to
Regulation
14A:
Report
of the
Audit
Committee,
which
ends
with the
subsection
entitled
Services
Provided
by
Deloitte.
PART IV
Item 15. Exhibits
and Financial
Statement
Schedules.
1. Financial
Statements:
The following
Consolidated
-- 180 of 242 --
Financial
Statements of
The Procter &
Gamble
Company and
subsidiaries,
management's
report and the
reports of the
independent
registered public
accounting firm
are incorporated
by reference in
Part II, Item 8 of
this Form 10-K.
• Management's
Report on
Internal
Control over
Financial
Reporting
• Report of
Independent
Registered
Public
Accounting
Firm on
Internal
Control over
Financial
Reporting
• Report of
Independent
Registered
Public
Accounting
Firm on
Consolidated
Financial
Statements
• Consolidated
Statements
of Earnings -
for years
ended
June 30,
2020, 2019
and 2018
• Consolidated
Statements
of Other
Comprehensive
Income - for
years ended
June 30,
2020, 2019
and 2018
• Consolidated
Balance
Sheets - as
of June 30,
2020 and
2019
• Consolidated
Statements
of
Shareholders'
Equity - for
years ended
June 30,
2020, 2019
-- 181 of 242 --
and 2018
• Consolidated
Statements
of Cash
Flows - for
years ended
June 30,
2020, 2019
and 2018
• Notes to
Consolidated
Financial
Statements
2. Financial
Statement
Schedules:
These schedules
are omitted
because of the
absence of the
conditions under
which they are
required or
because the
information is set
forth in the
Consolidated
Financial
Statements or
Notes thereto.
EXHIBITS
Exhibit (3-
1) -
Amended
Articles of
Incorporation
(as amended
by
shareholders
at the annual
meeting on
October 11,
2011 and
consolidated
by the Board
of Directors
on April 8,
2016)
(Incorporated
by reference
to Exhibit (3-
1) of the
Company's
Annual
Report on
Form 10-K
for the year
ended June
30, 2016).
(3-2) - Regulations
(as approved
by the Board
of Directors
on April 8,
2016,
pursuant to
authority
granted by
shareholders
at the annual
meeting on
October 13,
2009)
(Incorporated
-- 182 of 242 --
by reference
to Exhibit (3-
2) of the
Company's
Annual
Report on
Form 10-K
for the year
ended June
30, 2016).
Exhibit (4-
1) -
Indenture,
dated as of
September 3,
2009,
between the
Company
and Deutsche
Bank Trust
Company
Americas, as
Trustee
(Incorporated
by reference
to Exhibit (4-
1) of the
Company's
Annual
Report on
Form 10-K
for the year
ended June
30, 2015).
(4-2) - The
Company
agrees to
furnish to the
Securities
and
Exchange
Commission,
upon request,
a copy of any
other
instrument
defining the
rights of
holders of the
Company’s
long-term
debt.
(4-3) - Description
of the
Company’s
Common
Stock
(Incorporated
by reference
to Exhibit (4-
3) of the
Company’s
Annual
report on
Form 10-K
for the year
ended June
30, 2019).
(4-4) - Description
of the
Company’s
0.625%
Notes due
2024,
-- 183 of 242 --
1.200%
Notes due
2028, and
1.875%
Notes due
2038
(Incorporated
by reference
to Exhibit (4-
4) of the
Company’s
Annual
report on
Form 10-K
for the year
ended June
30, 2019).
(4-5) - Description
of the
Company’s
4.125% EUR
notes due
December
2020,
4.875% EUR
notes due
May 2027,
6.250% GBP
notes due
January
2030, and
5.250% GBP
notes due
January 2033
(Incorporated
by reference
to Exhibit (4-
5) of the
Company’s
Annual
report on
Form 10-K
for the year
ended June
30, 2019).
(4-6) - Description
of the
Company’s
0.500%
Notes due
2024 and
1.250%
Notes due
2029
(Incorporated
by reference
to Exhibit (4-
6) of the
Company’s
Annual
report on
Form 10-K
for the year
ended June
30, 2019).
-- 184 of 242 --
68 The Procter &
Gamble Company
(4-7) - Description of
the Company’s
1.375% Notes
due 2025 and
1.800% Notes
due 2029
(Incorporated
by reference to
Exhibit (4-7) of
the Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019).
(4-8) - Description of
the Company’s
1.125% Notes
due 2023
(Incorporated
by reference to
Exhibit (4-8) of
the Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019).
(4-9) - Description of
the Company’s
2.000% Notes
due 2021
(Incorporated
by reference to
Exhibit (4-10)
of the
Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019).
(4-10) - Description of
the Company’s
2.000% Notes
due 2022
(Incorporated
by reference to
Exhibit (4-11)
of the
Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019).
Exhibit (10-
1) -
The Procter &
Gamble 2001
Stock and
Incentive
Compensation
Plan (as
amended),
which was
originally
adopted by
shareholders at
-- 185 of 242 --
the annual
meeting on
October 9,
2001
(Incorporated
by reference to
Exhibit (10-1)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2018); and
related
correspondence
and terms and
conditions
(Incorporated
by reference to
Exhibit (10-1)
of the
Company's
Form 10-Q for
the quarter
ended
December 31,
2013).*
(10-2) - The Procter &
Gamble 1992
Stock Plan (as
amended
December 11,
2001), which
was originally
adopted by the
shareholders at
the annual
meeting on
October 12,
1992
(Incorporated
by reference to
Exhibit (10-2)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2018).*
(10-3) - The Procter &
Gamble
Executive
Group Life
Insurance
Policy
(Incorporated
by reference to
Exhibit (10-3)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2018).*
(10-4) - Summary of
the Company’s
Retirement
Plan
Restoration
Program
-- 186 of 242 --
(Incorporated
by reference to
Exhibit (10-5)
of the
Company's
Form 10-Q for
the quarter
ended
December 31,
2019); and
related
correspondence
and terms and
conditions
(Incorporated
by reference to
Exhibit (10-8)
of the
Company's
Form 10-Q for
the quarter
ended
September 30,
2015). *
(10-5) - Summary of
the Company’s
Long-Term
Incentive
Program
(Incorporated
by reference to
Exhibit (10-3)
of the
Company's
Form 10-Q for
the quarter
ended
December 31,
2019); related
correspondence
and terms and
conditions
(Incorporated
by reference to
Exhibit (10-6)
of the
Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019).*
(10-6) - The Procter &
Gamble
Company
Executive
Deferred
Compensation
Plan
(Incorporated
by reference to
Exhibit (10-2)
of the
Company's
Form 10-Q for
the quarter
ended March
31, 2020).*
(10-7) - Summary of
the Company's
Short Term
Achievement
Reward
-- 187 of 242 --
Program
(Incorporated
by reference to
Exhibit (10-4)
of the
Company’s
Form 10-Q for
the quarter
ended
December 31,
2019); related
correspondence
and terms and
conditions
(Incorporated
by reference to
Exhibit (10-2)
of the
Company's
Form 10-Q for
the quarter
ended
September 30,
2015).*
(10-8) - Company's
Forms of
Separation
Agreement &
Release
(Incorporated
by reference to
Exhibit (10-1)
of the
Company's
Form 10-Q for
the quarter
ended March
31, 2020) ;
Company's
Form of
Separation
Letter and
Release
(Incorporated
by reference to
Exhibit (10-6)
of the
Company's
Form 10-Q for
the quarter
ended
December 31,
2019).*
(10-9) - Summary of
personal
benefits
available to
certain officers
and non-
employee
directors
(Incorporated
by reference to
Exhibit (10-3)
of the
Company's
Form 10-Q for
the quarter
ended
September 30,
2018).*
(10-10) - The Gillette
Company
-- 188 of 242 --
Executive Life
Insurance
Program
(Incorporated
by reference to
Exhibit (10-14)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2017). *
(10-11) - The Gillette
Company
Personal
Financial
Planning
Reimbursement
Program
(Incorporated
by reference to
Exhibit (10-15)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2017). *
(10-12) - The Gillette
Company
Senior
Executive
Financial
Planning
Program
(Incorporated
by reference to
Exhibit (10-16)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2017). *
(10-13) - The Gillette
Company
Estate
Preservation
(Incorporated
by reference to
Exhibit (10-17)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2017). *
(10-14) - The Gillette
Company
Deferred
Compensation
Plan
(Incorporated
by reference to
Exhibit (10-18)
of the
Company’s
Annual Report
-- 189 of 242 --
on Form 10-K
for the year
ended June 30,
2017). *
(10-15) - Senior
Executive
Recoupment
Policy
(Incorporated
by reference to
Exhibit (10-19)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2018).*
(10-16) - The Gillette
Company
Deferred
Compensation
Plan (for salary
deferrals prior
to January 1,
2005) as
amended
through August
21, 2006
(Incorporated
by reference to
Exhibit (10-20)
of the
Company's
Annual Report
on Form 10-K
for the year
ended June 30,
2017). *
(10-17) - The Procter &
Gamble 2009
Stock and
Incentive
Compensation
Plan, which
was originally
adopted by
shareholders at
the annual
meeting on
October 13,
2009
(Incorporated
by reference to
Exhibit (10-21)
of the
Company's
Annual Report
on Form 10-K
for the year
ended June 30,
2017), and the
Regulations of
the
Compensation
and Leadership
Development
Committee for
The Procter &
Gamble 2009
Stock and
Incentive
Compensation
-- 190 of 242 --
Plan, The
Procter &
Gamble 2001
Stock and
Incentive
Compensation
Plan, The
Procter &
Gamble 1992
Stock Plan,
The Procter &
Gamble 1992
Stock Plan
(Belgium
Version), The
Gillette
Company 2004
Long-Term
Incentive Plan
and the Gillette
Company 1971
Stock Option
Plan
(Incorporated
by reference to
Exhibit (10-21)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2018). *
-- 191 of 242 --
The Procter &
Gamble Company
69
(10-18) - The Procter &
Gamble 2009
Stock and
Incentive
Compensation
Plan -
Additional
terms and
conditions and
related
correspondence
(Incorporated
by reference to
Exhibit (10-2)
of the Company
Form 10-Q for
the quarter
ended
December 31,
2013). *
(10-19) - The Procter &
Gamble
Performance
Stock Program
Summary
(Incorporated
by reference to
Exhibit (10-3)
of the
Company's
Form 10-Q for
the quarter
ended March
31, 2020);
related
correspondence
and terms and
conditions
(Incorporated
by reference to
Exhibit (10-22)
of the
Company's
Annual Report
on Form 10-K
for the year
ended June 30,
2019).*
(10-20) - The Procter &
Gamble 2013
Non-Employee
Directors' Stock
Plan
(Incorporated
by reference to
Exhibit (10-3)
of the
Company's
Form 10-Q for
the quarter
ended
December 31,
2013). *
(10-21) - The Procter &
Gamble 2014
Stock and
Incentive
Compensation
-- 192 of 242 --
Plan, which was
originally
adopted by
shareholders at
the annual
meeting on
October 14,
2014
(Incorporated
by reference to
Exhibit (10-25)
of the
Company's
Annual Report
on Form 10-K
for the year
ended June 30,
2016); and the
Regulations of
the
Compensation
and Leadership
Development
Committee for
The Procter &
Gamble 2019
Stock and
Incentive
Compensation
Plan and The
Procter &
Gamble 2014
Stock and
Incentive
Compensation
Plan
(Incorporated
by reference to
Exhibit (10-1)
of the
Company's
Form 10-Q for
the quarter
ended
December 31,
2019). *
(10-22) - The Procter &
Gamble 2014
Stock and
Incentive
Compensation
Plan -
Additional
terms and
conditions
(Incorporated
by reference to
Exhibit (10-26)
of the
Company's
Annual Report
on Form 10-K
for the year
ended June 30,
2017), and The
Procter &
Gamble 2014
Stock and
Incentive
Compensation
Plan - Related
correspondence
(Incorporated
by reference to
-- 193 of 242 --
Exhibit (10-1)
of the
Company's
Form 10-Q for
the quarter
ended
December 31,
2016). *
(10-23) - The Procter &
Gamble 2019
Stock and
Incentive
Compensation
Plan, which was
originally
adopted by
shareholders at
the annual
meeting on
October 8, 2019
(Incorporated
by reference to
Exhibit (10-1)
of the
Company’s
Current Report
on Form 8-K
filed October
11, 2019); and
the Regulations
of the
Compensation
and Leadership
Development
Committee for
The Procter &
Gamble 2019
Stock and
Incentive
Compensation
Plan and The
Procter &
Gamble 2014
Stock and
Incentive
Compensation
Plan
(Incorporated
by reference to
Exhibit (10-1)
of the Company
Form 10-Q for
the quarter
ended
December 31,
2019). *
(10-24) - The Procter &
Gamble 2019
Stock and
Incentive
Compensation
Plan -
Additional
terms and
conditions. * +
(10-25) - The Procter &
Gamble 2019
Stock and
Incentive
Compensation
Plan - Related
correspondence.
* +
-- 194 of 242 --
Exhibit (21) - Subsidiaries of
the Registrant.
+
Exhibit (23) - Consent of
Independent
Registered
Public
Accounting
Firm. +
Exhibit (31) - Rule 13a-
14(a)/15d-14(a)
Certifications. +
Exhibit (32) - Section 1350
Certifications. +
Exhibit (99-
1) -
Summary of
Directors and
Officers
Insurance
Program. +
101.INS (1) Inline XBRL
Instance
Document
101.SCH (1) Inline XBRL
Taxonomy
Extension
Schema
Document
101.CAL (1) Inline XBRL
Taxonomy
Extension
Calculation
Linkbase
Document
101.DEF (1) Inline XBRL
Taxonomy
Definition
Linkbase
Document
101.LAB (1) Inline XBRL
Taxonomy
Extension Label
Linkbase
Document
101.PRE (1) Inline XBRL
Taxonomy
Extension
Presentation
Linkbase
Document
104 Cover Page
Interactive Data
File (formatted
in Inline XBRL
and contained
in Exhibit 101)
(1) Pursuant to
Rule 406T of
Regulation S-T,
these interactive
data files are
deemed not
filed or part of a
registration
statement or
prospectus for
purposes of
Sections 11 or
12 of the
Securities Act
-- 195 of 242 --
of 1933 or
Section 18 of
the Securities
Exchange Act
of 1934 and
otherwise are
not subject to
liability.
* Compensatory
plan or
arrangement.
+ Filed herewith.
Item 16. Form
10-K Summary.
Not applicable.
-- 196 of 242 --
70 The Procter &
Gamble Company
SIGNATURES
Pursuant to the
requirements of
Section 13 or
15(d) of the
Securities
Exchange Act of
1934, the
registrant has
duly caused this
report to be
signed on its
behalf by the
undersigned,
thereunto duly
authorized in the
city of
Cincinnati, State
of Ohio.
THE
PROCTER &
GAMBLE
COMPANY
By
/s/ DAVID
S.
TAYLOR
(David S.
Taylor)
Chairman
of the
Board,
President
and Chief
Executive
Officer
August 06,
2020
Pursuant to the
requirements of
the Securities
Exchange Act of
1934, this report
has been signed
below by the
following
persons in the
capacities and on
the dates
indicated.
Signature Title Date
/s/ DAVID S.
TAYLOR
(David S.
Taylor)
Chairman
of the
Board,
President
and Chief
Executive
Officer
(Principal
Executive
Officer)
August
06,
2020
Vice
Chairman,
Chief
-- 197 of 242 --
/s/ JON R.
MOELLER
(Jon R.
Moeller)
Operating
Officer and
Chief
Financial
Officer
(Principal
Financial
Officer)
August
06,
2020
/s/ VALARIE
L.
SHEPPARD
(Valarie L.
Sheppard)
Controller
and
Treasurer
and Group
Executive
Vice
President -
Company
Transition
Leader
(Principal
Accounting
Officer)
August
06,
2020
/s/ FRANCIS
S. BLAKE
(Francis S.
Blake) Director
August
06,
2020
/s/ ANGELA
F. BRALY
(Angela F.
Braly) Director
August
06,
2020
/s/ AMY L.
CHANG
(Amy L.
Chang) Director
August
06,
2020
/s/ SCOTT D.
COOK
(Scott D.
Cook) Director
August
06,
2020
/s/ JOSEPH
JIMENEZ
(Joseph
Jimenez) Director
August
06,
2020
/s/ TERRY J.
LUNDGREN
(Terry J.
Lundgren) Director
August
06,
2020
/s/
CHRISTINE
M.
MCCARTHY
(Christine M.
McCarthy) Director
August
06,
2020
/s/ W. JAMES
MCNERNEY,
JR.
(W. James
McNerney,
Jr.) Director
August
06,
2020
/s/ NELSON
PELTZ
(Nelson Peltz) Director
August
06,
2020
/s/
MARGARET
C.
WHITMAN
(Margaret C.
Whitman) Director
August
06,
2020
-- 198 of 242 --
/s/ PATRICIA
A. WOERTZ
(Patricia A.
Woertz) Director
August
06,
2020
-- 199 of 242 --
The Procter &
Gamble Company
71
EXHIBIT
INDEX
Exhibit (3-
1) -
Amended
Articles of
Incorporation
(as amended by
shareholders at
the annual
meeting on
October 11,
2011 and
consolidated by
the Board of
Directors on
April 8, 2016)
(Incorporated
by reference to
Exhibit (3-1) of
the Company's
Annual Report
on Form 10-K
for the year
ended June 30,
2016).
(3-2) - Regulations (as
approved by
the Board of
Directors on
April 8, 2016,
pursuant to
authority
granted by
shareholders at
the annual
meeting on
October 13,
2009)
(Incorporated
by reference to
Exhibit (3-2) of
the Company's
Annual Report
on Form 10-K
for the year
ended June 30,
2016).
Exhibit (4-
1) - Indenture,
dated as of
September 3,
2009, between
the Company
and Deutsche
Bank Trust
Company
Americas, as
Trustee
(Incorporated
by reference to
Exhibit (4-1) of
the Company's
Annual Report
on Form 10-K
for the year
ended June 30,
2015).
(4-2) - The Company
agrees to
furnish to the
Securities and
Exchange
Commission,
upon request, a
copy of any
other
instrument
defining the
rights of
holders of the
Company’s
long-term debt.
-- 200 of 242 --
(4-3) - Description of
the Company’s
Common Stock
(Incorporated
by reference to
Exhibit (4-3) of
the Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019) +
(4-4) - Description of
the Company’s
0.625% Notes
due 2024,
1.200% Notes
due 2028, and
1.875% Notes
due 2038
(Incorporated
by reference to
Exhibit (4-4) of
the Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019). +
(4-5) - Description of
the Company’s
4.125% EUR
notes due
December
2020, 4.875%
EUR notes due
May 2027,
6.250% GBP
notes due
January 2030,
and 5.250%
GBP notes due
January 2033
(Incorporated
by reference to
Exhibit (4-5) of
the Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019). +
(4-6) - Description of
the Company’s
0.500% Notes
due 2024 and
1.250% Notes
due 2029
(Incorporated
by reference to
Exhibit (4-6) of
the Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019). +
(4-7) - Description of
the Company’s
1.375% Notes
due 2025 and
1.800% Notes
due 2029
(Incorporated
by reference to
Exhibit (4-7) of
the Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019). +
(4-8) - Description of
the Company’s
1.125% Notes
due 2023
(Incorporated
by reference to
Exhibit (4-8) of
the Company’s
-- 201 of 242 --
the Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019). +
(4-9) - Description of
the Company’s
2.000% Notes
due 2021
(Incorporated
by reference to
Exhibit (4-10)
of the
Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019). +
(4-10) - Description of
the Company’s
2.000% Notes
due 2022
(Incorporated
by reference to
Exhibit (4-11)
of the
Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019). +
Exhibit (10-
1) -
The Procter &
Gamble 2001
Stock and
Incentive
Compensation
Plan (as
amended),
which was
originally
adopted by
shareholders at
the annual
meeting on
October 9,
2001
(Incorporated
by reference to
Exhibit (10-1)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2018); and
related
correspondence
and terms and
conditions
(Incorporated
by reference to
Exhibit (10-1)
of the
Company's
Form 10-Q for
the quarter
ended
December 31,
2013).
(10-2) - The Procter &
Gamble 1992
Stock Plan (as
amended
December 11,
2001), which
was originally
adopted by the
shareholders at
the annual
meeting on
October 12,
1992
(Incorporated
by reference to
Exhibit (10-2)
of the
Company’s
-- 202 of 242 --
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2018).
(10-3) - The Procter &
Gamble
Executive
Group Life
Insurance
Policy
(Incorporated
by reference to
Exhibit (10-3)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2018).
(10-4) - Summary of
the Company’s
Retirement
Plan
Restoration
Program
(Incorporated
by reference to
Exhibit (10-5)
of the
Company's
Form 10-Q for
the quarter
ended
December 31,
2019); and
related
correspondence
and terms and
conditions
(Incorporated
by reference to
Exhibit (10-8)
of the
Company's
Form 10-Q for
the quarter
ended
September 30,
2015).
(10-5) - Summary of
the Company’s
Long-Term
Incentive
Program
(Incorporated
by reference to
Exhibit (10-3)
of the
Company's
Form 10-Q for
the quarter
ended
December 31,
2019); related
correspondence
and terms and
conditions
(Incorporated
by reference to
Exhibit (10-6)
of the
Company’s
Annual report
on Form 10-K
for the year
ended June 30,
2019).
(10-6) - The Procter &
Gamble
Company
Executive
Deferred
Compensation
Plan
(Incorporated
by reference to
Exhibit (10-2)
of the
-- 203 of 242 --
of the
Company's
Form 10-Q for
the quarter
ended March
31, 2020).
(10-7) - Summary of
the Company's
Short Term
Achievement
Reward
Program
(Incorporated
by reference to
Exhibit (10-4)
of the
Company’s
Form 10-Q for
the quarter
ended
December 31,
2019); related
correspondence
and terms and
conditions
(Incorporated
by reference to
Exhibit (10-2)
of the
Company's
Form 10-Q for
the quarter
ended
September 30,
2015).
(10-8) - Company's
Forms of
Separation
Agreement &
Release
(Incorporated
by reference to
Exhibit (10-1)
of the
Company's
Form 10-Q for
the quarter
ended March
31, 2020) ;
Company's
Form of
Separation
Letter and
Release
(Incorporated
by reference to
Exhibit (10-6)
of the
Company's
Form 10-Q for
the quarter
ended
December 31,
2019).
-- 204 of 242 --
72 The Procter &
Gamble Company
(10-9) - Summary of the
Company's
Short Term
Achievement
Reward
Program
(Incorporated
by reference to
Exhibit (10-10)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2018); related
correspondence
and terms and
conditions
(Incorporated
by reference to
Exhibit (10-2)
of the
Company's
Form 10-Q for
the quarter
ended
September 30,
2015).
(10-10) - The Gillette
Company
Executive Life
Insurance
Program
(Incorporated
by reference to
Exhibit (10-14)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2017).
(10-11) - The Gillette
Company
Personal
Financial
Planning
Reimbursement
Program
(Incorporated
by reference to
Exhibit (10-15)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2017).
(10-12) - The Gillette
Company
Senior
Executive
Financial
Planning
Program
(Incorporated
by reference to
Exhibit (10-16)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2017).
(10-13) - The Gillette
Company Estate
Preservation
(Incorporated
by reference to
Exhibit (10-17)
of the
Company’s
-- 205 of 242 --
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2017).
(10-14) - The Gillette
Company
Deferred
Compensation
Plan
(Incorporated
by reference to
Exhibit (10-18)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2017).
(10-15) - Senior
Executive
Recoupment
Policy
(Incorporated
by reference to
Exhibit (10-19)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2018).
(10-16) - The Gillette
Company
Deferred
Compensation
Plan (for salary
deferrals prior
to January 1,
2005) as
amended
through August
21, 2006
(Incorporated
by reference to
Exhibit (10-20)
of the
Company's
Annual Report
on Form 10-K
for the year
ended June 30,
2017).
(10-17) - The Procter &
Gamble 2009
Stock and
Incentive
Compensation
Plan, which was
originally
adopted by
shareholders at
the annual
meeting on
October 13,
2009
(Incorporated
by reference to
Exhibit (10-21)
of the
Company's
Annual Report
on Form 10-K
for the year
ended June 30,
2017), and the
Regulations of
the
Compensation
and Leadership
Development
Committee for
The Procter &
Gamble 2009
Stock and
Incentive
Compensation
Plan, The
-- 206 of 242 --
Plan, The
Procter &
Gamble 2001
Stock and
Incentive
Compensation
Plan, The
Procter &
Gamble 1992
Stock Plan, The
Procter &
Gamble 1992
Stock Plan
(Belgium
Version), The
Gillette
Company 2004
Long-Term
Incentive Plan
and the Gillette
Company 1971
Stock Option
Plan
(Incorporated
by reference to
Exhibit (10-21)
of the
Company’s
Annual Report
on Form 10-K
for the year
ended June 30,
2018).
(10-18) - The Procter &
Gamble 2009
Stock and
Incentive
Compensation
Plan -
Additional
terms and
conditions and
related
correspondence
(Incorporated
by reference to
Exhibit (10-2)
of the Company
Form 10-Q for
the quarter
ended
December 31,
2013).
(10-19) - The Procter &
Gamble
Performance
Stock Program
Summary
(Incorporated
by reference to
Exhibit (10-3)
of the
Company's
Form 10-Q for
the quarter
ended March
31, 2020);
related
correspondence
and terms and
conditions
(Incorporated
by reference to
Exhibit (10-22)
of the
Company's
Annual Report
on Form 10-K
for the year
ended June 30,
2019).
(10-20) - The Procter &
Gamble 2013
Non-Employee
Directors' Stock
Plan
(Incorporated
by reference to
Exhibit (10-3)
of the
Company's
Form 10-Q for
-- 207 of 242 --
Form 10-Q for
the quarter
ended
December 31,
2013).
(10-21) - The Procter &
Gamble 2014
Stock and
Incentive
Compensation
Plan, which was
originally
adopted by
shareholders at
the annual
meeting on
October 14,
2014
(Incorporated
by reference to
Exhibit (10-25)
of the
Company's
Annual Report
on Form 10-K
for the year
ended June 30,
2016); and the
Regulations of
the
Compensation
and Leadership
Development
Committee for
The Procter &
Gamble 2019
Stock and
Incentive
Compensation
Plan and The
Procter &
Gamble 2014
Stock and
Incentive
Compensation
Plan
(Incorporated
by reference to
Exhibit (10-1)
of the
Company's
Form 10-Q for
the quarter
ended
December 31,
2019).
(10-22) - The Procter &
Gamble 2014
Stock and
Incentive
Compensation
Plan -
Additional
terms and
conditions
(Incorporated
by reference to
Exhibit (10-26)
of the
Company's
Annual Report
on Form 10-K
for the year
ended June 30,
2017), and The
Procter &
Gamble 2014
Stock and
Incentive
Compensation
Plan - Related
correspondence
(Incorporated
by reference to
Exhibit (10-1)
of the
Company's
Form 10-Q for
the quarter
ended
December 31,
2016).
-- 208 of 242 --
(10-23) - The Procter &
Gamble 2019
Stock and
Incentive
Compensation
Plan, which was
originally
adopted by
shareholders at
the annual
meeting on
October 8, 2019
(Incorporated
by reference to
Exhibit (10-1)
of the
Company’s
Current Report
on Form 8-K
filed October
11, 2019); and
the Regulations
of the
Compensation
and Leadership
Development
Committee for
The Procter &
Gamble 2019
Stock and
Incentive
Compensation
Plan and The
Procter &
Gamble 2014
Stock and
Incentive
Compensation
Plan
(Incorporated
by reference to
Exhibit (10-1)
of the Company
Form 10-Q for
the quarter
ended
December 31,
2019).
(10-24) - The Procter &
Gamble 2019
Stock and
Incentive
Compensation
Plan -
Additional
terms and
conditions. +
(10-25) - The Procter &
Gamble 2019
Stock and
Incentive
Compensation
Plan - Related
correspondence.
+
Exhibit (21) - Subsidiaries of
the Registrant.
+
Exhibit (23) - Consent of
Independent
Registered
Public
Accounting
Firm. +
Exhibit (31) - Rule 13a-
14(a)/15d-14(a)
Certifications. +
Exhibit (32) - Section 1350
Certifications. +
-- 209 of 242 --
The Procter &
Gamble Company
73
Exhibit (99-
1) -
Summary of
Directors
and Officers
Insurance
Program. +
101.INS (1) Inline
XBRL
Instance
Document
101.SCH (1) Inline
XBRL
Taxonomy
Extension
Schema
Document
101.CAL (1) Inline
XBRL
Taxonomy
Extension
Calculation
Linkbase
Document
101.DEF (1) Inline
XBRL
Taxonomy
Definition
Linkbase
Document
101.LAB (1) Inline
XBRL
Taxonomy
Extension
Label
Linkbase
Document
101.PRE (1) Inline
XBRL
Taxonomy
Extension
Presentation
Linkbase
Document
104 Cover Page
Interactive
Data File
(formatted
in Inline
XBRL and
contained in
Exhibit
101)
(1) Pursuant to
Rule 406T
of
Regulation
S-T, these
interactive
data files
are deemed
not filed or
part of a
registration
statement or
prospectus
for purposes
of Sections
11 or 12 of
the
-- 210 of 242 --
Securities
Act of 1933
or
Section 18
of the
Securities
Exchange
Act of 1934
and
otherwise
are not
subject to
liability.
+ Filed
herewith.
-- 211 of 242 --
EXHIBIT (10-24)
The Procter & Gamble 2019 Stock and Incentive
Compensation Plan - Additional Terms and Conditions
-- 212 of 242 --
______________________________________________________________________ RSU Form BOD
FORM BOD AWARD AGREEMENT
______________________________________________________________________
<NAME> <DATE>
Number of Restricted Stock Units: [# SHARES]
Grant Date: [GRANT_DATE]
Vest Date: [DATE (Day Before Next Annual Meeting Following Grant)]
Original Settlement Date: One Year Following Termination of Directorship
Subject: Award of Restricted Stock Units
This is to advise you that The Procter & Gamble Company (“Company”) hereby grants to you Restricted Stock Units (“RSUs”) of Procter & Gamble
Common Stock as follows:
This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including
any applicable sub-plan) (the “Plan”), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors
(“Committee”), and this Award Agreement, including Attachment A-BOD. Any capitalized terms used in this Agreement that are not otherwise
defined herein are defined in the Plan.
Voting Rights and Dividend Equivalents
As a holder of RSUs, during the period from the Grant Date until the date the RSUs are paid, each time a cash dividend or other cash distribution is
paid with respect to Common Stock, you will receive additional RSUs (“Dividend Equivalent RSUs”). The number of Dividend Equivalent RSUs will
be determined as follows: multiply the number of RSUs and Dividend Equivalent RSUs currently held by the per share amount of the cash dividend
or other cash distribution on Common Stock, then divide the result by the price of the Common Stock on the date of the dividend or distribution.
These Dividend Equivalent RSUs will be subject to the same terms and conditions as the original RSUs that gave rise to them, including vesting and
settlement terms, except that if there is a fractional number of Dividend Equivalent RSUs on the date the RSUs are paid, the Dividend Equivalent
RSUs will be rounded up to the nearest whole number of RSUs. This Award represents an unfunded, unsecured right to receive payment in the
future, and does not entitle you to voting rights or dividend rights as a shareholder.
Vesting and Payment
If you remain a Non-Employee Director through the Vest Date, the Award will be paid on the Original Settlement Date or Agreed Settlement Date,
whichever is applicable, except in the case of death or Disability. In the case of death or Disability, the Award will be fully vested and payment will be
made by the later of the end of the calendar year or two and a half months following the date of death or Disability, as applicable.
Notwithstanding the foregoing, in the event of a Change in Control, payment shall be made pursuant to the terms provided in the Plan.
-- 213 of 242 --
Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by the Committee pursuant to
the Plan, subject to applicable tax withholding.
Deferral Election
At any time prior to Termination of Directorship, you and the Company may agree to postpone the Original Settlement Date to such later date
(“Agreed Settlement Date”) as may be elected by you, which date shall be at least five years later than the Original Settlement Date and in
accordance with Internal Revenue Code Section 409A.
This Award Agreement including Attachment A-BOD, the Plan and Regulations of the Committee together constitute an agreement between the
Company and you in accordance with the terms thereof and hereof, and no other understanding and/or agreements that have been entered by you
with the Company regarding this specific Award. Any legal action related to this Award may be brought in any federal or state court located in
Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from said courts
solely for legal actions related to this Award.
THE PROCTER & GAMBLE COMPANY
Tracey Grabowski
Chief Human Resources Officer
______________________________________________________________________ RSU Form BOD
Attachment A-BOD
Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be
inconsistent with any applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said
Common Stock and that any outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail
to comply with the terms and conditions governing this Award.
Nature of the Award
By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter &
Gamble Company (“P&G”), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are
voluntary and occasional and this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even
if Awards have been granted repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my
participation in the Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation for any purposes
including, but not limited to, calculating any termination, severance, resignation, redundancy, end of service payments, bonuses, long-service
awards, pension or retirement benefits or similar payments; vi) the Award will not be interpreted to form an employment relationship with P&G; and
furthermore, the Award will not be interpreted to form an employment contract with P&G; vii) the future value of the shares purchased under the Plan
is unknown and cannot be predicted with certainty, may increase or decrease in value and potentially have no value; viii) my participation in the Plan
shall not interfere with the ability of P&G to terminate my directorship at any time, with or without cause; ix) and no claim or entitlement to
compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares purchased and I irrevocably
release P&G from any such claim that may arise.
Data Privacy
I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this
document by and among, as applicable, The Procter & Gamble Company
-- 214 of 242 --
and its subsidiaries and affiliates (“P&G”) for the exclusive purpose of implementing, administering and managing my participation in the Plan.
I understand that P&G holds certain personal information about me, including, but not limited to, my name, home address and telephone number,
date of birth, social insurance number or other identification number, salary, nationality, , any shares of stock or directorships held in P&G, details of
all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of
implementing, administering and managing the Plan (“Data”). I understand that Data may be transferred to any third parties assisting in the
implementation, administration and management of the Plan, that these recipients may be located in my country or elsewhere (including countries
outside the European Economic Area), and that the recipient’s country may have different data privacy laws and protections than my country. I
understand that I may request a list with the names and addresses of any potential recipients of the Data by contacting my local human resources
representative. I authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of
implementing, administering and managing my participation in the Plan, including any requisite transfer of such Data as may be required to a broker
or other third party with whom I may elect to deposit any shares of stock acquired upon exercise or settlement of the Award. I understand that Data
will be held only as long as is necessary to implement, administer and manage my participation in the Plan. I understand that I may, at any time,
view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or
withdraw the consents herein, in any case without cost, by contacting in writing my local human resources representative. I understand, however,
that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more information on the consequences of my refusal to
consent or withdrawal of consent, I understand that I may contact my local human resources representative.
Responsibility for Taxes
Regardless of any action P&G takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related
withholding (“Tax-Related Items”), I acknowledge that the ultimate liability for all Tax-Related Items is and remains my responsibility and that P&G
(1) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award,
including the issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents
or the potential impact of current or future tax legislation in any jurisdiction; and (2) does not commit to structure the terms of the Award or any
aspect of the Award to reduce or eliminate my liability for Tax-Related Items.
Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G to satisfy all withholding and payment
on account obligations of P&G. In this regard, I authorize P&G to withhold all applicable Tax-Related Items from my wages or other cash
compensation paid to me by P&G or from proceeds of the sale of the shares. Alternatively, or in addition, if permissible under local law, P&G may (1)
sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax-Related Items, and/or (2) withhold in shares, provided
that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G any amount of Tax-
Related Items that P&G may be required to withhold as a result of my participation in the Plan or my purchase of shares that cannot be satisfied by
the means previously described. P&G may refuse to honor the exercise and refuse to deliver the shares if I fail to comply with my obligations in
connection with the Tax-Related Items as described in this section.
-- 215 of 242 --
______________________________________________________________________ RSU Form RTN2
FORM RTN2 AWARD AGREEMENT
______________________________________________________________________
<Name>
Subject: RESTRICTED STOCK UNIT SERIES RTN2
In recognition of your contributions to the future success of the business, The Procter & Gamble Company (“Company”) hereby grants to you
Restricted Stock Units (“RSUs”) of Procter & Gamble Common Stock as follows:
Grant Date: <GRANT DATE>
Stock Price on Grant Date: <GRANT PRICE>
Number of Restricted Stock Units: <SHARES1>
Vest Date: <VEST DATE 1>
Settlement Date: See Payment and Vesting Details Below
Number of Restricted Stock Units: <SHARES2>
Vest Date: <VEST DATE 2>
Settlement Date: See Payment and Vesting Details Below
Total Number of Restricted Stock Units: <TOTAL SHARES>
This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including
any applicable sub-plan) (the “Plan”), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors
(“Committee”), this Award Agreement including Attachments, and the Settlement Instructions in place as may be revised from time to time. Any
capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan. You may access the Plan by activating this
hyperlink: The Procter & Gamble 2019 Stock and Incentive Compensation Plan and the Regulations and Sub Plans by activating this hyperlink:
Regulations of the Committee. If you have difficulty accessing the materials online, please send an email to [_______] for assistance.
Voting Rights and Dividend Equivalents
As a holder of RSUs, during the period from the Grant Date until the date the RSUs are paid, each time a cash dividend or other cash distribution is
paid with respect to Common Stock, you will receive additional RSUs (“Dividend Equivalent RSUs”). The number of Dividend Equivalent RSUs will
be determined as follows: multiply the number of RSUs and Dividend Equivalent RSUs currently held by the per share amount of the cash dividend
or other cash distribution on Common Stock, then divide the result by the price of the Common Stock on the date of the dividend or distribution.
These Dividend Equivalent RSUs will be subject to the same terms and conditions as the original RSUs that gave rise to them, including vesting and
settlement terms, except that if there is a fractional number of Dividend Equivalent RSUs on the date the RSUs are paid, the Dividend Equivalent
RSUs will be rounded up to the nearest whole number of RSUs. This Award represents an
-- 216 of 242 --
unfunded, unsecured right to receive payment in the future, and does not entitle you to voting rights or dividend rights as a shareholder.
Payment and Vesting
If you remain employed through the Vest Dates, the Award will be paid on the Vest Date(s) according to the vesting schedule except if you are a
Board-Designated Section 16 Officer of the Company on the Vest Date(s) and in the case of death, as described below. If your Termination of
Employment occurs for any reason before a Vest Date except for the reasons listed below, the Award will be forfeited. For the purposes of this
Award, Termination of Employment will be effective as of the date that you are no longer actively employed and will not be extended by any notice
period required under local law.
________________________________________________________________________________________ RSU Form RTN2
1. Termination on Account of Death or Disability. In the case of death or disability, the Award will be fully vested and payment will be made by
the later of the end of the calendar year or two and a half months following the date of death or disability.
2. Termination without Cause Pursuant to a Written Separation Agreement. In the event of your Termination of Employment from the Company
or a Subsidiary without Cause, your Award is forfeited unless the Chief Human Resources Officer authorizes the retention of the Award and
you have executed a written separation agreement with the Company that provides for retention of the Award. If the Award is retained
pursuant to CHRO authorization, the Award will be delivered on the Vest Date(s) as long as you remain in compliance with the terms of the
Plan, the Regulations, and your separation agreement.
3. Vesting for Board-Designated Section 16 Officers. Payment will be on the Vest Date(s) except when the Vest Date(s) is outside of an open
trading window as designated by the Company in accordance with the Company’s Insider Trading Policy and the Section 16 Officer does
not have a valid 10b5-1 plan in place instructing the sale of Common Stock to cover taxes and administrative costs, in which case payment
will be made on the first day of the first such open trading window following the Vest Date(s).
Notwithstanding the foregoing, in the event of a Change in Control, payment shall be made pursuant to the terms provided in the Plan.
Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by the Committee pursuant to
the Plan, subject to applicable tax withholding.
This Award Agreement including Attachment A, the Plan and Regulations of the Committee together constitute an agreement between the Company
and you in accordance with the terms thereof and hereof, and no other understandings and/or agreements that have been entered by you with the
Company regarding this specific Award. Any legal action related to this Award, including Article 6 of the Plan, may be brought in any federal or state
court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from
said courts solely for legal actions related to this Award.
THE PROCTER & GAMBLE COMPANY
Tracey Grabowski
Chief Human Resources Officer
-- 217 of 242 --
______________________________________________________________________
RSU Form RTN2
Attachment A
Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be inconsistent with any
applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said Common Stock and that any
outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions
governing this Award.
Nature of the Award
By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter & Gamble Company
(“P&G”), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are voluntary and occasional and
this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been granted repeatedly
in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my participation in the Plan is voluntary; v) this Award is
an extraordinary item and not part of normal or expected compensation or salary for any purposes including, but not limited to, calculating any termination,
severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments; vi) in the event
that my employer is not P&G, the Award will not be interpreted to form an employment relationship with P&G; and furthermore, the Award will not be interpreted
to form an employment contract with my employer (“Employer”); vii) the future value of the shares purchased under the Plan is unknown and cannot be predicted
with certainty, may increase or decrease in value and potentially have no value; viii) my participation in the Plan shall not create a right to further employment
with my employer and shall not interfere with the ability of my employer to terminate my employment relationship at any time, with or without cause; ix) and no
claim or entitlement to compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares purchased and I
irrevocably release P&G and my employer from any such claim that may arise.
Data Privacy
I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this document
by and among, as applicable, my Employer and The Procter & Gamble Company and its subsidiaries and affiliates (“P&G”) for the exclusive purpose of
implementing, administering and managing my participation in the Plan.
I understand that P&G and my Employer hold certain personal information about me, including, but not limited to, my name, home address and telephone
number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in P&G,
details of all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of
implementing, administering and managing the Plan (“Data”). I understand that Data may be transferred to any third parties assisting in the implementation,
administration and management of the Plan, that these recipients may be located in my country or elsewhere (including countries outside the European
Economic Area), and that the recipient’s country may have different data privacy laws and protections than my country. I understand that I may request a list with
the names and addresses of any potential recipients of the Data by contacting my local human resources representative. I authorize the recipients to receive,
possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation in the
Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of stock
acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary to implement, administer and manage my
participation in the Plan. I understand that I may, at any time, view Data, request additional information about the storage and processing of Data, require any
necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human resources
representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more information on the
consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.
Responsibility for Taxes
Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related
withholding (“Tax-Related Items”), I acknowledge that the ultimate liability for all Tax-Related Items is and remains my responsibility and that P&G and/or my
Employer (1) make no
-- 218 of 242 --
representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including the issuance, vesting or
exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents or the potential impact of current or future tax
legislation in any jurisdiction; and (2) do not commit to structure the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-
Related Items.
Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my Employer to satisfy all withholding and
payment on account obligations of P&G and/or my employer. In this regard, I authorize P&G and/or my Employer to withhold all applicable Tax-Related Items
from my wages or other cash compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in addition, if
permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax-Related Items, and/or (2)
withhold in shares, provided that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G or
my Employer any amount of Tax-Related Items that P&G or my Employer may be required to withhold as a result of my participation in the Plan or my purchase
of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and refuse to deliver the shares if I fail to comply
with my obligations in connection with the Tax-Related Items as described in this section.
-- 219 of 242 --
Exhibit (10-25)
The Procter & Gamble 2019 Stock and Incentive
Compensation Plan – Related Correspondence
-- 220 of 242 --
Preferences and Deferral Elections
Recoupment Policy Acknowledgement
¨ Selecting this box indicates that you have read (click here) and agree to the Senior Executive Officer Recoupment
Policy. You must click the link and you must read the full policy before proceeding with making your Preference and
EDCP Deferral Elections.
Source Election Format Amount Deferred
Choose your Executive Deferred Compensation Plan (DCP) Base Pay Deferral Elections:
2020 Base Pay DCP Deferral Percentage _____%
Enter percentage as a whole number less than or equal to 75%
Choose your Preference for STAR Award payments made in 2020.
Sum of DCP Deferral, Cash and Stock Options payment options must equal 100%
2020 STAR Award DCP Deferral Percentage _____%
Enter percentage as a whole number between 0 and 100%
STAR Award Cash Percentage _____%
Enter percentage as a whole number between 0 and 100%
STAR Award Stock Options Percentage _____%
Enter percentage as a whole number between 0 and 100%
Choose your Preference for Long Term Incentive Program (LTIP) Award payments made in 2020.
Sum of Stock Options and Restricted Stock Unit payment options must equal 100%
LTIP Stock Options Percentage ____%
Enter a percentage as a whole number. (0, 25, 50, 75, or 100 only)
LTIP Restricted Stock Units (RSUs) Percentage ____%
Enter a percentage as a whole number. (0, 25, 50, 75, or 100 only)
-- 221 of 242 --
Payment Elections (DCP)
2020 Base Pay DCP Deferral 2020 STAR Award DCP Deferral
Preferences and Deferral Elections ___% ___%
Choose a payment method for each deferral source Base Pay STAR Award
I would like to receive my 2020 deferrals in the form of an in-service distribution. ¨ ¨
I would like to receive my 2020 deferrals when I separate from the company. ¨ ¨
In-Service Payment Elections
Enter year of in-service distribution. Must be at least one year following the deferral year. Payment will be made in lump sum in
January of year selected.
Deferral Source Payment Year
Base Pay _______
STAR Award _______
Separation Payment Elections
Enter percentage as a whole number from 0 to 100 for each separation event and form of payment. A combination of lump sum and/or
annual installment (2-10) can be selected. The sum of your elections must equal 100% for each deferral source and each payment
event.
Deferral Source Payment Form Retirement Death Disability
Base Pay Lump Sum ____% ____% ____%
STAR Award Annual Installment ____% ____% ____%
-- 222 of 242 --
EXHIBIT (21)
The Procter & Gamble Company and Subsidiaries
Subsidiaries of the Registrant
-- 223 of 242 --
The Procter & Gamble Company and Subsidiaries
The registrant's subsidiaries are listed below, omitting certain entities that have de minimis activity that, if considered in the aggregate as a single subsidiary, would
not constitute a significant subsidiary as of June 30, 2020.
Procter & Gamble Algeria EURL Algeria
Procter & Gamble Argentina SRL Argentina
"Procter & Gamble Services" LLC Russia
"Procter & Gamble" LLC Russia
1837, LLC Ohio
Agile Pursuits Franchising, Inc. Ohio
Agile Pursuits, Inc. Ohio
Arbora & Ausonia, S.L.U. Spain
Biohagen Farmaceutica do Brasil Ltda Brazil
Braun (Shanghai) Co., Ltd. China
Braun GmbH Germany
Celtic Insurance Company, Inc. Vermont
Charlie Banana (USA), LLC Delaware
Consumer Health Distribution S.A. de C.V. Mexico
Corporativo Procter & Gamble, S. de R.L. de C.V. Mexico
Cosmetic Products Pty. Ltd. Australia
Detergent Products B.V. Netherlands
Detergent Products SARL Switzerland
Detergenti S.A. Romania
Fameccanica Data S.p.A. Italy
Fameccanica Indùstria e Comèrcio Do Brasil LTDA. Brazil
Fameccanica Machinery (Shanghai) Co., Ltd. China
Fameccanica North America, Inc. Delaware
Fater Central Europe SRL Romania
Fater Eastern Europe LLC Russia
Fater Portugal Unipessoal Lda Portugal
Fater S.p.A. Italy
Fater Temizlik Urunleri Ltd STI Turkey
First Aid Beauty Limited Delaware
Fountain Square Music Publishing Co., Inc. Ohio
FPG Oleochemicals Sdn. Bhd. Malaysia
Gillette (China) Limited China
Gillette (Shanghai) Ltd. China
Gillette Australia Pty. Ltd. Australia
Gillette Commercial Operations North America Massachusetts
Gillette del Uruguay, S.A. Uruguay
Gillette Diversified Operations Pvt. Ltd. India
Gillette Egypt S.A.E. Egypt
Gillette Group UK Ltd U.K.
Gillette Holding Company LLC Delaware
Gillette Holding GmbH Germany
Gillette India Limited India
Gillette Industries Ltd. U.K.
Gillette International B.V. Netherlands
Gillette Latin America Holding B.V. Netherlands
Gillette Management, LLC Delaware
Gillette Pakistan Limited Pakistan
Gillette Poland International Sp. z.o.o. Poland
-- 224 of 242 --
Gillette U.K. Limited U.K.
-- 225 of 242 --
Hyginett KFT Hungary
iMFLUX Inc. Delaware
Industries Marocaines Modernes SA Morocco
Laboratoire Mediflor S.A.S. France
Laboratorios Vicks, S.L.U. Spain
Lamberts Healthcare Ltd. U.K.
Liberty Street Music Publishing Company, Inc. Ohio
Limited Liability Company 'Procter & Gamble Trading Ukraine' Ukraine
LLC "Procter & Gamble Distributorskaya Compania" Russia
LLC "Procter & Gamble Novomoskovsk" Russia
LLC “Procter & and Gamble Ukraine” Ukraine
Modern Industries Company - Dammam Saudi Arabia
Modern Products Company - Jeddah Saudi Arabia
Nature's Best Health Products Ltd. U.K.
New Chapter Canada Inc. Canada
New Chapter, Inc. Delaware
Olay LLC Puerto Rico
Oral-B Laboratories Delaware
P&G Consumer Health Germany GmbH Germany
P&G Distribution East Africa Limited Kenya
P&G Distribution Morocco SAS Morocco
P&G Hair Care Holding, Inc. Delaware
P&G Health Austria GmbH & Co. OG Austria
P&G Health France S.A.S. France
P&G Health Germany GmbH Germany
P&G Industrial Peru S.R.L. Peru
P&G Innovation Godo Kaisha Japan
P&G Investment Management Ltd. United Arab Emirates
P&G Israel M.D.O. Ltd. Israel
P&G K.K. Japan
P&G Northeast Asia Pte. Ltd. Singapore
P&G Prestige Godo Kaisha Japan
P&G South African Trading (Pty.) Ltd. South Africa
Petersburg Products International LLC Russia
PG13 Launchpad Alpha, Inc. Delaware
PG13 Launchpad Beta, Inc. Delaware
PG13 Launchpad Gamma, Inc. Delaware
PGT Health Care (Zhejiang) Limited China
PGT Healthcare LLP Delaware
Phase II Holdings Corporation Philippines
Procter & Gamble (Chengdu) Ltd. China
Procter & Gamble (China) Ltd. China
Procter & Gamble (China) Sales Co., Ltd. China
Procter & Gamble (Egypt) Manufacturing Company Egypt
Procter & Gamble (Guangzhou) Consumer Products Co., Ltd. China
Procter & Gamble (Guangzhou) Enterprise Management Service Company Limited China
Procter & Gamble (Guangzhou) Ltd. China
Procter & Gamble (Guangzhou) Technology Innovation Co., LTD. China
Procter & Gamble (Health & Beauty Care) Limited U.K.
Procter & Gamble (Jiangsu) Ltd. China
Procter & Gamble (L&CP) Limited U.K.
Procter & Gamble (Malaysia) Sdn Bhd Malaysia
-- 226 of 242 --
Procter & Gamble (Manufacturing) Ireland Limited Ireland
Procter & Gamble (Singapore) Pte. Ltd. Singapore
Procter & Gamble Amazon Holding B.V. Netherlands
-- 227 of 242 --
Procter & Gamble Amiens S.A.S. France
Procter & Gamble Australia Proprietary Limited Australia
Procter & Gamble Azerbaijan Services LLC Azerbaijan
Procter & Gamble Bangladesh Private Ltd. Bangladesh
Procter & Gamble Blois S.A.S. France
Procter & Gamble Brazil Holdings B.V. Netherlands
Procter & Gamble Bulgaria EOOD Bulgaria
Procter & Gamble Business Services Canada Company Canada
Procter & Gamble Canada Holding B.V. Netherlands
Procter & Gamble Chile Limitada Chile
Procter & Gamble Chile, Inc. Ohio
Procter & Gamble Colombia Ltda. Colombia
Procter & Gamble Commercial LLC Puerto Rico
Procter & Gamble Czech Republic s.r.o. Czech Republic
Procter & Gamble d.o.o. za trgovinu Croatia
Procter & Gamble Danmark ApS Denmark
Procter & Gamble de Venezuela, S.C.A. Venezuela
Procter & Gamble de Venezuela, S.R.L. Venezuela
Procter & Gamble Detergent (Beijing) Ltd. China
Procter & Gamble Deutschland GmbH Germany
Procter & Gamble Distributing (Philippines) Inc. Philippines
Procter & Gamble Distributing New Zealand Limited New Zealand
Procter & Gamble Distribution Company (Europe) BVBA Belgium
Procter & Gamble Distribution S.R.L. Romania
Procter & Gamble do Brasil LTDA. Brazil
Procter & Gamble do Brazil, LLC Delaware
Procter & Gamble do Nordeste S/A Brazil
Procter & Gamble DS Polska Sp. z o.o. Poland
Procter & Gamble Eastern Europe, LLC Ohio
Procter & Gamble Ecuador Cia. Ltda. Ecuador
Procter & Gamble Egypt Egypt
Procter & Gamble Egypt Distribution Egypt
Procter & Gamble Egypt Holding Egypt
Procter & Gamble Egypt Supplies Egypt
Procter & Gamble Energy Company LLC Ohio
Procter & Gamble España, S.A. Spain
Procter & Gamble Europe SA Switzerland
Procter & Gamble Exportadora e Importadora Ltda. Brazil
Procter & Gamble Far East, Inc. Ohio
Procter & Gamble Finance (U.K.) Ltd. U.K.
Procter & Gamble Finance Holding Ltd. U.K.
Procter & Gamble Finance Management S.a.r.l. Luxembourg
Procter & Gamble Financial Investments LLP U.K.
Procter & Gamble Financial Services Ltd. U.K.
Procter & Gamble Financial Services S.a.r.l. Luxembourg
Procter & Gamble Finland OY Finland
Procter & Gamble France S.A.S. France
Procter & Gamble Germany GmbH Germany
Procter & Gamble Germany GmbH & Co. Operations oHG Germany
Procter & Gamble Ghana Trading Limited Ghana
Procter & Gamble GmbH Germany
Procter & Gamble Grundstucks-und Vermogensverwaltungs GmbH & Co. KG Germany
-- 228 of 242 --
Procter & Gamble Gulf FZE United Arab Emirates
Procter & Gamble Hair Care, LLC Delaware
Procter & Gamble Health Belgium BVBA Belgium
-- 229 of 242 --
Procter & Gamble Health Limited India
Procter & Gamble Health Ltd. U.K.
Procter & Gamble Health Poland Sp. z.o.o. Poland
Procter & Gamble Hellas Single Member Ltd. Greece
Procter & Gamble Holding (Thailand) Limited Thailand
Procter & Gamble Holding France S.A.S. France
Procter & Gamble Holding GmbH Germany
Procter & Gamble Holding S.r.l. Italy
Procter & Gamble Holdings (UK) Ltd. U.K.
Procter & Gamble Home Products Private Limited India
Procter & Gamble Honduras S de RL Honduras
Procter & Gamble Hong Kong Limited Hong Kong
Procter & Gamble Hungary Wholesale Trading Partnership (KKT) Hungary
Procter & Gamble Hygiene & Health Care Limited India
Procter & Gamble Inc. Canada
Procter & Gamble India Holdings, Inc. Ohio
Procter & Gamble Indochina Company Limited Vietnam
Procter & Gamble Industrial - 2012 C.A. Venezuela
Procter & Gamble Industrial e Comercial Ltda. Brazil
Procter & Gamble Industrial S.C.A. Venezuela
Procter & Gamble Interamericas de Costa Rica, Limitada Costa Rica
Procter & Gamble Interamericas de El Salvador, Limitada de Capital Variable El Salvador
Procter & Gamble Interamericas de Guatemala, Limitada Guatemala
Procter & Gamble Interamericas de Panama, S. de R.L. Panama
Procter & Gamble International Operations Pte Ltd Singapore
Procter & Gamble International Operations SA Switzerland
Procter & Gamble International Operations SA-ROHQ Philippines
Procter & Gamble International S.a.r.l. Switzerland
Procter & Gamble Investment Company (UK) Ltd. U.K.
Procter & Gamble Investment Holding B.V. Netherlands
Procter & Gamble Italia, S.p.A. Italy
Procter & Gamble Japan K.K. Japan
Procter & Gamble Kazakhstan Distribution LLP Kazakhstan
Procter & Gamble Kazakhstan LLP Kazakhstan
Procter & Gamble Korea S&D Co. Korea
Procter & Gamble Korea, Inc. Korea
Procter & Gamble Leasing LLC Ohio
Procter & Gamble Levant S.A.L. Lebanon
Procter & Gamble Limited U.K.
Procter & Gamble Manufacturing (Thailand) Limited Thailand
Procter & Gamble Manufacturing (Tianjin) Co. Ltd. China
Procter & Gamble Manufacturing Belgium N.V. Belgium
Procter & Gamble Manufacturing Berlin GmbH Germany
Procter & Gamble Manufacturing GmbH Germany
Procter & Gamble Manufacturing Mexico S. de R.L. de C.V. Mexico
Procter & Gamble Manufacturing SA (Pty) Ltd South Africa
Procter & Gamble Marketing and Services doo Serbia and Montenegro
Procter & Gamble Marketing Romania SRL Romania
Procter & Gamble Mataro, S.L.U. Spain
Procter & Gamble Mexico Holding B.V. Netherlands
Procter & Gamble Mexico Inc. Delaware
Procter & Gamble Middle East FZE United Arab Emirates
-- 230 of 242 --
Procter & Gamble Nederland B.V. Netherlands
Procter & Gamble Netherlands Services B.V. Netherlands
Procter & Gamble Nigeria Limited Nigeria
-- 231 of 242 --
Procter & Gamble Nordic, LLC Ohio
Procter & Gamble Norge AS Norway
Procter & Gamble Operations Polska Sp. z o.o. Poland
Procter & Gamble Overseas India B.V. Netherlands
Procter & Gamble Overseas Ltd. U.K.
Procter & Gamble Pakistan (Private) Limited Pakistan
Procter & Gamble Peru S.R.L. Peru
Procter & Gamble Pharmaceuticals France SAS France
Procter & Gamble Philippines, Inc. Philippines
Procter & Gamble Polska Sp. z o.o Poland
Procter & Gamble Portugal - Produtos De Consumo, Higiene e Saúde S.A. Portugal
Procter & Gamble Product Supply (U.K.) Limited U.K.
Procter & Gamble Productions, Inc. Ohio
Procter & Gamble Productos de Consumo, S.L.U. Spain
Procter & Gamble Retail Services SARL Switzerland
Procter & Gamble RHD, Inc. Ohio
Procter & Gamble RSC Regional Service Company Ltd. Hungary
Procter & Gamble S.r.l. Italy
Procter & Gamble Service, GmbH Germany
Procter & Gamble Services (Switzerland) SA Switzerland
Procter & Gamble Services Company N.V. Belgium
Procter & Gamble Sverige AB Sweden
Procter & Gamble Switzerland SARL Switzerland
Procter & Gamble Taiwan Limited Taiwan
Procter & Gamble Taiwan Sales Company Limited Taiwan
Procter & Gamble Technical Centres Limited U.K.
Procter & Gamble Technology (Beijing) Co., Ltd. China
Procter & Gamble Trading (Thailand) Limited Thailand
Procter & Gamble Tuketim Mallari Sanayii A.S. Turkey
Procter & Gamble UK U.K.
Procter & Gamble UK Group Holdings Ltd U.K.
Procter & Gamble UK Parent Company Ltd. U.K.
Procter & Gamble Universal Holding B.V. Netherlands
Procter & Gamble Vietnam Company Limited Vietnam
Procter & Gamble, Spol. s.r.o. (Ltd.) Slovak Republic
Procter & Gamble-Rakona s.r.o. Czech Republic
Procter and Gamble Lanka (Private) Limited Sri Lanka
Progam Realty & Development Corporation Philippines
PT Procter & Gamble Home Products Indonesia Indonesia
PT Procter & Gamble Operations Indonesia Indonesia
Redmond Products, Inc. Minnesota
Richardson-Vicks Real Estate Inc. Ohio
Riverfront Music Publishing Co., Inc. Ohio
Rosemount LLC Delaware
Series Acquisition B.V. Netherlands
Seven Seas Limited U.K.
Shulton, Inc. New Jersey
Snowberry IP Limited New Zealand
Snowberry New Zealand Limited New Zealand
SPD Development Company Limited U.K.
SPD Swiss Precision Diagnostics GmbH Switzerland
Sunflower Distributing LLC Delaware
-- 232 of 242 --
Tambrands Inc. Delaware
TAOS - FL, LLC Florida
TAOS Retail, LLC Delaware
-- 233 of 242 --
Temple Trees Impex & Investment Private Limited India
The Art of Shaving - FL, LLC Florida
The Dover Wipes Company Ohio
The Gillette Company LLC Delaware
The Procter & Gamble Distributing LLC Delaware
The Procter & Gamble Global Finance Company, LLC Ohio
The Procter & Gamble Manufacturing Company Ohio
The Procter & Gamble Paper Products Company Ohio
The Procter & Gamble U.S. Business Services Company Ohio
This is L. Inc. Delaware
US CD LLC Delaware
Vidal Sassoon (Shanghai) Academy China
Walker & Co. Brands, Inc. Delaware
Zenlen, Inc. Delaware
-- 234 of 242 --
EXHIBIT (23)
Consent of Independent Registered Public Accounting Firm
-- 235 of 242 --
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following registration statements of our reports dated August 6, 2020, relating to
the consolidated financial statements of The Procter & Gamble Company and the effectiveness of The Procter & Gamble Company’s
internal control over financial reporting, appearing in this Annual Report on Form 10-K for the year ended June 30, 2020:
1. Post-Effective Amendment No. 1 to Registration Statement No. 33-49289 on Form S-8 for The Procter & Gamble 1992
Stock Plan;
2. Registration Statement No. 33-47656 on Form S-8 for The Procter & Gamble International Stock Ownership Plan;
3. Registration Statement No. 33-50273 on Form S-8 for The Procter & Gamble Commercial Company Employees’ Savings
Plan;
4. Registration Statement No. 33-51469 on Form S-8 for The Procter & Gamble 1993 Non-Employee Directors’ Stock Plan;
5. Registration Statement No. 333-14381 on Form S-8 for Profit Sharing Retirement Plan of The Procter & Gamble
Commercial Company;
6. Registration Statement No. 333-21783 on Form S-8 for The Procter & Gamble 1992 Stock Plan (Belgian Version);
7. Registration Statement No. 333-37905 on Form S-8 for The Procter & Gamble Future Shares Plan;
8. Registration Statement No. 333-51213 on Form S-8 for Group Profit Sharing, Incentive and Employer Contribution Plan
(France);
9. Registration Statement No. 333-51219 on Form S-8 for Procter & Gamble Ireland Employees Share Ownership Plan;
10. Registration Statement No. 333-51221 on Form S-8 for Employee Stock Purchase Plan (Japan);
11. Registration Statement No. 333-34606 on Form S-8 for The Procter & Gamble Future Shares Plan;
12. Registration Statement No. 333-44034 on Form S-8 for Procter & Gamble International Stock Ownership Plan;
13. Registration Statement No. 333-47132 on Form S-8 for Employee Stock Purchase Plan (Japan);
14. Registration Statement No. 333-75030 on Form S-8 for The Procter & Gamble 2001 Stock and Incentive Compensation Plan;
15. Registration Statement No. 333-100561 on Form S-8 for The Procter & Gamble (U.K.) 1-4-1 Plan;
16. Registration Statement No. 333-108991 on Form S-8 for The Procter & Gamble 1992 Stock Plan (Belgian Version);
17. Registration Statement No. 333-108993 on Form S-8 for Employee Stock Purchase Plan (Japan);
18. Registration Statement No. 333-108994 on Form S-8 for Procter & Gamble Ireland Employees Share Plan;
19. Registration Statement No. 333-108995 on Form S-8 for Group Profit Sharing, Incentive and Employer Contribution Plan
(France);
20. Registration Statement No. 333-108997 on Form S-8 for Procter & Gamble International Stock Ownership Plan;
21. Registration Statement No. 333-108998 on Form S-8 for The Procter & Gamble 1993 Non-Employee Directors’ Stock Plan;
22. Registration Statement No. 333-108999 on Form S-8 for The Procter & Gamble 1992 Stock Plan;
23. Registration Statement No. 333-111304 on Form S-8 for The Procter & Gamble 2003 Non-Employee Directors’ Stock Plan;
24. Amendment No. 1 to Registration Statement No. 333-113515 on Form S-3 for The Procter & Gamble Company Debt
Securities and Warrants;
25. Amendment No. 3 to Registration Statement No. 333-123309 on Form S-4 for The Procter & Gamble Company;
-- 236 of 242 --
26. Registration Statement No. 333-128859 on Form S-8 for certain employee benefit plans of The Gillette Company (2004
Long-Term Incentive Plan of The Gillette Company; 1971 Stock Option Plan of The Gillette Company; James M. Kilts Non-
Statutory Stock Option Plan; The Gillette Company Employees’ Savings Plan; The Gillette Company Supplemental Savings
Plan; The Gillette Company Global Employee Stock Ownership Plan (GESOP));
27. Registration Statement No. 333-143801 on Form S-8 for The Procter & Gamble Savings Plan;
28. Registration Statement No. 333-155046 on Form S-8 for Employee Stock Purchase Plan (Japan);
29. Registration Statement No. 333-161725 on Form S-8 for The Procter & Gamble Savings Plan;
30. Registration Statement No. 333-164612 on Form S-8 for The Procter & Gamble 2009 Stock and Incentive Compensation
Plan;
31. Registration Statement No. 333-192841 on Form S-8 for The Procter & Gamble 1992 Stock Plan (Belgian Version);
32. Registration Statement No. 333-199592 on Form S-8 for The Procter & Gamble 2014 Stock and Incentive Compensation
Plan;
33. Registration Statement No. 333-208407 on Form S-8 for The Profit Sharing Retirement Plan of The Procter & Gamble
Commercial Company;
34. Registration Statement No. 333-208408 on Form S-8 for Procter & Gamble Ireland Employees Share Plan;
35. Registration Statement No. 333-208409 on Form S-8 for Procter & Gamble International Stock Ownership Plan;
36. Registration Statement No. 333-208410 on Form S-8 for The Procter & Gamble (U.K.) 1-4-1 Plan;
37. Registration Statement No. 333-208411 on Form S-8 for The Procter & Gamble Commercial Company Employees' Savings
Plan;
38. Registration Statement No. 333-208412 on Form S-8 for Group Profit Sharing, Incentive and Employer Contribution Plan
(France);
39. Registration Statement No. 333-221035 on Form S-3 for Debt Securities 2017 Registration;
40. Registration Statement No. 333-221037 on Form S-3 for The Procter & Gamble Company Direct Stock Purchase Plan 2017;
41. Registration Statement No. 333-221038 on Form S-3 for The Procter & Gamble U.K. Share Investment Scheme;
42. Registration Statement No. 333-234131 on Form S-8 for The Procter & Gamble 2019 Stock and Incentive Compensation
Plan; and
43. Post-Effective Amendment No. 1 to Registration Statement No. 333-119592 on Form S-8 for The Procter & Gamble 2014
Stock and Incentive Compensation Plan.
/s/ Deloitte & Touche LLP
Cincinnati, Ohio
August 6, 2020
-- 237 of 242 --
EXHIBIT (31)
Rule 13a-14(a)/15d-14(a) Certifications
I, David S. Taylor, certify that:
(1) I have reviewed this Form 10-K of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
i) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
us by others within those entities, particularly during the period in which this report is being prepared;
ii) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;
iii) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation;
iv) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant's internal control over financial reporting; and
(5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent
functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
internal control over financial reporting.
/s/ DAVID S. TAYLOR
(David S. Taylor)
Chairman of the Board, President and Chief Executive Officer
August 6, 2020
Date
-- 238 of 242 --
EXHIBIT (31)
Rule 13a-14(a)/15d-14(a) Certifications
I, Jon R. Moeller, certify that:
(1) I have reviewed this Form 10-K of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
i) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
us by others within those entities, particularly during the period in which this report is being prepared;
ii) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;
iii) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation;
iv) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant's internal control over financial reporting; and
(5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent
functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
internal control over financial reporting.
/s/ JON R. MOELLER
(Jon R. Moeller)
Vice Chairman, Chief Operating Officer and Chief Financial Officer
August 6, 2020
Date
-- 239 of 242 --
EXHIBIT (32)
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter &
Gamble Company (the “Company”) certifies to his knowledge that:
(1) Form 10-K of the Company for the year ended June 30, 2020 fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-K fairly presents, in all material respects, the financial conditions and results of operations
of the Company.
/s/ DAVID S. TAYLOR
(David S. Taylor)
Chairman of the Board, President and Chief Executive Officer
August 6, 2020
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The
Procter & Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.
-- 240 of 242 --
EXHIBIT (32)
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter &
Gamble Company (the “Company”) certifies to his knowledge that:
(1) Form 10-K of the Company for the year ended June 30, 2020 fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-K fairly presents, in all material respects, the financial conditions and results of operations
of the Company.
/s/ JON R. MOELLER
(Jon R. Moeller)
Vice Chairman, Chief Operating Officer and Chief Financial Officer
August 6, 2020
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The
Procter & Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.
-- 241 of 242 --
EXHIBIT (99-1)
Summary of Directors and Officers Insurance Program
The Procter & Gamble Company purchases Directors and Officers Liability insurance from various insurance carriers. The policy limits for the period from June
30, 2018 to June 30, 2019 were $300 million.
-- 242 of 242 --